Search
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

Search Term: Metastatic Brain Tumor

NCT Trial Name# of Centers

NCT02239120

  Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
449

NCT02313909

  Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
414

NCT02523014

  A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas
340

NCT00892177

  Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
308

NCT01814813

  Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
286

NCT02152982

  Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
273

NCT01648348

  Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
242

NCT01781468

  Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
240

NCT02834013

  Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
224

NCT02670083

  CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
212

NCT02997228

  Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
211

NCT00991029

  Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
210

NCT00869401

  Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
207

NCT01480479

  Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
206

NCT02100696

  A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors
205

NCT02490878

  Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
203

NCT02360215

  Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
187

NCT00085735

  Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
184

NCT02614794

  Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
179

NCT01609790

  Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
175

NCT01231906

  Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
171

NCT00978458

  Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
168

NCT00898079

  Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
167

NCT01080521

  Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
164

NCT02477800

  221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
163

NCT00919750

  Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
160

NCT02484547

  221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
160

NCT00887146

  Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
156

NCT02724579

  Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
152

NCT01096368

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
150

NCT01085630

  Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
145

NCT00736749

  Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
143

NCT02179086

  Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
142

NCT01217437

  Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
138

NCT01649089

  Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
135

NCT00336024

  Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
131

NCT02568267

  Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
129

NCT00329719

  Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
121

NCT00772200

  Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)
119

NCT01055197

  Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
115

NCT03155620

  Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
113

NCT01657799

  A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
109

NCT00437060

  Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
106

NCT03281954

  Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
106

NCT00020566

  Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma
104

NCT01154816

  MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
101

NCT01977651

  A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
93

NCT00653068

  Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
87

NCT00916409

  Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
86

NCT03068468

  Study of BIIB092 in Participants With Progressive Supranuclear Palsy
85

NCT02831959

  Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)
85

NCT01602666

  Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
85

NCT01622868

  Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
85

NCT02760602

  A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
85

NCT03180268

  Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
83

NCT03233204

  Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
83

NCT02760433

  Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Have Active Disease
79

NCT01390948

  A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma
78

NCT00716976

  Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
77

NCT02796261

  Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
76

NCT01553149

  Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
76

NCT01835236

  Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
74

NCT00895622

  Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
74

NCT01564056

  Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment
72

NCT03220035

  Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
71

NCT00045968

  Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
70

NCT03210714

  Pediatric MATCH: Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations
70

NCT02066220

  International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
68

NCT00389181

  A Randomized Trial of Unruptured Brain AVMs
66

NCT02915744

  A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
66

NCT00377156

  Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
65

NCT02017964

  Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma
65

NCT02546102

  Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
64

NCT02414165

  The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
63

NCT02667587

  An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
62

NCT03179020

  Donation Network to Optimize Organ Recovery Study
60

NCT02982954

  A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
60

NCT02573324

  A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification ( Intellance1 )
59

NCT01381718

  Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor
59

NCT03269175

  BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
59

NCT02730455

  Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
59

NCT01708174

  A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
58

NCT03213678

  Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations
58

NCT03130959

  An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies
54

NCT00749723

  Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
54

NCT02283853

  Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
54

NCT02511405

  A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
53

NCT03083665

  A Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Asian Subjects (>=16 to 80 Years of Age) With Epilepsy
53

NCT01862640

  A Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
51

NCT03213665

  Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
50

NCT02417324

  International HIT-MED Registry (I-HIT-MED)
50

NCT01598597

  An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
50

NCT03149003

  A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
49

NCT01960075

  Established Status Epilepticus Treatment Trial
49

NCT02596035

  A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374)
49

NCT01843062

  Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
47

NCT01441596

  Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
47

NCT02234050

  Trabectedin for Recurrent Grade II/III Meningioma
47

NCT02274766

  Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
47

NCT01838668

  An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
46

NCT02790632

  Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage
46

NCT02034110

  Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
45

NCT02308020

  A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
45

NCT02136914

  ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
45

NCT00898755

  Collecting and Storing Tissue From Young Patients With Cancer
44

NCT01498328

  A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
43

NCT02601209

  Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
42

NCT01582269

  A Study in Recurrent Glioblastoma (GB)
40

NCT02430532

  BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS)
40

NCT02162537

  Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases
39

NCT01693562

  A Phase 1/2 Study to Evaluate MEDI4736
39

NCT01004523

  Study of Tissue and Blood Samples From Patients With Low-Grade Glioma
38

NCT01955707

  Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
37

NCT01372774

  Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
37

NCT01378975

  A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
36

NCT01062399

  Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
36

NCT02576431

  Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
36

NCT01417507

  Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
35

NCT03526250

  Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
35

NCT00958841

  Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
35

NCT02039947

  Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
35

NCT02320058

  An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
35

NCT02526017

  Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers
35

NCT01412424

  Efficacy and Safety of Octreolin for Acromegaly
34

NCT02617589

  An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
34

NCT01399372

  Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
34

NCT02875314

  HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
34

NCT01555320

  Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure
33

NCT02180217

  Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
33

NCT01947907

  Safety, PK/PD and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
32

NCT02258919

  Decompressive Hemicraniectomy in Intracerebral Hemorrhage
32

NCT02329080

  A Trial on a New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
32

NCT02006134

  Pediatric Vasculitis Initiative
31

NCT01730950

  Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
31

NCT01677572

  Multiple Dose Study of BIIB037 (Recombinant, Fully Human Anti-A? IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
30

NCT01696045

  Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
30

NCT02052778

  A Study of TAS-120 in Patients With Advanced Solid Tumors
30

NCT02439411

  Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
29

NCT01164189

  Bevacizumab in Recurrent Grade II and III Glioma
28

NCT02265770

  An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma
28

NCT02276053

  Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors
28

NCT02709889

  Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
28

NCT01716117

  Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms
27

NCT00939770

  Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
26

NCT01283009

  Extended Steroid in CAP(e)
25

NCT00987454

  Erythropoietin in Traumatic Brain Injury (EPO-TBI)
25

NCT02639546

  Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
25

NCT02416492

  A Study of Modified Stem Cells in Traumatic Brain Injury (TBI)
25

NCT01677741

  A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
24

NCT01871805

  A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer
24

NCT03243461

  International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)
23

NCT02034708

  Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
23

NCT01011920

  Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
23

NCT01273090

  Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
23

NCT01182350

  Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
23

NCT02167256

  A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
23

NCT03257631

  A Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
22

NCT01632228

  A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma
22

NCT02201108

  Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
22

NCT02357147

  Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).
22

NCT02539927

  Validation Study of the SAGIT® Instrument in Acromegaly
22

NCT01582061

  An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease
21

NCT01421524

  Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
21

NCT02323880

  Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
21

NCT02761070

  Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III
21

NCT00514397

  Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma
21

NCT01878617

  A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
21

NCT01503827

  Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
21

NCT02590263

  Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
21

NCT03053297

  Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)
21

NCT01701050

  Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
20

NCT01074021

  Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
20

NCT02095132

  Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
20

NCT01465347

  Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) With Concomitant Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM)
20

NCT03148457

  Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial
20

NCT02218047

  AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.
20

NCT01442662

  Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas
19

NCT02997423

  Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)
19

NCT02684838

  Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry
19

NCT02571036

  A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
19

NCT01288573

  A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
19

NCT01303497

  Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas
19

NCT00482677

  Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
19

NCT01703481

  A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
19

NCT02536339

  Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
19

NCT02564198

  A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
19

NCT02650401

  Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
19

NCT01414933

  High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents
18

NCT01073007

  Stroke Treatment With Acute Reperfusion and Simvastatin
18

NCT02335918

  A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
18

NCT02300766

  Cerebellar Mutism Syndrome Study
18

NCT01922076

  WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
18

NCT01378273

  Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)
17

NCT01558843

  Sodium Management in Acute Neurological Injury
17

NCT01597414

  Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1
17

NCT01576666

  Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
17

NCT01710605

  Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers
17

NCT02780804

  Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
17

NCT01748149

  Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas
17

NCT01734512

  PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
17

NCT01800695

  Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
17

NCT01356290

  Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma
17

NCT01324479

  Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
17

NCT00528437

  Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
17

NCT01026493

  Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
17

NCT02048059

  ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
17

NCT02162732

  Molecular-Guided Therapy for Childhood Cancer
17

NCT02460250

  Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death
17

NCT03115333

  DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
16

NCT01934361

  Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
16

NCT02078648

  Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
16

NCT02124772

  Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
16

NCT02052648

  Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
16

NCT02585713

  Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
16

NCT02697734

  Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
16

NCT02804789

  European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS)
16

NCT01358084

  Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma
15

NCT01132664

  Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab
15

NCT00859885

  International PFO Consortium
15

NCT02126124

  Evaluation of Deep Transcranial Magnetic Stimulation (DTMS) With the H-ADD Coil as an Aid to Smoking Cessation.
15

NCT01602588

  A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)
15

NCT00601003

  Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
15

NCT01614132

  Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults
15

NCT00418899

  Gliogene: Brain Tumor Linkage Study
15

NCT00987688

  The Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury
14

NCT03018288

  Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
14

NCT03215511

  Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
14

NCT02960230

  H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas
14

NCT02632370

  5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
14

NCT01288560

  IMAGE-HF Project I-A: Cardiac Imaging in Ischemic Heart Failure (AIMI-HF)
14

NCT01228331

  Clofarabine or High-Dose Cytarabine, Pegaspargase, and Combination Chemotherapy Followed by Daunorubicin Hydrochloride or Doxorubicin Hydrochloride in Treating Young Patients With Acute Lymphoblastic Leukemia
14

NCT00626990

  Radiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic Glioma
14

NCT00867178

  Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
14

NCT01353625

  Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
14

NCT02343406

  Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE 2)
14

NCT01949948

  Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke
13

NCT01910259

  MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
13

NCT02798406

  Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
13

NCT03393000

  Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
13

NCT02379572

  Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas
13

NCT02212574

  Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
13

NCT01723020

  A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
13

NCT01177397

  Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
13

NCT01450449

  Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme
13

NCT00276640

  Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas
13

NCT01089101

  Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
13

NCT01432171

  Lacosamide for Seizure Prophylaxis in High-Grade Gliomas
13

NCT01528046

  Metformin in Children With Relapsed or Refractory Solid Tumors
13

NCT03184090

  Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC
13

NCT03389802

  Phase I Study of APX005M in Pediatric CNS Tumors
12

NCT03212274

  Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
12

NCT01822522

  Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
12

NCT01990768

  Prehospital Tranexamic Acid Use for Traumatic Brain Injury
12

NCT01218529

  Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors
12

NCT01507506

  Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma
12

NCT01149109

  Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients
12

NCT01520870

  Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
12

NCT01158651

  Study of RAD001 (Everolimus) for Children With NF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
12

NCT02209948

  Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.
12

NCT02019576

  Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib
12

NCT01631552

  Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
12

NCT02537600

  Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis
12

NCT02658279

  Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
12

NCT02285439

  Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors
12

NCT03216148

  18F-FET PET in Childhood Brain Tumours
12

NCT03044834

  Review of the Paediatric Pleuropulmonary Blastoma French Series
12

NCT02395016

  A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer
12

NCT02135926

  Comparison of Thrombectomy and Standard Care for Ischemic Stroke in Patients Ineligibility for Tissue Plasminogen Activator Treatment
12

NCT02353598

  A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease
12

NCT02008721

  Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach
11

NCT02091999

  A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
11

NCT02381886

  A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
11

NCT02743078

  Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
11

NCT02255461

  Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
11

NCT01125800

  A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
11

NCT02047214

  Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
11

NCT02073994

  Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
11

NCT01975116

  p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
11

NCT01967810

  ANG1005 in Patients With Recurrent High-Grade Glioma
11

NCT01802567

  Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
11

NCT01012609

  External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
11

NCT01494662

  HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
11

NCT01514201

  Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
11

NCT01220271

  A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
11

NCT01239316

  Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
11

NCT02240264

  Effect of Omega-3 LCPUFA Intervention on Learning, Cognition, Behaviour and Visual Processing.
11

NCT02450552

  Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
11

NCT02717455

  Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
10

NCT02748135

  A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
10

NCT02658981

  Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma
10

NCT02844439

  Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
10

NCT03080883

  Apixaban in Preventing Secondary Cancer Related Blood Clots in Cancer Patients Who Have Completed Anticoagulation Therapy
10

NCT01386580

  An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
10

NCT01354002

  Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility
10

NCT00796978

  Trastuzumab in Treating Older Women With Early-Stage Breast Cancer
10

NCT01156584

  A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma
10

NCT01503086

  Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy
10

NCT01836549

  Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
10

NCT02017717

  A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
10

NCT01756729

  Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
10

NCT02197637

  Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
10

NCT01248949

  A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
10

NCT02273739

  Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
10

NCT02115139

  GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases
10

NCT02311920

  Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
10

NCT02423343

  A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma
10

NCT02357498

  Transsphenoidal Extent of Resection Study
10

NCT02616393

  Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
10

NCT02746081

  Phase I Study of BAY 1436032 in Patients With IDH1-mutant Solid Tumors
10

NCT01282437

  Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC
9

NCT01446744

  Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)
9

NCT01454102

  Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
9

NCT01997684

  Colonic Stenting With Elective Surgery Versus Emergency Surgery in the Management of Acute Malignant Colonic Obstruction
9

NCT02104986

  A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
9

NCT02056236

  TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation
9

NCT02899715

  Panobinostat in Treating Younger Patients With Progressive Diffuse Intrinsic Pontine Glioma
9

NCT02971319

  Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma
9

NCT02858895

  Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
9

NCT02866747

  A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma
9

NCT03033992

  Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
9

NCT02971501

  Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
9

NCT02974621

  Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
9

NCT03180502

  Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
9

NCT02455245

  A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
9

NCT02481154

  Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
9

NCT01165333

  Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma
9

NCT01587144

  Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)
9

NCT01345370

  Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients
9

NCT01449461

  A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
9

NCT02013297

  Study of SBRT Efficacy on Intra and Extra -Cranial Tumors or Metastasis in Pediatrics Population (SBRT Pediatrics)
9

NCT01790503

  A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
9

NCT03098511

  CT-Perfusion for Neurological Diagnostic Evaluation
9

NCT02498665

  A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
9

NCT02532569

  Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj
9

NCT02213263

  A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
9

NCT03373370

  Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology
9

NCT03034135

  Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
8

NCT02962167

  Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
8

NCT03216499

  HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
8

NCT02993146

  Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
8

NCT02589522

  VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
8

NCT03107780

  MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma
8

NCT02677545

  Ticagrelor Versus Clopidogrel in Carotid Artery Stenting
8

NCT01780675

  Hippocampus Avoidance PCI vs PCI
8

NCT01349660

  Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
8

NCT00687765

  Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma
8

NCT01137682

  Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
8

NCT01283542

  Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.
8

NCT02454634

  Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas
8

NCT02389855

  Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry
8

NCT02337491

  Pembrolizumab +/- Bevacizumab for Recurrent GBM
8

NCT02336165

  Phase 2 Study of MEDI4736 in Patients With Glioblastoma
8

NCT01964300

  Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery
8

NCT03240653

  Gaucherite - A Study to Stratify Gaucher Disease
8

NCT02272855

  A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
8

NCT02327078

  A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
8

NCT02008877

  Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
7

NCT02058056

  Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLC
7

NCT01763606

  Enoxaparin Versus Aspirin in Patients With Cancer and Stroke
7

NCT01349842

  Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast Cancer
7

NCT01222221

  Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
7

NCT01151631

  Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache
7

NCT00512109

  Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)
7

NCT02798029

  Frameless Fractionated Stereotactic Radiation Therapy (FSRT) for Brain Mets Study
7

NCT02147028

  Hippocampal Sparing Whole Brain Radiotherapy vs Conventional Whole Brain Radiotherapy in Patients With Brain Metastases
7

NCT02903069

  Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
7

NCT03276286

  Nativis Voyager for Newly Diagnosed GBM
7

NCT02977780

  INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
7

NCT02981940

  A Study of Abemaciclib in Recurrent Glioblastoma
7

NCT02101905

  Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
7

NCT02133183

  Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
7

NCT01812616

  A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients
7

NCT02185352

  Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy in Breast Cancer With Brain Metastases
7

NCT02299089

  Phase II Study of Subcutaneous Injection Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
7

NCT02429570

  Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
7

NCT02395692

  Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma
7

NCT02415153

  Pomalidomide in Treating Younger Patients With Recurrent, Progressive or Refractory Central Nervous System Tumors
7

NCT02530320

  Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
7

NCT02650752

  Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
7

NCT02725684

  Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
7

NCT01390571

  Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma
7

NCT01339052

  Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
7

NCT01310868

  Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
7

NCT01480050

  Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
7

NCT01604512

  A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression
7

NCT01651078

  Laser Ablation After Stereotactic Radiosurgery
7

NCT01601184

  Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
7

NCT01755624

  Effect of NovoTTF-100A in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)
7

NCT01933815

  Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
7

NCT02034799

  Phase IV Bioseal Study in Meningioma Surgery
7

NCT01870726

  Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
7

NCT01892397

  Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
7

NCT02536261

  Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus
7

NCT02601950

  A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
7

NCT03186638

  Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy
7

NCT02698917

  Carbon Dioxide, Oxygen and Mean Arterial Pressure After Cardiac Arrest and Resuscitation
7

NCT02835599

  Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now
7

NCT03058289

  A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
6

NCT03245151

  Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
6

NCT02852655

  A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
6

NCT02926222

  Regorafenib in Relapsed Glioblastoma
6

NCT02750891

  A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
6

NCT03054363

  Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
6

NCT03637764

  Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
6

NCT03520504

  Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases
6

NCT03423628

  A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
6

NCT03526900

  Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis
6

NCT02797366

  Proton Radiotherapy for Primary Central Nervous System Tumours in Adults
6

NCT03449381

  This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)
6

NCT02974803

  Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
6

NCT03343197

  Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
6

NCT01739933

  The MENDSII Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
6

NCT01425944

  Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome
6

NCT01607905

  Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer
6

NCT01473095

  Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
6

NCT02022293

  Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis
6

NCT02049489

  A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma
6

NCT01483820

  Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
6

NCT01621906

  18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain
6

NCT01724606

  Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)
6

NCT01470794

  Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
6

NCT01349036

  A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma
6

NCT01402063

  PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
6

NCT01226940

  Lenalidomide and Radiation Therapy in Treating Young Patients With Pontine Glioma or High-Grade Glioma
6

NCT01222754

  Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
6

NCT00392327

  Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
6

NCT00883688

  Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
6

NCT00602667

  Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
6

NCT00826241

  Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
6

NCT02659800

  IL-7 in Increasing Low CD4 Counts After Concurrent Radiation and Temozolomide Treatment in Patients With High Grade Gliomas
6

NCT02574728

  Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
6

NCT02498951

  Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete Response
6

NCT02026271

  A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
6

NCT02149225

  GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
6

NCT02726074

  Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures
6

NCT02639767

  Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma
6

NCT02575365

  Effect of Fingolimod on Neurodegeneration
6

NCT02535312

  Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and Pemetrexed
6

NCT02540356

  Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
6

NCT02509156

  Stem Cell Injection in Cancer Survivors
6

NCT02397928

  Safety and Efficacy of TTFields Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma
6

NCT02192333

  Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors
6

NCT01976936

  Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
5

NCT01858168

  Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma
5

NCT01443078

  Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
5

NCT01770353

  Pilot Study to Determine Biodistribution of MM-398 and Feasibility of Ferumoxytol as a Tumor Imaging Agent
5

NCT01747863

  Prospective Research in Infants With Mild Encephalopathy
5

NCT01675765

  Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
5

NCT01638533

  Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
5

NCT01221246

  Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
5

NCT00904735

  Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma
5

NCT01014767

  Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
5

NCT02423863

  In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
5

NCT02765165

  Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM)
5

NCT02353000

  Whole Brain Radiotherapy (WBRT) Versus Stereotactic Radiosurgery (SRS) for 4 Upto 10 Brain Metastases
5

NCT00394628

  AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
5

NCT03213704

  Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
5

NCT03220646

  The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.
5

NCT03206021

  Treatment of Children With Recurrent Refractory Brain/Solid Tumors and Recurrent Ependymoma
5

NCT03149575

  VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
5

NCT02274987

  Molecular Profiling for Individualized Treatment Plan for DIPG
5

NCT02215512

  Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
5

NCT02154529

  Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
5

NCT02115074

  Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas
5

NCT02386826

  INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
5

NCT02455557

  SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
5

NCT02394626

  Surgery for Recurrent Glioblastoma
5

NCT02375841

  Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers
5

NCT02330562

  Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
5

NCT02365662

  A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
5

NCT00879437

  Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
5

NCT01392209

  Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma
5

NCT01462695

  Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
5

NCT01478178

  Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
5

NCT01543542

  A Phase II Multi-institutional Study Assessing Simultaneous In-field Boost Helical Tomotherapy for 1-3 Brain Metastases
5

NCT00859222

  LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
5

NCT01145170

  Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma
5

NCT01106508

  A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
5

NCT01621542

  Clinical Study of WT2725 in Patients With Advanced Malignancies
5

NCT01305122

  Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma
5

NCT01478321

  Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
5

NCT01970865

  A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
5

NCT01989884

  An Efficacy Study Of Ortataxel In Recurrent Glioblastoma
5

NCT01792310

  A Phase 1/2A Study of Minerval in Adult Patients With Advanced Solid Tumours
5

NCT01849146

  Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
5

NCT02194231

  ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)
5

NCT02244541

  Phase 2a Dose Finding, PK/PD and 6 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease
5

NCT02223052

  Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
5

NCT02457039

  Acupuncture Prevents Chemobrain in Breast Cancer Patients
5

NCT02469922

  Positron Emission Tomography (PET) During Radio-chemotherapy to Treat Otorhinolaryngological Cancer
5

NCT02752178

  Peripheral Immunomarker Validation in Treatment-resistant Depression
5

NCT02880956

  A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
5

NCT03032471

  Swiss SOS MoCA - DCI Study
5

NCT02906020

  A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation
5

NCT03343613

  A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
5

NCT03424980

  A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors
5

NCT02880410

  Feasibility Study on LITT for Newly Diagnosed Glioblastoma
4

NCT02968940

  Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
4

NCT02619864

  mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
4

NCT02909777

  Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
4

NCT02490800

  Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
4

NCT02859857

  Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors
4

NCT02768389

  Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
4

NCT02799238

  Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma
4

NCT02399254

  The Trajectory of Physical Activity Following Pulmonary Rehabilitation
4

NCT03466450

  Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma
4

NCT02167022

  Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy
4

NCT03416530

  ONC201 in Pediatric H3 K27M Gliomas
4

NCT03355794

  A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
4

NCT03297346

  Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer
4

NCT03561896

  Hypofractionated Brain Radiationcavity
4

NCT00006128

  Study of Neurobehavioral Outcome in Children or Adolescents With Closed Head Injuries
4

NCT00576654

  Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
4

NCT00766987

  Cardiac FDG PET Viability Registry
4

NCT00830531

  Pilot Study of Bumetanide for Newborn Seizures
4

NCT01371201

  First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
4

NCT01290809

  Prophylactic Cranial Irradiation (PCI) Cognitive Tests in Non-small Cell Lung Cancer (NSCLC) Patients
4

NCT01362803

  AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
4

NCT01332929

  Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis
4

NCT01764529

  Modifiers of Disease Severity in Cerebral Cavernous Malformations
4

NCT01735188

  A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies
4

NCT01475006

  AMG 595 First-in-Human in Recurrent Gliomas
4

NCT01856738

  Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease
4

NCT01783847

  Traumatic Optic Neuropathy Treatment Trial (TONTT)
4

NCT01905228

  A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
4

NCT01934894

  Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
4

NCT01849952

  Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
4

NCT01985256

  Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
4

NCT02014844

  Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
4

NCT01564914

  A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab
4

NCT01107522

  Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
4

NCT00902577

  MRI and PET Scan Using 18F-Fluoromisonidazole In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
4

NCT01599052

  Social Cognition in Children Treated for a Brain Tumour
4

NCT01518413

  Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
4

NCT01257594

  EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
4

NCT00293475

  Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
4

NCT01170000

  Timely End-of-Life Communication to Parents of Children With Brain Tumors
4

NCT01112527

  PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
4

NCT02336451

  A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
4

NCT02359565

  Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
4

NCT02374242

  Anti?PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
4

NCT02460068

  A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
4

NCT02155920

  Everolimus for Children With Recurrent or Progressive Ependymoma
4

NCT02296476

  A Trial With Dose Optimization of OTX015 in Recurrent Glioblastoma Multiforme (GBM) Patients
4

NCT02607397

  ROCOCO - Low Grade Glioma - Planning Study
4

NCT02644460

  Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
4

NCT03336931

  PRecISion Medicine for Children With Cancer
4

NCT02928692

  Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium
4

NCT02996084

  MS PATHS Normative Sub-Study
4

NCT03056729

  Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease
4

NCT03192332

  Bridging Thrombolysis Versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke
4

NCT03129438

  Continuous EEG Randomized Trial in Adults
4

NCT03098732

  Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial
4

NCT03127709

  A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis
4

NCT03222258

  Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
4

NCT02775136

  An Evaluation of a Non-invasive Brain Monitor
4

NCT02480985

  The PIT-TBI Pilot Study
4

NCT02578979

  Serial ECG Versus Holter to Detect Atrial Fibrillation in Elderly Ischemic Stroke Patients
4

NCT02227576

  Prevention of Thrombocytopenia in Glioblastoma Patients
4

NCT02295826

  Dabigatran Following Transient Ischemic Attack and Minor Stroke
4

NCT01931579

  Assessment of Probe Based Confocal Laser Endo-microscopy for In-vivo Diagnosis of Peripheral Lung Nodules and Masses.
3

NCT01840449

  Somatuline Predictive Factors in Acromegaly and NET
3

NCT01848652

  Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.
3

NCT01955395

  Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
3

NCT02098005

  Pain Neuroscience Education Combined With Cognition-targeted Motor Control Training
3

NCT02065297

  Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
3

NCT02066103

  Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients
3

NCT02122185

  Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
3

NCT01778855

  Hypothermia in Acute Stroke With Thrombolysis Imaging Evaluation of Revascularization
3

NCT01796015

  Intracranial Hypertension and Optic Nerve Sheath Diameter
3

NCT01239134

  Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
3

NCT00716066

  Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy
3

NCT00649207

  A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
3

NCT01054599

  Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?
3

NCT00398437

  Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
3

NCT03589014

  Treat_CCM: Propranolol in Cerebral Cavernous Malformation
3

NCT03610763

  Harnessing Neuroplasticity to Enhance Functional Recovery During Chronic Recovery From Upper Extremity Nerve Repair
3

NCT03491683

  INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
3

NCT03551600

  Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
3

NCT03522298

  Safety, Pharmacokinetics and Efficacy of GDC-0084 in Newly-diagnosed Glioblastoma Multiforme
3

NCT03525002

  Dopamine Action on Metabolism in Relation to Genotype
3

NCT03395587

  Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma
3

NCT03398694

  Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients With Brain Metastases
3

NCT03143322

  Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 3 Bone-only Metastases
3

NCT02895360

  Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma
3

NCT03373487

  Cognitive Rehabilitation in Brain Tumor Patients After Neurosurgery
3

NCT03189381

  Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases
3

NCT03382977

  Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
3

NCT03411408

  Accelerated Hypofractionated Intensity - Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent High Grade Glioma.
3

NCT03422679

  Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
3

NCT02774681

  Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
3

NCT02364206

  Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
3

NCT02768337

  Cambridge Brain Mets Trial 1
3

NCT02576665

  A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
3

NCT02465268

  Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
3

NCT02783300

  Dose Escalation Study of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
3

NCT02871843

  Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
3

NCT02885324

  Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children
3

NCT03071874

  Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
3

NCT03137888

  Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
3

NCT03208387

  Understanding the Late Effects of Surviving a Pediatric Brain Tumor
3

NCT03250299

  Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
3

NCT03295396

  ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
3

NCT03330197

  A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG
3

NCT02525692

  Oral ONC201 in Adult Recurrent Glioblastoma and H3 K27M-mutant Glioma
3

NCT02704858

  Safety and Efficacy Study in Recurrent Grade IV Glioma
3

NCT02288962

  Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas
3

NCT02286531

  Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma
3

NCT02270034

  Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
3

NCT02082587

  Toronto BNB Pilot Study
3

NCT02430727

  The Safety and Efficacy Study of Afatinib (CT) Compared With Afatinib (GIOTRIF) in Patients With Solid Tumors (Including Mutations Identified EGFR)
3

NCT02332889

  Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
3

NCT02315534

  A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
3

NCT02338609

  Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301
3

NCT02282917

  Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
3

NCT01189266

  Vorinostat and Radiation Therapy Followed By Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Pontine Glioma
3

NCT00899834

  DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
3

NCT00916630

  Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
3

NCT00302159

  Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
3

NCT00275067

  Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
3

NCT00766467

  A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
3

NCT01295762

  Immunomonitoring of Children With Neuroblastoma
3

NCT01295944

  Carboplatin and Bevacizumab for Recurrent Ependymoma
3

NCT01326104

  Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
3

NCT01380782

  BIBF 1120 for Recurrent High-Grade Gliomas
3

NCT01525459

  Gene Expression, Immunological Status and Metabolome in Glioma Patients
3

NCT01445691

  More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
3

NCT01551680

  A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases
3

NCT00551122

  Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
3

NCT01138033

  Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors
3

NCT01149850

  Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
3

NCT01189240

  R04929097 and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
3

NCT01236560

  Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
3

NCT01621295

  Assessing the Patient Experience in Cancer Care
3

NCT01617733

  Pasireotide Therapy in Patients With Nelson's Syndrome
3

NCT01466686

  Low Dose Radiation Therapy for Glioblastoma Multiforme
3

NCT01295632

  Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049 AM1)
3

NCT01391143

  Safety Study of MGA271 in Refractory Cancer
3

NCT01670890

  Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas
3

NCT02038218

  Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors
3

NCT01898130

  Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
3

NCT01812603

  A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
3

NCT02359097

  Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma
3

NCT02228369

  Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
3

NCT02533921

  Does Outpatient Palliative Care Improve Patient-centered Outcomes in Parkinson's Disease?
3

NCT02637674

  Uterine Allotransplantations Using Uterine Grafts From Brain-dead Female Donors
3

NCT02633501

  P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
3

NCT02626377

  Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté
3

NCT02601339

  NIRS Monitoring in Premature Infants
3

NCT02505165

  Illness Management and Parental Adjustment to Cancer Treatment
3

NCT02704819

  Proof of Concept Study of EMBalance Decision Support System to Evaluate Balance Disorders
3

NCT03143894

  Reducing Breast Cancer-related Fatigue and Improving Cognition With Non-Invasive Brain Stimulation
3

NCT03208413

  The Therapeutic Effect of Thalidomide in RN
3

NCT03248557

  Prognostic Value of Ventricular Fibrillation Spectral Analysis in Sudden Cardiac Death
3

NCT03095417

  Improving the Recovery and Outcome Every Day After the ICU
3

NCT03091634

  The Efficacy and Safety of the Xue-Fu-Zhu-Yu Capsule in Treatment of Qi Stagnation and Blood Stasis Syndrome.
3

NCT02920580

  The NEUROlogically-impaired Extubation Timing Trial
3

NCT02997995

  Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure
3

NCT02946866

  The Natural History of Prospective Symptomatic Hemorrhage in Adult Patients With Cerebral Cavernous Malformation
3

NCT03242824

  The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
3

NCT03470857

  Oxidoreductive Balance and Lysosomal Activity in Cancer Patients.
3

NCT03332355

  Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
3

NCT03371004

  DM-CHOC-PEN Plus Radiation for Brain Tumors
3

NCT03439215

  PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer
3

NCT03279692

  Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
2

NCT03181477

  Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas
2

NCT03184038

  Assessment of Neurocognitive Function in Patients With Multiple Brain Metastases Undergoing Stereotactic Radiosurgery or Stereotactic Body Radiation Therapy
2

NCT03139916

  Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
2

NCT03152318

  A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
2

NCT03075072

  Whole Brain Radiation Versus Stereotactic Radiation (SRS) in Patients With 5-20 Brain Metastases: A Phase III, Randomized Clinical Trial
2

NCT03088579

  Intraoperative Brachytherapy for Central Nervous System Lesions: A Validation Study of a Radioactive Seed Loading Device
2

NCT02766699

  A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)
2

NCT02858869

  Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
2

NCT00002647

  Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
2

NCT02853565

  A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme
2

NCT02847559

  Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
2

NCT02928575

  Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma
2

NCT02886585

  Pembrolizumab In Central Nervous System Metastases
2

NCT02644291

  Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
2

NCT02307604

  SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access
2

NCT02693990

  A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
2

NCT02771301

  Safety and Efficacy of IDH1R132H-DC Vaccine in Gliomas
2

NCT02663271

  TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
2

NCT03429803

  TAK-580 In Gliomas and Other Tumors
2

NCT02575794

  Terameprocol in Treating Patients With Recurrent High Grade Glioma
2

NCT03412955

  A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes
2

NCT03048084

  Seizure Treatment in Glioma
2

NCT03383978

  Intracranial Injection of NK-92/5.28.z (HER2.taNK) Cells in Patients With Recurrent HER2-positive Glioblastoma (Quilt 3.C001)
2

NCT02982122

  CPPopt Guided Therapy: Assessment of Target Effectiveness
2

NCT03224104

  Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma
2

NCT03523923

  TBI Care: Collaborative Care for Pain After Traumatic Brain Injury (TBI)
2

NCT03487601

  Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function
2

NCT03595878

  Trial of Parotid Sparing Whole Brain Radiation
2

NCT03476070

  Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS)
2

NCT03496181

  Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently
2

NCT03574974

  Neurofeedback of Amygdala Activity for Post-traumatic Stress Disorder
2

NCT03623828

  Treating Severe Brain-injured Patients With Apomorphine
2

NCT03632135

  Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma
2

NCT03633552

  Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma
2

NCT03633955

  Pilot Imaging Study of Leukemia
2

NCT03636477

  A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
2

NCT03639896

  Endothelial Injury Mechanism of in Elderly Patients Undergoing Major Surgery
2

NCT00185848

  Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
2

NCT00240760

  Memantine and Down's Syndrome
2

NCT01158170

  Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)
2

NCT01042730

  Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)
2

NCT01066156

  Post-Traumatic Stress Disorder (PTSD) and Seroquel
2

NCT00905281

  Study of Impact of Routine "Clinical Cancer Department/Supportive Care Department" Consultation on the Prescription of an Additional Line of Chemotherapy
2

NCT01217411

  RO4929097 And Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
2

NCT01252875

  Treat Stroke to Target
2

NCT01197144

  Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab
2

NCT01205334

  Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
2

NCT01176487

  Palliative 3-Dimensional Conformal Radiation Therapy in Reducing Radiation Side Effects in Patients With Lung Cancer
2

NCT01339039

  Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
2

NCT01339858

  The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
2

NCT01301391

  Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
2

NCT01322100

  Electrochemotherapy as a Palliative Treatment for Brain Metastases
2

NCT01332916

  Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging
2

NCT01371760

  BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis)
2

NCT01387490

  CONcussion Treatment After Combat Trauma (CONTACT)
2

NCT01395407

  Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
2

NCT01797159

  Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer
2

NCT01768052

  Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
2

NCT01748448

  Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome
2

NCT01682824

  MyChoice: An Application of the Three-Factor Eating Questionnaire (TFEQ-R18v2) Among Adolescent and Young Adult Survivors of Central Nervous System (CNS) Tumors
2

NCT01706094

  Head Position in Stroke Trial
2

NCT01722305

  Study of Pomalidomide for Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma and Newly Diagnosed or Relapsed/Refractory Intraocular Lymphoma
2

NCT01570283

  ARMS - Rapidly Generated Multivirus-Specific CTLs for the Prophylaxis And Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus
2

NCT01423201

  Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk
2

NCT01514214

  Winged Perimeter Versus Traditional Plastic Biliary Stent for Malignant Bile Duct Obstruction
2

NCT02122107

  Cognition in Older Breast Cancer Survivors: Treatment Exposure, APOE and Smoking History
2

NCT02024438

  Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer
2

NCT02019147

  BiHiVE2 Study. The Investigation and Validation of Predictive Biomarkers in Hypoxic-ischaemic Encephalopathy.
2

NCT02019654

  An Investigation of the Biological and Neuronal Mechanisms of Post Traumatic Stress Disorder, Depression and Post-Concussive Syndrome Onset Following a Traumatic Brain Injury
2

NCT01999309

  Simvastatin Addition for Patients With Recent-onset Schizophrenia
2

NCT01992432

  Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)
2

NCT01962779

  Sleep, Aging and Risk for Alzheimer's Disease
2

NCT01851083

  Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury
2

NCT01854385

  Sumatriptan as Treatment for Post-traumatic Headache
2

NCT01831622

  Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder
2

NCT01836354

  Discharge Educational Strategies for Reduction of Vascular Events
2

NCT01836536

  Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
2

NCT01870947

  Assisted Exercise in Obese Endometrial Cancer Patients
2

NCT01861145

  Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea
2

NCT01866228

  Clinical Trial of the Impact of Treatment Consultation Recordings on Cancer Patient Outcomes
2

NCT01874756

  The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
2

NCT01886131

  Motor Control During Rapid Eye Movement (REM) Sleep Behaviour Disorder
2

NCT01774253

  Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
2

NCT01857453

  Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas
2

NCT02028325

  Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions
2

NCT02015117

  Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
2

NCT01751308

  Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
2

NCT01894061

  NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
2

NCT01872221

  Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study
2

NCT01975701

  A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
2

NCT01921335

  ARRY-380 + Trastuzuamab for Breast w/ Brain Mets
2

NCT01868906

  FMISO-PET in Brain Tumors and SCS Effect
2

NCT01737671

  Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study
2

NCT01502605

  Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
2

NCT01466036

  Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
2

NCT01290939

  Bevacizumab and Lomustine for Recurrent GBM
2

NCT01702792

  Derivation of Tumor Specific Hybridomas
2

NCT01703507

  Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases
2

NCT01248754

  Positron Emission Tomography (PET) With 3,4-dihydroxy-6-18F-fluoro-L-enylalanine (18F-FDOPA) Study
2

NCT01497860

  Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
2

NCT01290263

  Amgen 386 for Recurrent Glioblastoma
2

NCT01486459

  A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer
2

NCT01062425

  Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
2

NCT00967330

  A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma
2

NCT00821080

  Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
2

NCT01469247

  Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
2

NCT01538095

  Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
2

NCT01568359

  Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors
2

NCT01218542

  Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
2

NCT01438307

  Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
2

NCT01478854

  Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide
2

NCT01331291

  Bosutinib in Adult Patients With Recurrent Glioblastoma
2

NCT01419067

  A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection
2

NCT01269918

  A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
2

NCT01182415

  High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma
2

NCT01188096

  A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
2

NCT00634231

  A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
2

NCT00862173

  Gene-expression Profiles in CNS-metastatic Non-small Cell Lung Cancer
2

NCT00452959

  Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors
2

NCT00461188

  Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
2

NCT00470366

  Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
2

NCT00303849

  Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
2

NCT01063114

  Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma
2

NCT00983398

  Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
2

NCT00992602

  Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer
2

NCT01144988

  Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma
2

NCT00890786

  A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
2

NCT01109095

  CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
2

NCT02311582

  MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
2

NCT02481960

  Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade Glioma
2

NCT02466828

  qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.
2

NCT02478164

  Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
2

NCT02452294

  Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)
2

NCT02581839

  Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
2

NCT02502708

  Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
2

NCT02340156

  Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
2

NCT02402075

  Spinal Motor Evoked Potentials in Brain Surgery
2

NCT02430363

  Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
2

NCT02286167

  Glioma Modified Atkins-based Diet in Patients With Glioblastoma
2

NCT02260531

  Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
2

NCT02157103

  A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
2

NCT02234297

  Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery
2

NCT02153957

  Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors
2

NCT01978236

  Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
2

NCT02137759

  MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
2

NCT02142803

  TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
2

NCT02073968

  PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer
2

NCT02129335

  Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner
2

NCT02077543

  Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma
2

NCT02100891

  Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors
2

NCT02729558

  Local Radiotherapy Following Complete Resection of a Brain Metastasis
2

NCT03239938

  Modern Pain Neuroscience Applied to Chronic Pain in Patients With Chronic Whiplash Associated Disorders
2

NCT03370653

  A Study in MPS VI to Assess Safety and Efficacy of Odiparcil
2

NCT03248544

  Therapeutic Benefit of Preoperative Supplemental Vitamin D in Patients Undergoing Brain Tumor Surgery
2

NCT03288168

  Multi-center Study on Children's and Adolescents' Medulloblastoma Molecular Subgroups in China
2

NCT03344419

  Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders
2

NCT02902029

  Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
2

NCT02987413

  Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients
2

NCT02937077

  Atrial Fibrillation in Cryptogenic Stroke and TIA
2

NCT03089918

  A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain
2

NCT03048032

  Lithuanian Echocardiography Study of Dyspnea in Acute Settings
2

NCT03016741

  Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
2

NCT03103022

  Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus
2

NCT03113799

  A Study Evaluate Aqueduct's Smart External Drain
2

NCT03124641

  HOPE for Human Extended Criteria and Donation After Brain Death Donor (ECD-DBD) Liver Allografts
2

NCT03166592

  Evaluation of Intra Axial Brain Masses Based on Magnetic Resonance in Adults
2

NCT03191409

  Interaction Research on Cognitive Impairment and Emotional Disorder in End-stage Renal Disease
2

NCT03215342

  Cognitive Rehabilitation in Pediatric Acquired Brain Injury
2

NCT03234686

  Deferiprone to Delay Dementia (The 3D Study)
2

NCT02706964

  Imaging the Patterns of Breast Cancer Early Metastases
2

NCT02698384

  Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
2

NCT02684773

  In-Centre Nocturnal Hemodialysis (INHD): A Long-Term Follow-Up Study
2

NCT02675491

  Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors
2

NCT02646319

  Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
2

NCT02779712

  Remote Ischaemic Conditioning After Stroke Trial (ReCAST-2)
2

NCT02782975

  Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
2

NCT02811250

  Stereotactic Radiotherapy for Renal Cancers
2

NCT02893553

  The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury
2

NCT02844504

  Neurophysiological Evaluation of Training Effect on Cancer-Related Weakness
2

NCT02519907

  Surface Electrical Stimulation for Treatment of Phantom Limb Pain
2

NCT02521051

  Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
2

NCT02475057

  Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists
2

NCT02410200

  Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
2

NCT02402543

  Pre-Emptive Analgesia in Ano-Rectal Surgery
2

NCT02402777

  A Study Of Effectiveness Of Axitinib (CT), In Comparison With Axitinib - Pfizer (INLYTA) Confirmed Objective Response (ORR) In Patients With Solid Tumors
2

NCT02431572

  A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
2

NCT02418351

  A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
2

NCT02422641

  Prospective Evaluation of High-dose (8 g/m2) Systemic Methotrexate in Patients With Breast Cancer and Leptomeningeal Metastasis
2

NCT02587806

  A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
2

NCT02630732

  Back School or Brain School for Patients Undergoing Surgery for Lumbar Radiculopathy?
2

NCT02604667

  Mechanisms of Ischemic Stroke in Cancer Patients
2

NCT02641405

  Efficacy of Proprioceptive Focal Stimulation (EQUISTASI) on Gait Parameters in Parkinson. Italian Multicentric Study
2

NCT02541032

  PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke
2

NCT02552628

  WILSTIM - DBS (WILson STIMulation - Deep Brain Stimulation)
2

NCT02227433

  A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.
2

NCT02558569

  The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block
2

NCT02239978

  Effect of Levodopa on Postural Motor Learning in Parkinson Disease
2

NCT02240199

  Perioperative Pregabalin and Lidocaine to Reduce Chronic Breast Cancer Pain
2

NCT02252315

  Written Versus Verbal Education for Mild Traumatic Brain Injury
2

NCT02161055

  Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury
2

NCT02162329

  Meditation on Cognitive Function
2

NCT02378883

  Apollo™ Onyx™ Delivery Micro Catheter Post Market Safety Study
2

NCT02325505

  Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma
2

NCT02347917

  A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
2

NCT02330679

  Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis
2

NCT02290834

  Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
2

NCT02292368

  Neurological Effects of Acupuncture
2

NCT02305264

  Imaging of Intracerebral Inflammation in MS
2

NCT01890590

  A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
1

NCT01894802

  Cortical Recording and Stimulating Array Brain-Machine Interface
1

NCT01897025

  Combined Transcranial Direct Current Stimulation and Motor Imagery-based Robotic Arm Training for Stroke Rehabilitation
1

NCT01903525

  DHA For The Treatment of Pediatric Concussion Related to Sports Injury
1

NCT01881191

  Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months
1

NCT01884194

  Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging
1

NCT01873911

  Neurobehavioral Phenotypes in MPS III
1

NCT01874119

  Fosaprepitant for Nausea and Vomiting During High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Renal Cell Carcinoma
1

NCT01866813

  Internet-Delivered Cognitive Training For Breast Cancer Survivors With Cognitive Complaints
1

NCT01868490

  The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells
1

NCT01869673

  A Comparison of the Face Mask and Oral Mask Ventilation After Nasal Surgery
1

NCT01861990

  Valproic Acid in Childhood Progressive Brain Tumors
1

NCT01933269

  FACBC for Head and Neck Cancers
1

NCT01905917

  The Singapore Tele-technology Aided Rehabilitation in Stroke (STARS) Study
1

NCT01905995

  Basal Ganglia Local Field Potentials in Gait and Speech
1

NCT01913093

  N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors
1

NCT01913782

  The Impact of Epidural Steroid Analgesia on Functional MRI for Patients With LBP
1

NCT01917903

  Walking While Talking: The Effect of Doing Two Things at Once in Individuals With Neurological Injury or Disease
1

NCT01931488

  124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.
1

NCT01949961

  The Norwegian Sonothrombolysis in Acute Stroke Study
1

NCT01949376

  Mild Cognitive Impairment in Breast Cancer Patients
1

NCT01935011

  DBS Frequency on Swallowing Function in Parkinson's Disease
1

NCT01936792

  Pathology in the Brain After mTBI - A Multimodal MRI Study
1

NCT01941147

  Extremely Low Frequency Magnetic Fields in Acute Ischemic Stroke
1

NCT01941927

  Trametinib With GSK2141795 in BRAF Wild-type Melanoma
1

NCT01947413

  New Protocols in the Treatment of Upper Limb Dysfunctions of Patients With Stroke.
1

NCT01836640

  Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer
1

NCT01832350

  Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease
1

NCT01839396

  Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease
1

NCT01793168

  Rare Disease Patient Registry: Coordination of Rare Diseases at Sanford
1

NCT01793714

  Presurgical Language Mapping With fMRI: Comparison of BOLD and fASL Techniques
1

NCT01794858

  Therapeutic Hypothermia for Severe Acute Pancreatitis
1

NCT01781026

  Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
1

NCT01822964

  Oxygenation of the Cerebrum and Cooling During Transcatheter Aortic Valve Implantation (TAVI) Procedures - Part II
1

NCT01829425

  Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy
1

NCT01856270

  Amitriptyline to Prevent Headache After Traumatic Brain Injury
1

NCT01849042

  Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease
1

NCT01843673

  Image-Guided Adaptive Radiotherapy for in Detecting Tumors During Treatment in Patients With Head and Neck Cancer
1

NCT01847157

  Transcranial Direct Current Stimulation Combined Sensory Modulation Intervention in Chronic Stroke Patients
1

NCT01848327

  Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis
1

NCT01856842

  Reperfusion of Pulmonary Arteriovenous Malformations After Embolotherapy
1

NCT01860118

  LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease
1

NCT01860794

  Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease
1

NCT01864655

  Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease
1

NCT01865045

  Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
1

NCT01865578

  Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis
1

NCT01962883

  Effects of Osteopathic Treatment on Vestibular Disturbed Active Post Concussed Individual
1

NCT01970345

  A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder
1

NCT01973322

  Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study
1

NCT01959256

  Visual Perceptual Learning for the Treatment of Visual Field Defect
1

NCT01962064

  Social Cognition in Ageing and in Frontotemporal Lobar Degeneration
1

NCT01962415

  Reduced Intensity Conditioning in Patients Aged ?30 With Non-Malignant Disorders Undergoing Cord Blood Transplantation
1

NCT01981525

  A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome
1

NCT01984476

  Impact of Age on Cardiovascular, Cerebrovascular and Cognitive Health in Spinal Cord Injury
1

NCT01984892

  Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
1

NCT01985113

  Correlation Research of Thioredoxin Reductase in Lung Cancer
1

NCT01985750

  Understanding the Importance of Plasticity in the Brain Mechanisms of Dyspnoea Perception
1

NCT01986764

  E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy
1

NCT01988584

  Safety and Effectiveness of Banked Cord Blood or Bone Morrow Stem Cells in Children With Cerebral Palsy (CP).
1

NCT01995370

  Cilostazol Stroke Prevention Study for Antiplatelet Combination
1

NCT01997255

  Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
1

NCT02000986

  Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors
1

NCT02004028

  Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.
1

NCT02005237

  Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity
1

NCT02006121

  Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease
1

NCT02019693

  A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
1

NCT02019810

  Impact of Cardiac Blood Flow on Cerebral Blood Flow in Patients With Severe Traumatic Brain Injury
1

NCT02012114

  A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications
1

NCT02018497

  Essential Hypotension and Adaptability Registry
1

NCT02026596

  SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage
1

NCT02027987

  Traumatic Neuroprotection and Epilepsy Prevention of Valproate Acid
1

NCT02033291

  Blood-brain Barrier Quantification in Cerebral Small Vessel Disease
1

NCT02033941

  Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)
1

NCT02024412

  Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC
1

NCT02036853

  An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome
1

NCT02039791

  Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer
1

NCT02044471

  The IMPULSE Study: Pilot
1

NCT02046447

  Neuroimaging of Dystonia
1

NCT02051530

  Mood, Serotonin and Social Interaction
1

NCT02052024

  Myobloc Atrophy Study
1

NCT02052115

  Behavioral Weight Loss and Exercise After Treatment (BEAT)
1

NCT02054052

  Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer
1

NCT02058043

  Study of MRI 3Tesla Infusion Without Arterial Spin Labeling Injection (ASL) in Cognitive Atypical and Comparison to the FDG-PET
1

NCT02070887

  Inhibiting COMT in Parkinson's Disease
1

NCT02071056

  Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)
1

NCT02073396

  Assessment of Thrombotic Status in Patients at Risk of Cardiovascular Thrombosis
1

NCT02076711

  Myocardial Efficiency of the Left Ventricle in Asymptomatic Patients With Aortic Valve Stenosis - a Prognostic Marker and a Target for Intervention?
1

NCT02085278

  Safety of Apollo Micro Catheter in Pediatric Patients
1

NCT02087631

  Safety and Tolerability of Quetiapine in Multiple Sclerosis
1

NCT02091453

  Early Training of Attention After Acquired Brain Injury
1

NCT02098252

  Treatment of Brain AVMs (TOBAS) Study
1

NCT02098759

  Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex
1

NCT02061345

  PET Imaging in MCI Following ADT for PCa
1

NCT02092181

  A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)
1

NCT02097693

  Effect of DBS on Quality of Life in Dyskinetic Cerebral Palsy
1

NCT02097875

  Safety Study of a Fluorescent Marker to Visualize Cancer Cells
1

NCT02101879

  Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes
1

NCT02103465

  Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease
1

NCT02122991

  Cardiovascular, Cerebrovascular, and Cognitive Function in Spinal Cord Injury
1

NCT02125006

  The Effect of an Inter-Disciplinary Program, Including MBSR, in Breast Cancer Survivors With Chronic Neuropathic Pain
1

NCT02128152

  Mobility Training Using Exoskeletons for Functional Recovery After Stroke
1

NCT02107755

  Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
1

NCT02107989

  Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy
1

NCT02108210

  Cytokine Inhibition in Chronic Fatigue Syndrome Patients
1

NCT02110017

  Exploration of Neural Bases in Social Cognition
1

NCT02115165

  A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors
1

NCT01516983

  Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
1

NCT01532687

  Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma
1

NCT01540123

  The Time Effects of a Berry Extract Upon Cerebral Blood Flow.
1

NCT01545297

  Comparison of Dexmedetomidine and Propofol-Remifentanil Conscious Sedation for Awake Craniotomy for Tumor Surgery
1

NCT01547546

  A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
1

NCT01550523

  Pilot Immunotherapy Trial for Recurrent Malignant Gliomas
1

NCT01553916

  Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain
1

NCT01508494

  Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment
1

NCT01509612

  Additive Homeopathy in Cancer Patients
1

NCT01511588

  Hormonal Regulation of Puberty and Fertility
1

NCT01483196

  Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery
1

NCT01490060

  Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
1

NCT01497652

  A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients Receiving Dopaminergic Therapy
1

NCT01497808

  RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma
1

NCT01417520

  Clinical and Basic Investigations Into Erdheim Chester Disease
1

NCT01417546

  NHS-IL12 for Solid Tumors
1

NCT01428245

  Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition
1

NCT01429909

  Optimization of fMRI for the Study of Basal Ganglia Activation in Parkinson's Disease
1

NCT01432899

  Studying Childhood-Onset Hemidystonia
1

NCT01434355

  DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings
1

NCT01443468

  Clinical and Genetic Studies of Li-Fraumeni Syndrome
1

NCT01453621

  Traumatic Brain Injury - Knowledge Translation
1

NCT01459237

  Effects of Hormone Stimulation on Brain Scans for Cushing s Disease
1

NCT01460706

  Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT
1

NCT01465165

  Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression
1

NCT01468324

  AZD7451 for Recurrent Gliomas
1

NCT01570699

  Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients
1

NCT01573455

  The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells
1

NCT01575275

  Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
1

NCT01588821

  Cabozantinib in Advanced Solid Malignancies
1

NCT01588847

  Anesthesia and Cancer Recurrence im Malignant Melanoma
1

NCT01590160

  Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma
1

NCT01591772

  Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer
1

NCT01473693

  Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging
1

NCT01556178

  Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research
1

NCT01558687

  Cilengitide Imaging Trial in Glioblastoma
1

NCT01563614

  A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain
1

NCT01563731

  Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives
1

NCT01564693

  Cancer Anorexia and the Central Nervous System
1

NCT01566903

  Neurovascular Non Contrast-Enhanced MR Angiography at 3T
1

NCT01578083

  Chemotherapy-Induced Cognitive Impairment
1

NCT01580280

  Manual Therapy and Exercise in Patients With Cervicogenic Headache
1

NCT01600742

  Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis
1

NCT01602432

  Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients
1

NCT01603849

  Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma With High Risk of Brain Metastasis
1

NCT01610570

  Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma
1

NCT01614990

  Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
1

NCT01617395

  Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility
1

NCT01621880

  Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma
1

NCT01626638

  Confocal Micro-endoscopy in Head and Neck Cancer/Micro Endoscopie Confocale (MEC)Oto-Rhino-Laryngologie (ORL)
1

NCT01627535

  Feasibility of Intraoperative Optical Imaging and Spectroscopy in Brain Tumors
1

NCT01628029

  Multimodal Therapy for the Treatment of Sleep Disturbance in Patients With Advanced Cancer
1

NCT01728129

  DANA Compared to MACE in Evaluation of Suspected Acute Concussion
1

NCT01730495

  Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
1

NCT01733173

  Functional Imaging of Cerebellar Mutism Syndrome
1

NCT01734122

  Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
1

NCT01734733

  Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson's Disease
1

NCT01719315

  Neurophysiologic Correlates of Hypersomnia
1

NCT01721018

  Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
1

NCT01712074

  Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
1

NCT01712542

  Curcumin Bioavailability in Glioblastoma Patients
1

NCT01714531

  Improving Outcomes After Traumatic Injury: A Goal Management Approach
1

NCT01701284

  Repetitive Transcranial Magnetic Stimulation in Breast Cancer Patients With Depression and Anxiety
1

NCT01705210

  Functional MRI Biomarkers of Cognitive Decrements in Diabetes
1

NCT01632709

  Pathophysiology of Post Amputation Pain
1

NCT01637090

  Everolimus in Treating Cutaneous T-cell Lymphoma
1

NCT01686685

  Correlation of CXCR4 Expression in Premature Infants With a Diagnosis of Autism at 24 Months
1

NCT01690702

  Study of Nab-Paclitaxel in High Risk Early Breast Cancer
1

NCT01690819

  Protective Ventilatory Strategy in Severe Acute Brain Injury
1

NCT01698450

  MR-Guided Functional Ultrasound-Neurosurgery for Movement Disorders
1

NCT01699269

  Histopathologic Evaluation of High Grade Brain Tumors by High Order Diffusion Tensor Imaging
1

NCT01700166

  Umbilical Cord Blood in the Treatment of Stroke in Children.
1

NCT01639911

  MLN8237 and Pazopanib in Combination for Solid Tumors
1

NCT01641068

  Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms
1

NCT01641562

  Diagnosis and Prediction of Taxanes Induced Cardiac Dysfunction
1

NCT01642147

  Cerebral Blood Perfusion Changes After General Anesthesia for Craniotomy
1

NCT01644591

  Melanoma Gamma Knife
1

NCT01644994

  Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
1

NCT01652768

  PRESENCE Project: An Early Palliative Care Intervention in Brain Tumors
1

NCT01662414

  Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease
1

NCT01663545

  Brain P-gp and Inflammation in People With Epilepsy
1

NCT01672021

  Initial Assessment of 18FDG-PET/MRIin Determining the Extent of Systemic Disease in Breast Cancer Patients
1

NCT01674244

  Integrative Exercise for Post-Deployment Stress
1

NCT01750268

  Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI
1

NCT01752621

  Epidemiology of Acromegaly
1

NCT01754103

  Neuroplasticity in Blind Subjects After Repetitive Tactile Stimulation
1

NCT01757652

  Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma
1

NCT01757730

  Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues
1

NCT01758211

  Functional Magnetic Resonance Imagine(fMRI)Navigation in Intracranial Arteriovenous Malformation Surgery
1

NCT01759888

  Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism
1

NCT01773837

  Clinical Trial to Evaluate Short-term Efficacy of Palliative Methylphenidate in Asthenia in Advanced Cancer Patients
1

NCT01775332

  Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools
1

NCT01778530

  TRC105 for Recurrent Glioblastoma
1

NCT01747590

  Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T
1

NCT01763892

  Physiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI)
1

NCT01764451

  Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins
1

NCT01768832

  Exercise and Parkinson's: Comparing Interventions and Exploring Neural Mechanisms
1

NCT01782742

  Bexarotene Amyloid Treatment for Alzheimer's Disease
1

NCT01783431

  Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells
1

NCT01783535

  Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
1

NCT01798407

  A Pilot Study of Deep Brain Stimulation to the Lateral Habenulae in Treatment-Resistant Depression
1

NCT01799018

  Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage
1

NCT01801267

  Third Ventriculostomy Versus Shunt for Children With Hydrocephalus
1

NCT01801488

  Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm
1

NCT01802762

  A New Multi-parameter Neuromonitoring System to Save Patients' Lives in Stroke and Brain Injury
1

NCT01803984

  MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction
1

NCT01805440

  Placebo-Controlled Study of Uridine for Adolescent Bipolar Depression
1

NCT01809808

  A Prospective Study of Outcome After Therapy for Acromegaly
1

NCT01815112

  Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging
1

NCT01820117

  Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
1

NCT01820754

  Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
1

NCT01403324

  Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
1

NCT01413438

  Bevacizumab With or Without Surgery for Adult Glioblastomas
1

NCT01388842

  Evaluation of the Efficacy and Safety of Inhaled Nitric Oxide as Adjunctive Treatment for Cerebral Malaria in Children
1

NCT01393444

  ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis
1

NCT01375595

  Brain Areas Involved in Sound and Spoken Word Memory
1

NCT01376505

  Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
1

NCT01321437

  Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
1

NCT01295970

  Surgery Versus Radiosurgery for the Treatment of Single Brain Metastases
1

NCT01296893

  Can Exercise Improve Cancer Associated Cognitive Dysfunction?
1

NCT01345305

  Biomarker Development in Sturge-Weber Syndrome
1

NCT01345552

  Radiosurgery for Patients Recurrent Oligometastatic Disease
1

NCT01364480

  Microelectrode Brain-Machine Interface for Individuals With Tetraplegia
1

NCT01364792

  To Rescue Cognition With Valaciclovir
1

NCT01179958

  Cognitive Benefits of Aerobic Exercise Across the Age Span
1

NCT01186055

  Brain Activity and Smoking Cessation
1

NCT01186796

  Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women
1

NCT01212094

  Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
1

NCT01226654

  Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis
1

NCT01231932

  Investigating Molecular-Genetic Correlates of Fatigue Experienced by Cancer Patients Receiving Treatment
1

NCT01232374

  Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
1

NCT01234506

  Oxidative Stress and Nutritional Supplementation Intervention Study
1

NCT01259479

  Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
1

NCT01260740

  The Effect of Transcranial Magnetic Stimulation on Learning With Reward in Healthy Humans
1

NCT01262222

  Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events
1

NCT01266096

  PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study
1

NCT01266577

  Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle
1

NCT01273129

  Surgery as a Treatment for Medically Intractable Epilepsy
1

NCT01278225

  Neurofeedback and Pain
1

NCT01281696

  Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis
1

NCT01281956

  PRX-00023 Therapy in Localization-Related Epilepsy
1

NCT01286389

  Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition
1

NCT01246310

  Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients
1

NCT01247298

  A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
1

NCT01247610

  Adult Outcome of Children With Attention-deficit/Hyperactivity Disorder
1

NCT01251887

  Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition
1

NCT00906893

  Evaluation of [18F]-FMISO for Non Operated Glioblastoma
1

NCT00914823

  Administration of Kisspeptin to Subjects With Reproductive Disorders
1

NCT00875342

  Imaginal Exposure & D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)
1

NCT00889174

  The Nosology and Etiology of Leukodystrophies of Unknown Causes
1

NCT00891722

  Tumor Tissue, Blood Samples, and Family History in Predicting Tumor Development and Response to Treatment in Young Patients With Low-Grade Glioma
1

NCT00892411

  Prognostic Value of Measures of the Central Hypersensitivity in Patients With Acute Low Back Pain
1

NCT00896324

  Intellectual Impairment in Women With Breast Cancer
1

NCT00920829

  Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism
1

NCT00923897

  Palliative Radiotherapy (RT) for Liver Metastases (Mets) and Hepatocellular Carcinoma (HCC)(COLD 4)
1

NCT00924196

  Natural History Study of Patients With Neurofibromatosis Type I
1

NCT00924365

  Natural History Study of HIV Acquired in Infancy or Childhood
1

NCT00929994

  Effects of Cardiac Rehabilitation for Individuals With Transient Ischemic Attack
1

NCT00931931

  HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
1

NCT00936806

  Observational Study of the Differences in Characteristics of the Spontaneous Electroencephalogram, Derived From the Left and Right Hemisphere in Patients With Unilateral Intracranial Tumor During Routine Anesthesia: Comparison With a Control Group Without Intracranial Pathology
1

NCT00967577

  177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
1

NCT00980551

  Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma
1

NCT00659126

  Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
1

NCT00671099

  Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 Study
1

NCT00689715

  Efficacy Study of EUS-guided Ethanol Lavage With Paclitaxel Injection for Cystic Tumors of the Pancreas
1

NCT00708188

  Multidetector Raw CT as a Single Tool in the Setting of Ischemic Stroke
1

NCT00756639

  Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
1

NCT00757614

  Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
1

NCT00758108

  Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
1

NCT00734682

  A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
1

NCT00772278

  Comparing Carotid Stenting With Endarterectomy in Severe Asymptomatic Carotid Stenosis
1

NCT00795366

  Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
1

NCT00840047

  Methionine PET/CT Studies In Patients With Cancer
1

NCT00857519

  A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma
1

NCT00823524

  Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
1

NCT01067196

  Outcomes Study of Late Effects After Proton RT for Pediatric Tumors of the Brain, Head, and Neck
1

NCT01071941

  rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors
1

NCT01048008

  Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
1

NCT01050504

  Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
1

NCT00988013

  Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
1

NCT01014858

  Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease
1

NCT01016756

  Genetic Analysis of PHACE Syndrome (Hemangioma With Other Congenital Anomalies)
1

NCT01018082

  Longitudinal Study of Neurologic, Cognitive, and Radiologic Outcomes of PHACE Syndrome
1

NCT01032200

  Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
1

NCT01037790

  PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER
1

NCT01009866

  Study of Immunotoxin, MR1-1
1

NCT01014195

  Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors
1

NCT01163526

  Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
1

NCT01172899

  Bariatric Surgery in Children.
1

NCT01174121

  Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
1

NCT01175954

  Cognitive and Behavioral Effects of Lacosamide
1

NCT01135875

  Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients
1

NCT01142310

  Reversing Corticosteroid Induced Memory Impairment
1

NCT01082926

  Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
1

NCT01073514

  Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction
1

NCT01103531

  Exercise to Improve Outcomes of Treatment for Methamphetamine Users
1

NCT01111396

  Longitudinal Investigation of Hippocampal Function and Morphology in Acute Lymphatic Leukemia (ALL) Patients Treated With Chemotherapy
1

NCT01112800

  Markers of Anthracycline-Related Cardiac Muscle Injury
1

NCT01113398

  AMG 102 and Avastin for Recurrent Malignant Glioma
1

NCT00242151

  Prevalence of Delirium in Patients Undergoing Cardiac Surgery
1

NCT00285324

  Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis
1

NCT00305656

  AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
1

NCT00345865

  Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
1

NCT00237705

  Intravenous Metoclopramide for the Treatment of Post Concussive Headache: a Randomized Placebo Controlled Trial
1

NCT00046189

  Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum
1

NCT00067821

  Comparison of PET and Proton MRS Imaging to Evaluate Pediatric Brain Tumor Activity
1

NCT00068224

  Clinical and Molecular Investigations Into Ciliopathies
1

NCT00083512

  Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
1

NCT00106925

  Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
1

NCT00173446

  D2 Dopamine Receptor on Human Aldosterone-Producing Adenoma and Its Role in Aldosterone Secretion and Cell Proliferation
1

NCT00179764

  Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
1

NCT00180947

  Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse
1

NCT00397124

  The Role of the Vagus Nerve in Tumor-to-Brain Communication in Lung Cancer Patients
1

NCT00550134

  Cognitive Changes Associated With Breast Cancer Treatment
1

NCT00565903

  Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
1

NCT00504218

  Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors
1

NCT00579072

  The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older
1

NCT00581815

  Spectroscopy With Surface Coils and Decoupling
1

NCT00585572

  UW/VA Madison Brain Bank
1

NCT00593242

  Cord Blood for Neonatal Hypoxic-ischemic Encephalopathy
1

NCT00605254

  PET Imaging of P-glycoprotein Function Using [11C]dLop
1

NCT00632632

  Virtual Reality & D-cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)
1

NCT00636805

  Aloxi for Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan With Bevacizumab
1

NCT03641443

  non_invasive_aICP_Tumor
1

NCT03647787

  White Matter Integrity According to BDNF Genotype After Stroke
1

NCT00001238

  Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders
1

NCT00001981

  The Treatment and Natural History of Acromegaly
1

NCT00004129

  Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
1

NCT00005927

  Study of Adrenal Gland Tumors
1

NCT00026780

  Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
1

NCT00026884

  Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
1

NCT00035373

  Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols
1

NCT03638206

  Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
1

NCT03632317

  A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
1

NCT03593993

  A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas
1

NCT03594734

  Group Lifestyle Balance™ for Individuals With Traumatic Brain Injury (GLB-TBI)
1

NCT03627975

  Effect of Surgical Revascularization on Hemorrhagic Moyamoya Disease
1

NCT03628131

  Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors
1

NCT03629964

  Study to Develop Head Stabilizer for Use During Brain Radiation Therapy
1

NCT03630289

  Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM
1

NCT03576612

  GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas
1

NCT03581331

  Consequence of Unilateral Vestibular Loss on Visual Abilities
1

NCT03583528

  DOTATOC PET/CT for Imaging NET Patients
1

NCT03584477

  Robotic Rehabilitation of the Upper Limb After a Stroke
1

NCT03586258

  Neuropsychological and Brain Medical Imaging Study in Patients With Brain Damage 2
1

NCT03586401

  Creating a Decision Support System for the Corporate Management of Physical Therapy
1

NCT03614065

  Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC
1

NCT03614403

  The Effect of Vitamin D3 on Postoperative Pain in Patients Undergoing Craniotomy
1

NCT03615391

  Predictive Role and HuR Mechanisms of Regulation in the Brain Tumours
1

NCT03618667

  GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
1

NCT03619083

  Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer
1

NCT03619694

  Role of MR Spectroscopy in Brain Tumors
1

NCT03620032

  Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses
1

NCT03621397

  Online Spanish Cognitive Intervention Program for Spanish-Speaking Latino/Hispanic Subarachnoid Hemorrhage Patients
1

NCT03496402

  Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)
1

NCT03500991

  HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
1

NCT03501134

  Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields
1

NCT03507244

  Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors
1

NCT03508752

  Neurocognitive Decline in Patients With Brain Metastases
1

NCT03508765

  Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation
1

NCT03509597

  Brain Image Markers Associated With Cognitive Training and Aerobic Exercise in Schizophrenia
1

NCT03510208

  Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
1

NCT03512054

  Pilot Study Evaluating the Success (= Safe Decannulation) of a Standardized Tracheotomy Weaning Procedure in Brain-injury's Patients
1

NCT03514069

  Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
1

NCT03516162

  Linking Digital Smartphone Behaviour With Brain Function
1

NCT03477110

  Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma
1

NCT03483012

  Atezolizumab + Stereotactic Radiosurgery in Triple-negative Breast Cancer and Brain Metastasis
1

NCT03483740

  Psychosocial Intervention for Older HIV+ Adults With HAND
1

NCT03484104

  Cerebral Perfusion in Hypothermic Circulatory Arrest
1

NCT03425292

  A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
1

NCT03426826

  The Gut-Brain Study
1

NCT03428009

  Dystonia Genotype-Phenotype Correlation
1

NCT03430544

  Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder
1

NCT03435952

  Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
1

NCT03529149

  TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT
1

NCT03531307

  Lactate Levels Correlates With Ki-67 in Brain Tumor Surgery
1

NCT03531333

  Intraoperative Ultrasound Guided Glioma Surgery; a Randomised, Controlled Trial.
1

NCT03534050

  Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy
1

NCT03535350

  Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
1

NCT03536039

  RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor
1

NCT03536351

  Building Social Skills With Interdisciplinary Process Drama in ASD
1

NCT03537911

  Cognitive Support Program for Patients With Brain Metastases
1

NCT03538587

  Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children With High Grade Brain Tumors and Their Caregivers
1

NCT03539731

  [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
1

NCT03542409

  Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas
1

NCT03543020

  Radiation- Induced Alopecia in Patients Undergoing Radiation Therapy to the Brain
1

NCT03546387

  Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients
1

NCT03548571

  Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy
1

NCT03550391

  Stereotactic Radiosurgery Compared With Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
1

NCT03596086

  HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
1

NCT03597165

  Incidental Genomics
1

NCT03598140

  Sildenafil Treatment for Mild TBI
1

NCT03599609

  Central Nervous System Vascular Changes in Adult Sickle Cell Disease and the Effect of Treatment With Simvastatin
1

NCT03603405

  HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
1

NCT03604302

  Evaluation of Preoperative Functional Magnetic Resonance Imaging (fMRI) in Patients With Brain Tumors
1

NCT03606161

  Navigated Repetitive Transcranial Magnetic Stimulation in Improving Motor Rehabilitation in Participants With Grade II-IV Brain Tumors
1

NCT03609112

  Neurocognitive Risks in Children With Solid Tumors
1

NCT03563729

  Melanoma Metastasized to the Brain and Steroids
1

NCT03566199

  MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
1

NCT03566329

  Magnesium Sulphate Versus Lidocaine for Control of Emergence Hypertension
1

NCT03567135

  Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma
1

NCT03567486

  Predictive Factors of Visual Recovery After Paraoptic Tumors Removal
1

NCT03572530

  Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma
1

NCT03573986

  Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
1

NCT03573999

  Effect of Mannitol 20% Versus Hypertonic Saline 7.5% in Brain Metabolism and Oxygenation
1

NCT03574610

  Brain Targets in Patients With Bladder Emptying Difficulties
1

NCT03489681

  Acupuncture Treatment for Chronic Sciatica: the Neuroimaging Pain-network Study
1

NCT03493932

  Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
1

NCT03495037

  Preventing Cognitive and Functional Decline Among Seniors at Risk
1

NCT03520634

  PD-L1 PET Imaging in Melanoma Patients
1

NCT03520829

  Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery
1

NCT03520842

  Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
1

NCT03525301

  Short Course Radiation Therapy in Palliative Treatment of Brain Metastases
1

NCT03556384

  Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
1

NCT03561207

  3D-Prediction of Patient-Specific Response
1

NCT03526809

  Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and Neurology
1

NCT03526822

  Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.
1

NCT03230890

  HIRREM in Military Personnel
1

NCT03396575

  Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)
1

NCT03400917

  Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma
1

NCT03401996

  tDCS in Tourette (TIC-TDCS)
1

NCT03403361

  Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Patient Outcomes for Locally Advanced Lung and Brain Tumor Patients Treated With Proton Therapy
1

NCT03417297

  A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy
1

NCT03417726

  Evaluation of Pediatric Balance Scale and Quantitative Balance Parameters in Patients With Cerebral Palsy
1

NCT03419403

  A Study for Management of Ocular Side Effects in Subjects With Glioblastoma Receiving Depatuxizumab Mafodotin
1

NCT03451123

  FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors
1

NCT03451708

  OKS for the Treatment of Hemispatial Neglect
1

NCT03451799

  Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma
1

NCT03452579

  Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
1

NCT03452930

  EDO-S101 for MGMT Unmethylated Glioblastoma (nGBM)
1

NCT03458312

  Nurse-led Family and Network Consultations
1

NCT03460067

  Omission of Radiation in Patients With Her-2 Positive Breast Cancer
1

NCT03464253

  Prediction of Post-dural Puncture Headache in Parturients Undergoing Elective Caesarean Section
1

NCT03465423

  Comparison of Propofol Requirement Between Patients With Pituitary Somatotroph Tumor and With Nonfunctioning Pituitary Tumor in Transsphenoidal Pituitary Surgery Under Total Intravenous Anesthesia
1

NCT03471026

  Advanced MRI for Posterior Fossa Tumours
1

NCT03471546

  Early Palliative Care Intervention in Malignant Glioma
1

NCT03473301

  A Study of UCB and MSCs in Children With CP: ACCeNT-CP
1

NCT03299309

  PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
1

NCT03332589

  Study of E6201 for the Treatment of Central Nervous System Metastases (CNS)
1

NCT03334305

  Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas
1

NCT03341806

  Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma
1

NCT03353246

  Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas
1

NCT03361020

  Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
1

NCT03363217

  Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
1

NCT03368625

  A Study of Neoadjuvant Stereotactic Radiosurgery for Large Brain Metastases
1

NCT03370107

  Comparison of rTMS and H Coil in Neuropathic Pain
1

NCT03386357

  Radiotherapy With Pembrolizumab in Metastatic HNSCC
1

NCT03389230

  Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
1

NCT03391362

  Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-6 Brain Metastases
1

NCT03213561

  Stable and Independent Communication Brain-computer Interfaces
1

NCT03220854

  SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Progression on PD-1/PDL-1 Tx
1

NCT03221413

  Transcranial Alternating Current for Oscillopathies
1

NCT03258567

  Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
1

NCT03261310

  Use of IV Acetaminophen in the Treatment of Post Operative Pain in Patients Undergoing Craniotomy and Spine Surgery
1

NCT03279367

  Optimisation of Hearing Aid Fitting
1

NCT03283631

  Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
1

NCT03287063

  Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma
1

NCT03004443

  Inflammation-Induced CNS Glutamate Changes in Depression
1

NCT03049033

  NMT for Parkinson's Disease
1

NCT03134716

  Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis
1

NCT03151707

  The Effects of Nicotinamide Riboside Supplementation on NAD+/NADH Ratio and Bioenergetics
1

NCT03158389

  NCT Neuro Master Match - N²M² (NOA-20)
1

NCT03160313

  Effects of an Interdisciplinary Fitness and Social Engagement Intervention
1

NCT03184454

  Combined Cortical/Subcortical Recording and Stimulation as a Circuit-Oriented Treatment for Obsessive-Compulsive Disorder
1

NCT03208166

  Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis
1

NCT02846038

  Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
1

NCT02848885

  The Effects of tDCS on Illness Awareness in Schizophrenia
1

NCT02851056

  Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)
1

NCT02861807

  Mindfulness-Based Intervention and Transcranial Direct Current Brain Stimulation to Reduce Heavy Drinking
1

NCT02867137

  Biomarkers in Prehospital Rule-out of Intracranial Lesions in TBI Patients
1

NCT02887651

  Cavity Boost Radiation Therapy vs. Observation in Cerebral Metastases After Complete Surgical Resection
1

NCT03096743

  Evaluating Raised Intracranial Pressure Using MR Elastography
1

NCT03119064

  BrUOG 329 GBM Onyvide With TMZ
1

NCT03122587

  Non-Invasive Brain Stimulation and Substance Use
1

NCT02910193

  Alcohol Addiction: A Systems-oriented Approach
1

NCT02910700

  Study of the TRIplet Combination of Dabrafenib, Nivolumab, and Trametinib in Patients With Metastatic Melanoma (TRIDeNT)
1

NCT02917213

  Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
1

NCT02925988

  Combined Amplitude-integrated and Conventional EEG Monitoring in High-risk Critically Ill Neonates
1

NCT02927340

  A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
1

NCT02956798

  SAbR With Oligometastatic Renal Cell Carcinoma
1

NCT02966574

  Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers
1

NCT02968056

  One Staged Hybrid Approach of Surgical/Catheter Ablation for Persistent Atrial Fibrillation
1

NCT02680704

  Mechanical Ventilation in Severe Brain Injury: The Effect of Positive End Expiratory Pressure on Intracranial Pressure
1

NCT02683304

  S100B in the Care of Non-traumatic Headaches in the Emergency Department
1

NCT02693405

  Executive and Socio-cognitive Functions in Survivors of Primary Brain Tumor: Impact on Patients' Quality of Life
1

NCT02709369

  HIRREM Developmental Study
1

NCT02711683

  DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil
1

NCT02739347

  Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia
1

NCT02789709

  Metabolomic Phenotyping After Surgery for Colon Cancer: Study of Novel Predictive Biomarkers
1

NCT02792985

  Multisensory Stimulation and Enriched Environments During Post-traumatic Amnesia
1

NCT03390569

  Exercise in Patients With Glioblastoma
1

NCT03374943

  A Trial of KB004 in Patients With Glioblastoma
1

NCT03361033

  Components of Social Functioning in Survivors of Pediatric Brain Tumors
1

NCT02774291

  Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1
1

NCT03154996

  Chronic Convection Enhanced Delivery of Topotecan
1

NCT03176160

  LITT Palliative Treatment for Patients With Malignant Gliomas
1

NCT03231501

  HMPL-813 in Treating Patients With Glioblastoma
1

NCT03281889

  Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation
1

NCT03285932

  Stereotactic Radiotherapy of the Resection Cavity of Brain Metastases vs. Post-operative Whole-brain Radiotherapy
1

NCT03297463

  Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
1

NCT03297788

  Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases
1

NCT03303365

  Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence
1

NCT02898727

  A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer
1

NCT03353896

  NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma
1

NCT03363659

  Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme
1

NCT03367715

  Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
1

NCT03387020

  Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
1

NCT03414944

  Elective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain Metastases
1

NCT03412877

  Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer
1

NCT03403803

  Prognosis and Therapeutic Biomarkers for Glioblastoma Patients
1

NCT03405792

  Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
1

NCT03407781

  IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Lower Grade Glioma
1

NCT02606422

  tDCS Intervention in Primary Progressive Aphasia
1

NCT02608021

  Neurotrack Test Validation Protocol
1

NCT02513485

  Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa
1

NCT02538315

  Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients
1

NCT02405182

  MRI Biomarkers in ALS
1

NCT02129647

  Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
1

NCT02321501

  Phase I/Ib Dose Escalation & Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression
1

NCT02331615

  Application of Trans Cranial Direct Current Stimulation for Executive Dysfunction After Traumatic Brain Injury
1

NCT02358811

  Evaluation of the Impact of Sleep Apnea on Cerebral Volumetry According to Age
1

NCT03480867

  Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)
1

NCT02098265

  A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
1

NCT03430947

  Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases
1

NCT03434262

  SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
1

NCT03439332

  Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma
1

NCT03452774

  SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
1

NCT03458676

  Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
1

NCT03463733

  Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)
1

NCT03423992

  Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas
1

NCT03426891

  Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
1

NCT01166321

  Carbon Ion Radiotherapy for Atypical Meningiomas
1

NCT01360606

  Stereotactic Body Radiation Therapy (SBRT) for Liver Mets
1

NCT01481207

  Magnetic Resonance Imaging and Spectroscopy Biomarkers of Neonatal Hypoxic Ischemic Encephalopathy
1

NCT01811381

  Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease
1

NCT01874093

  IMPACT- 24Bt Post Mech. Thrombectomy and/or rtPA TRIAL IMPlant Augmenting Cerebral Blood Flow 24 Hours From Stroke Onset
1

NCT01876212

  Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
1

NCT01880632

  Oxaliplatin Plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma
1

NCT01904123

  Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma
1

NCT01945047

  Action of Ketamine in Treatment-Resistant Depression
1

NCT02002819

  Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability
1

NCT02669914

  MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
1

NCT02689336

  Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
1

NCT02698254

  Pilot Trial of Dose-Volume Constraints for Reirradiation of Recurrent Brain Tumors
1

NCT02715609

  Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
1

NCT02754544

  Using Electrocorticogram (ECoG) in Predicting Eloquent Cortex and Post-Op Functional Outcomes in Patients With Brain Tumors
1

NCT02774421

  Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma
1

NCT02781792

  Temozolomide Chronotherapy for High Grade Glioma
1

NCT02792608

  Mindfulness-Based Therapy for Brain Tumour Survivors
1

NCT02794883

  Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
1

NCT02824731

  Comparison of Proton and Photon Radiotherapy of Brain Tumors (ProtoChoice-Hirn)
1

NCT02829931

  Hypofractionated Stereotactic Irradiation With Nivolumab in Patients With Recurrent High Grade Gliomas
1

NCT02831257

  AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
1

NCT02839954

  CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
1

NCT02840123

  Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines
1

NCT02841332

  Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma
1

NCT02844062

  Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
1

NCT02783495

  Feasibility And Efficacy Of An iPad-Based Cognitive Rehabilitation Program In Brain Tumor Patients
1

NCT02791360

  Evaluation of Anatomy, Clinical and Neuropsychological Long-term Sequelae of Patients Treated With Radiation Therapy for Brain Tumor
1

NCT02792582

  A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
1

NCT02624388

  Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
1

NCT02626364

  Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
1

NCT02655536

  Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
1

NCT02800486

  Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
1

NCT02808364

  Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)
1

NCT02808416

  Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)
1

NCT02824133

  Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"
1

NCT02833701

  Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
1

NCT02378532

  The Addition of Chloroquine to Chemoradiation for Glioblastoma
1

NCT02780024

  Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM
1

NCT02769806

  Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma
1

NCT02648633

  Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
1

NCT02718443

  VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
1

NCT02313389

  Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma
1

NCT02457845

  HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
1

NCT02584400

  Tumor Hypoxia With HX4 PET in Several Diseases
1

NCT02751138

  Determination of Immune Phenotype in Glioblastoma Patients
1

NCT02753790

  Whole Brain Radiation Using IMRT for Patients With Brain Metastases
1

NCT02758366

  Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma
1

NCT02711137

  A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
1

NCT02722512

  Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
1

NCT02736513

  Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases
1

NCT02747303

  Frameless Stereotactic Radiosurgery for Intact Brain Metastases
1

NCT02747407

  Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
1

NCT02652897

  Hemostasis Alterations in Neurosurgical Patients
1

NCT02661282

  Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients
1

NCT02681549

  Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
1

NCT02598427

  Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer
1

NCT02605746

  Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis
1

NCT02896335

  Palbociclib In Progressive Brain Metastases
1

NCT02905110

  Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors
1

NCT02914067

  Cognitive Biomarkers in Pediatric Brain Tumor Patients
1

NCT02940483

  Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma
1

NCT02942264

  TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
1

NCT02947373

  Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors
1

NCT02953717

  Cognitive Outcome After SRS or WBRT in Patients With Multiple Brain Metastases (CAR-Study B)
1

NCT02953756

  Cognitive Outcome After Gamma Knife Radiosurgery in Patients With Brain Metastases (CAR-Study A)
1

NCT02933736

  Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
1

NCT02937844

  Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
1

NCT02939378

  Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study
1

NCT02941302

  Multimodality Imaging Combined With Multiple Targets Pathological Examination for Detecting of Biological Borders of Gliomas: a Clinical Application Study
1

NCT02423525

  Safety Study of Afatinib for Brain Cancer
1

NCT02770378

  A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
1

NCT02919332

  Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma
1

NCT02849171

  Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas
1

NCT02849743

  Intranasal Oxytocin in Hypothalamic Obesity
1

NCT02850744

  Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
1

NCT02851706

  Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
1

NCT02854228

  PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon
1

NCT02549833

  Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
1

NCT02861898

  Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
1

NCT02863484

  Cavernous Sinus Dissection and Bleeding in Meningiomas
1

NCT02876003

  Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
1

NCT02878707

  The Neuroprotective Effects of Dexmedetomidine During Brain Surgery
1

NCT02882984

  Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)
1

NCT02892708

  Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over
1

NCT02904525

  Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine Model
1

NCT02902757

  FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma
1

NCT00054496

  Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
1

NCT00180791

  High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
1

NCT00268684

  Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC
1

NCT00311857

  Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)
1

NCT02509442

  Measure of the Potential Evoked by Electric Stimulation
1

NCT02855086

  Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
1

NCT02864368

  Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
1

NCT02885272

  Dual Time Point FDG PET-MR Imaging Optimization for the Evaluation of Glioblastoma
1

NCT02978261

  Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas
1

NCT02992015

  Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
1

NCT02964416

  Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery
1

NCT02664363

  EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
1

NCT02696993

  Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer
1

NCT02717962

  Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma
1

NCT02749227

  Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
1

NCT02749877

  Efficacy of Cognitive and Physical Trainings in Pediatric Cancer Survivors
1

NCT02766270

  CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas
1

NCT02796729

  CEST- Glucose Enhanced MRI for Metastatic Brain Tumours
1

NCT02840409

  Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
1

NCT02886572

  SIMT Stereotactic Radiosurgery Outcomes Study
1

NCT02893137

  Enhancing Optune Therapy With Targeted Craniectomy
1

NCT02901925

  A Microdose Evaluation Study of ABY-029 in Recurrent Glioma
1

NCT03002532

  Hippocampal-sparing Whole Brain Radiotherapy for Brain Metastases From Breast Cancer
1

NCT03005132

  Integrative Analysis of Human Glioblastoma Multiforme
1

NCT03014687

  Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
1

NCT03019471

  Non Invasive Cancer Test (NICT): a Proof of Principle Study.
1

NCT03020602

  BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
1

NCT03027544

  Tomotherapy for Refractory Brain Metastases
1

NCT03028246

  A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects
1

NCT03028337

  Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases
1

NCT03030066

  Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
1

NCT02986815

  [11C]Acetate PET in Patients With Glioma
1

NCT03047473

  Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
1

NCT03068520

  Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease Progression?
1

NCT03076255

  Head and Neck Maskless Immobilization Device in Immobilizing Patients With Intracranial Tumors Undergoing Radiation Therapy
1

NCT02924038

  A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
1

NCT03052738

  Medical Marijuana in the Pediatric Central Nervous System Tumor Population
1

NCT03055208

  Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed Glioblastoma
1

NCT03058198

  The Research on 89Zr-ABT806 PET Imaging in High Grade Glioma
1

NCT03090386

  Evaluation of Cognitive-Communication Deficits Following Treatment of Primary Brain Tumor Patients
1

NCT03075514

  Ketogenic Diets as an Adjuvant Therapy in Glioblastoma
1

NCT03101813

  International Diffuse Intrinsic Pontine Glioma (DIPG) Registry and Repository
1

NCT01624766

  Anakinra or Denosumab and Everolimus in Advanced Cancer
1

NCT02344355

  A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme
1

NCT02460874

  Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)
1

NCT02507232

  A Phase II Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas
1

NCT02700763

  [18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis
1

NCT02756312

  The Perioperative Anesthetic Management and the Prognosis of Patients Undergoing Brain Malignant Glioma Resection
1

NCT02805179

  A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
1

NCT02843230

  Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI
1

NCT02848794

  Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma
1

NCT02869243

  A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients
1

NCT03086616

  CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With DIPG
1

NCT03091803

  QSM and Regional DCE MRI Permeability Using GOCART Technique
1

NCT03096431

  Impact of Cognitive Rehab and Physical Activity on Cognition in Patients With Metastatic Brain Tumors Undergoing RT
1

NCT03115138

  Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.
1

NCT03115164

  Astrocytoma / Desmoplastic Gamliogliomes (DIA / DIG) - Study of the French Cohort of the Last 20 Years : Clinical, Anatomopathological, Molecular and Radiological Charactersics
1

NCT03115398

  A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery
1

NCT03122197

  Study of Letrozole in Recurrent Gliomas
1

NCT03128047

  HUMC 1612: Optune NovoTTF-200A System
1

NCT03132259

  Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach
1

NCT02900248

  CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
1

NCT02970448

  Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas
1

NCT02978404

  Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
1

NCT02986178

  PVSRIPO With/Without Lomustine
1

NCT03020017

  NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
1

NCT03050736

  Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
1

NCT03055364

  Cognitive Function After Treatment of Primary CNS Malignancy
1

NCT03180697

  The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas
1

NCT03071913

  Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery
1

NCT03072134

  Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
1

NCT03160599

  Restricted Calorie Ketogenic Diet as a Treatment in Glioblastoma Multiforme
1

NCT03163368

  Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
1

NCT03168919

  Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma
1

NCT03173950

  Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers
1

NCT03174197

  Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM)
1

NCT03175432

  Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases
1

NCT03178032

  Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas
1

NCT03179176

  Evaluation of the Interest of Ultra-high Frequency Doppler Ultrasound (UFDU) in the Surgical Management of Patients Operated in an Awake Condition for a Cerebral Tumor
1

NCT03189420

  Glioma Microenvironment an Exploratory Study
1

NCT03190967

  T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
1

NCT03193463

  Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy
1

NCT03194906

  Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
1

NCT03194971

  NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy
1

NCT03197506

  Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
1

NCT03212157

  GlucoCEST MRI in Oncology
1

NCT03212235

  Hypofractionated Radiation Therapy for Glioblastoma
1

NCT03212742

  Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
1

NCT03213002

  Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
1

NCT03223675

  Neurocognitive Impact and Dose-Effect Relationship of Hippocampal Avoidance During Whole Brain Radiotherapy Plus Simultaneous Integrated Boost - A Prospective Follow-up Study
1

NCT03223922

  Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
1

NCT03225300

  Simultaneous Integrated Boost in Malignant Glioma Patients Treated With Chemoradiation
1

NCT03226483

  Intraoperative Radiotherapy After the Resection of Brain Metastases
1

NCT03232424

  NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
1

NCT03233152

  Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma
1

NCT03257735

  A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain Metastases
1

NCT03258021

  TTFields In GErmany in Routine Clinical Care
1

NCT03274037

  Evaluation of Cerebral Elastography by Magnetic Resonance: Comparison of Healthy Subjects and Patients With Glial Tumor
1

NCT03278249

  Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma
1

NCT03286023

  Stereotactic Radiotherapy for Brain Metastases
1

NCT03288272

  Evaluation of Repeated Whole Brain Radiotherapy Versus Best Supportive Care for Multiple Brain Metastases.
1

NCT03291314

  Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
1

NCT03291977

  Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)
1

NCT03294434

  Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study)
1

NCT02991456

  Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
1

NCT03043391

  Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
1

NCT02956291

  Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors
1

NCT03022578

  Study of Laser Interstitial Thermal Therapy (LITT) in Recurrent Glioblastoma
1

NCT03126266

  Re-Irradiation of Progressive or Recurrent DIPG
1

NCT03223103

  Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
1

NCT03234595

  A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
1

NCT03181581

  Improving Ultrasound Images in Brain Tumour Surgery With the Use of an Acoustic Coupling Fluid Mimicking Brain Tissue.
1

NCT03217747

  Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
1

NCT03244995

  An Online Dyadic Mind-Body Intervention for Glioma Patients and Their Partners
1

NCT03247127

  Memory Preservation of Hippocampal Avoidance Whole Brain Radiotherapy
1

NCT03291990

  5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme
1

NCT03293888

  Spectral Analysis Probe to Identify Glioblastoma Cells
1

NCT03294486

  Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients
1

NCT03251027

  Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
1

NCT03251989

  Outcomes and Risk in People With Ependymoma
1

NCT03257124

  Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS
1

NCT03257618

  Quality of Life and Neurocognitive Functioning
1

NCT03331601

  Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Breast Carcinoma Patients
1

NCT03332030

  Stem Cells in NF1 Patients With Tumors of the Central Nervous System
1

NCT03342586

  Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
1

NCT03347097

  PD1-PIK Cell Therapy for Patients With Glioblastoma Multiforme
1

NCT03352427

  Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR/FGFR Alterations
1

NCT03297125

  Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI
1

NCT03305588

  RAD 1601: EDGE Radiosurgery for Intractable Essential Tremor and Tremor-Dominant Parkinson's Disease
1

NCT03325166

  Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
1

NCT03328858

  Ketogenic Diet in Children With Malignant or Recurrent/Refractory Brain Tumor
1

NCT03328884

  Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients
1

NCT03267836

  Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
1

NCT03277638

  Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma
1

NCT03286335

  Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
1

NCT03346655

  Brain Metastases in Norway
1

NCT03347617

  Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma
1

NCT03366376

  Hippocampus-sparing WBRT and Simultaneous Integrated Boost for Multiple Brain Metastases From NSCLC
1

NCT03370926

  FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
1

NCT02731521

  Clinical Development of MR Spectroscopy and Imaging in Brain Cancers
1

NCT02666066

  Radiomics for Prediction of Survival in GBM
1

NCT02726568

  High Dose Icotinib For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
1

NCT02728349

  Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma
1

NCT02132598

  Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases
1

NCT02192359

  Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
1

NCT02213536

  Investigating the Efficacy of Hair Sparing Radiotherapy Treatment to the Whole Brain.
1

NCT02345824

  Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma
1

NCT02348255

  NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
1

NCT02441062

  Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
1

NCT02442297

  T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma
1

NCT02491827

  Confocal Laser Endomicroscopy (CLE) During Medically Induced Neurosurgery in Craniobasal and Glioma Tumours
1

NCT02514915

  Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases
1

NCT00945126

  Allogeneic Stem Cell Transplantation in Pediatric Patients With Malignant and Non-malignant High-risk Diseases
1

NCT01505569

  Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
1

NCT01541800

  Circulating microRNAs as Disease Markers in Pediatric Cancers
1

NCT01703962

  Non Invasive IDentification of Gliomas With IDH1 Mutation
1

NCT01923922

  CT Perfusion in the Prognostication of Cerebral High Grade Glioma
1

NCT02062372

  Spatial Analysis and Validation of Glioblastoma on 7 T MRI
1

NCT02095353

  Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients
1

NCT02653196

  A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
1

NCT02654964

  Cancer Stem Cell High-Throughput Drug Screening Study
1

NCT02594709

  Multisession Radiosurgery for Optic Nerve Sheath Meningiomas
1

NCT02597335

  Non Invasive Detection of IDH1/2 Mutation in Gliomas
1

NCT02600065

  Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)Therapy
1

NCT02603692

  Health Related Quality of Life in Pediatric Central Nervous System (CNS) Tumors: A Feasibility Study Utilizing PROMIS
1

NCT02617134

  CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
1

NCT02617745

  Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid
1

NCT02619890

  Brain Glioma Registry Combining Clinical and Imaging Information
1

NCT02621515

  Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases
1

NCT02629549

  Intraoperative Imaging of Pituitary Adenomas by OTL
1

NCT02629757

  A Study on ß-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas
1

NCT02630043

  Trial of Tolcapone With Oxaliplatin for Neuroblastoma or Medulloblastoma
1

NCT02631655

  POSitron Emission Imaging Using 18F-FDOPA in Neurooncology
1

NCT02636634

  Non Invasive Methods for Differential Diagnosis Radionecrosis/Recurrence After Radiosurgery of Brain Metastases
1

NCT02644512

  Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
1

NCT02645487

  Stereotactic Radiosurgery (SRS) for Brain Metastasis
1

NCT02649582

  Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients
1

NCT02707549

  Fluid Therapy During Brain Tumor Resection in Children
1

NCT02709226

  Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
1

NCT02709616

  Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)
1

NCT02713087

  Vasopressor Effects in Anesthetized Patients
1

NCT02714010

  EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC
1

NCT02715297

  Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma
1

NCT02716948

  SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
1

NCT02722928

  Ventilation With High Oxygen Content and Postoperative Pneumocephalus
1

NCT02669173

  Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
1

NCT02672241

  Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children
1

NCT02672995

  Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial
1

NCT02676687

  Supratotal Resection for Gliomas Within Noneloquent Areas
1

NCT02681705

  Radiation Therapy and Combination Chemotherapy for Medulloblastoma
1

NCT02684071

  Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
1

NCT02691923

  Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker
1

NCT02698280

  Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
1

NCT02529072

  Nivolumab With DC Vaccines for Recurrent Brain Tumors
1

NCT02534506

  Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
1

NCT02608762

  Neurobehavioral Outcomes and Quality of Life in Pediatric Patients With Brain or Head/Neck Tumors Receiving Proton or Photon Radiotherapy
1

NCT02613988

  Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas
1

NCT02540876

  Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
1

NCT02590497

  Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery
1

NCT02596828

  Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma
1

NCT02607124

  A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
1

NCT02648997

  A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma
1

NCT02654041

  Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients
1

NCT02630030

  Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
1

NCT02655744

  Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute
1

NCT02656407

  Intraoperative Functional Ultrasound
1

NCT02082119

  Hypofractionated IMRT With Temozolomide for HGG
1

NCT02084134

  Pituitary Steroid Study
1

NCT02085070

  MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
1

NCT02085304

  Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM
1

NCT02099487

  Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma
1

NCT02113358

  Comparison of Stroke Volume Variation-guided Normovolemic and Restrictive Fluid Management During Craniotomy: a Randomized Controlled Trial
1

NCT02119338

  5-ALA in Recurrent Glioma
1

NCT02122822

  Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
1

NCT02125786

  A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
1

NCT02129712

  Neuroplasticity-Based Cognitive Remediation for Pediatric Brain Tumor Survivors
1

NCT02150564

  3D Ultra Sound for Resection of Brain Tumors
1

NCT02139150

  Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy
1

NCT02103920

  A Retrospective Immunohistochemistry Study of the Expression of Glycine/ Serine Pathway Molecules in Solid Tumors
1

NCT02104193

  Simvastatin Effect on Radiation Therapy of Brain Metastases
1

NCT02104310

  A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas
1

NCT02104882

  INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study
1

NCT02105233

  Improving Ultrasound Images in Brain Tumor Surgery With the Use of Brain Mimicking Fluid
1

NCT02105337

  Tegaderm and Visual Evoked Potentials
1

NCT02108002

  Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
1

NCT02040376

  Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma
1

NCT00752323

  Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
1

NCT01805453

  Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma
1

NCT01867593

  MET-PET for Newly Diagnosed Glioblastoma
1

NCT01915303

  Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
1

NCT01957956

  Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
1

NCT01989052

  Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
1

NCT02000882

  STAR Cape+BKM120 MBC With Brain Met
1

NCT02015728

  Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
1

NCT02047747

  A Phase II Study of Dacomitinib in Progressive Brain Metastases
1

NCT01985087

  A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70
1

NCT02015819

  Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
1

NCT02017249

  Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme
1

NCT02023905

  Everolimus With and Without Temozolomide in Adult Low Grade Glioma
1

NCT02038348

  Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study
1

NCT01970644

  Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases
1

NCT01977677

  Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
1

NCT01881386

  Lactate Imaging as a Tumour Biomarker
1

NCT01925573

  Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)
1

NCT01961934

  C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
1

NCT02116530

  Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
1

NCT02155452

  Fluorescence and Glioma Heterogeneity
1

NCT02093117

  Neurosurgery Recruitment Maneuver Study
1

NCT02097732

  Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
1

NCT02060890

  A Pilot Trial Testing the Feasibility of Molecular Profiling in Recurrent/Progressive Glioblastoma
1

NCT02062827

  Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
1

NCT02065466

  Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
1

NCT02165995

  Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery Following Surgery
1

NCT02167204

  18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors
1

NCT02168270

  Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
1

NCT02176720

  Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
1

NCT02177578

  Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
1

NCT02179515

  Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)
1

NCT02186262

  Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas
1

NCT02187822

  Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
1

NCT02189109

  The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma
1

NCT02191488

  ALA-induced PpIX Fluorescence During Brain Tumor Resection
1

NCT02193568

  Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy
1

NCT02194452

  Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
1

NCT02197169

  DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
1

NCT02238496

  Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
1

NCT02238899

  Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma
1

NCT02250755

  MRI Perfusion on T1 and T2 Brain Lesion(s)
1

NCT02253212

  Safety of BBB Opening With the SonoCloud
1

NCT02259218

  Longitudinal Metabolomic and Epigenetic Profiling of Bodyfluids From Patients With Lung and Brain Cancer Receiving Radiation Therapy
1

NCT02263105

  Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas
1

NCT02265549

  Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases
1

NCT01778764

  Phase I Compare OS in Post-CyberKnife Radiosurgery Tx in 1-3 VS 4 or More Brain Metastases
1

NCT02201381

  Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
1

NCT02202993

  TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM
1

NCT02203526

  Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma
1

NCT02207010

  A Phase 0 Study of AZD1775 in Recurrent GBM Patients
1

NCT02208336

  Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy
1

NCT02209376

  Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
1

NCT02209428

  A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas
1

NCT02168075

  Mannitol Brain Relaxation Effect
1

NCT02231775

  Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo)
1

NCT01410006

  Neurofibromatosis Type 1 Patient Registry
1

NCT01444209

  Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas
1

NCT01837862

  A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
1

NCT01906385

  Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioblastoma
1

NCT01924351

  HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)
1

NCT01966809

  Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
1

NCT02029690

  Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
1

NCT02058745

  SmartCare: Innovations in Caregiving Interventions
1

NCT02058953

  CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases
1

NCT02269111

  Quantitative MRI in Assessing Disease in Patients With Brain Metastases
1

NCT02277561

  Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery
1

NCT02278510

  Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma
1

NCT02279992

  Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases
1

NCT02285959

  Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
1

NCT02271711

  Study of Intraventricular Infusions of Autologous ex Vivo-expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System. NOAH's (New Opportunity, Advancing Hope) Protocol
1

NCT02272270

  Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)
1

NCT02287428

  Ph I Personalized NeoAntigen Cancer Vaccine With Radiotherapy for Patients With MGMT Unmethylated, Newly Diagnosed Glioblastoma
1

NCT02092038

  Preoperative Chemoradiation for Glioblastoma
1

NCT02175745

  18F FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly Diagnosed or Recurrent Gliomas
1

NCT02186509

  Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
1

NCT02208362

  Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
1

NCT02220127

  RCT of the 4mm vs. the 8mm Collimator for GKR of Brain Micrometastases
1

NCT02220491

  Whole Brain Radiotherapy Versus Volumetric Modulated Arc Therapy for Brain Metastases
1

NCT02221986

  Interdisciplinary Specialised Rehabilitation Among Glioma Patients
1

NCT02233049

  Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
1

NCT02239861

  TAA-SPECIFIC CTLS FOR SOLID TUMORS (TACTASOM)
1

NCT02239952

  HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
1

NCT02254954

  Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed GBM.
1

NCT02462629

  Study of BLZ-100 in Pediatric Subjects With CNS Tumors
1

NCT02458339

  Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors
1

NCT02458508

  Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy
1

NCT02433171

  Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery
1

NCT02433392

  Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Surgically Resectable Glioblastoma Multiforme.
1

NCT02439268

  The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf®) in Advanced Patients Harboring the V600 BRAF Mutation
1

NCT02441088

  Theranostics: 68GaDOTATOC and 90YDOTATOC
1

NCT02441322

  Evaluating Therapeutic Response to Novo-TTF
1

NCT02450019

  Protective Ventilation in Neurosurgery, a Pilot Study
1

NCT02451215

  Laser Interstitial Thermal Therapy (LITT) for the Treatment of Pediatric Central Nervous System Tumors
1

NCT02410577

  89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme
1

NCT02419664

  Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
1

NCT02425072

  NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer
1

NCT02390518

  Stereotactic Radiosurgery Dose Escalation for Brain Metastases
1

NCT02390752

  Phase I/II Trial of PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
1

NCT02391246

  Radionecrosis and FDG PET
1

NCT02391493

  Neural Correlates of Language Control in Bilinguals. Functional MRI and Stimulation Mapping Data in Awake Surgery.
1

NCT02393131

  Neurocognitive Outcome of Conformal WBRT w/wo Hippocampal Avoidance for Brain Metastases
1

NCT02388659

  Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas
1

NCT02389738

  Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
1

NCT02374983

  Gamma Knife Dosimetric Differences, TMR 10 Versus Convolution Algorithm
1

NCT02375334

  Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy
1

NCT02363075

  Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia
1

NCT02363933

  Perampanel in Seizure Patients With Primary Glial Brain Tumors
1

NCT02343224

  Phase II Pegylated Interferon
1

NCT02358187

  A Vaccine Trial for Low Grade Gliomas
1

NCT02367469

  Tryptophan Metabolism in Human Brain Tumors
1

NCT02367482

  Tryptophan Metabolism in Human Brain Tumors
1

NCT02370563

  PET Imaging of Intracranial Cancers With 18F-FSPG
1

NCT02371031

  FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas
1

NCT02337686

  Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma
1

NCT02338011

  Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)
1

NCT02338037

  Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors
1

NCT02343549

  A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
1

NCT02343991

  Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound
1

NCT02351700

  Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors
1

NCT02355613

  Comparative Evaluation of Two Different Radiosurgery
1

NCT02328300

  FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
1

NCT02329795

  Image-derived Prediction of Response to Chemo-radiation in Glioblastoma
1

NCT02337426

  Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
1

NCT02331498

  Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
1

NCT02331693

  CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
1

NCT02302235

  Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study
1

NCT02303678

  D2C7 for Adult Patients With Recurrent Malignant Glioma
1

NCT02303938

  Effects of Exercise on Cognitive Function in Glioma Patients
1

NCT02305056

  Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC)
1

NCT02310516

  Prospective Evaluation of the Impact of Pre-operative Device on the Personal Experience of Brain Awake Surgery
1

NCT02311556

  Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance Imaging
1

NCT02312622

  Phase II Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
1

NCT02313272

  Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
1

NCT02504788

  A Prospective Study of the Impact of Hippocampal Avoidance During Whole Brain Radiotherapy on Neurocognitive Function Decline
1

NCT02507583

  Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
1

NCT02510950

  Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
1

NCT02518061

  11C-Methionine PET as Prognostic Marker of Gliomas
1

NCT02520492

  Non Invasive Measurements of Intracranial Pressure in Patients With Malignant Glioma
1

NCT02520635

  Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients
1

NCT02520882

  68Ga-NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas
1

NCT02537106

  A Comparison of the Effect of 1.5 Versus 3% NaCl on Brain Relaxation and Microcirculation
1

NCT02540161

  Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
1

NCT02541370

  Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
1

NCT02544178

  Study of Neurological Complication After Radiotherapy for High Grade Glioblastoma
1

NCT02546453

  Use of Specific Genetic Alteration s of Tumoral Cells Identified by the Next Generation Sequencing Techniques (NGS) to Follow Peripheral Samples of Children With Metastatic and/or High Risk Solid Tumor - NGSKids
1

NCT02550249

  Neoadjuvant Nivolumab in Glioblastoma
1

NCT02556593

  IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
1

NCT02558335

  CTCs for High Grade Glioma
1

NCT02559752

  Computer-based Neurocognitive Assessment in Children With Central Nervous System Tumors Receiving Proton Beam Radiation Therapy
1

NCT02563925

  Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
1

NCT02500459

  Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection
1

NCT02574793

  Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects
1

NCT02575261

  CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
1

NCT02576522

  Tumor Bed Hypofractionated IMRT After Surgery for Patients With Single,Large Brain Metastases From Solid Tumor
1

NCT02580045

  Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer
1

NCT02530502

  Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
1

NCT02530749

  Frailty as a Predictor of Neurosurgical Outcomes in Brain Tumor Patients
1

NCT02565433

  Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases (PRAMECE-1302)
1

NCT02567539

  Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma
1

NCT02567643

  Stereotactic Radiosurgery (SRS) for Multiple CNS Mets
1

NCT02571530

  Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer
1

NCT02484755

  Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease
1

NCT02489071

  Cognitive Intervention After a Brain Tumor
1

NCT02490930

  A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
1

NCT02496741

  Metformin And Chloroquine in IDH1/2-mutated Solid Tumors
1

NCT02420613

  Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG)
1

NCT02473380

  Fluorescence Spectroscopy Guided Surgery
1

NCT02389530

  Use of Fluorescein Dye for the Removal of Brain Tumors
1

NCT02394665

  MRSI Guided Dose Escalated Radiation in Glioblastoma
1

NCT02366728

  DC Migration Study for Newly-Diagnosed GBM
1

NCT02372409

  Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
1

NCT02439164

  Case-cohort Study of Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma
1

NCT02444000

  gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas
1

NCT02444546

  Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
1

NCT02473484

  Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas
1

NCT02478346

  Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions
1

NCT02334722

  1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
1

NCT02120287

  Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme
1

NCT02149459

  Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy
1

NCT02166658

  A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)
1

NCT02193347

  IDH1 Peptide Vaccine for Recurrent Grade II Glioma
1

NCT02201563

  Minocycline Therapy for Management of Adverse Radiation Effects
1

NCT02230306

  Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
1

NCT01110876

  Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
1

NCT01105702

  Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
1

NCT01106794

  Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
1

NCT01046123

  Volumetric Modulated Arc Therapy (VMAT) for Brain Metastases
1

NCT01051557

  Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
1

NCT01115777

  Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
1

NCT01116661

  Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain
1

NCT01117168

  Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group
1

NCT01117844

  Proton Radiation For Meningiomas and Hemangiopericytomas
1

NCT01120639

  PI/II of Temozolomide & Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
1

NCT01122888

  Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
1

NCT01124461

  BIRN (Biomedical Informatics Research Network) Resources Facilitate the Personalization of Malignant Brain Tumor
1

NCT01125046

  Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
1

NCT01128218

  A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
1

NCT01130077

  A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
1

NCT01135550

  Low Dose Versus Usual Dose Dexamethasone for Symptom Control in Children Undergoing Cranial or Craniospinal Radiation
1

NCT01165632

  Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
1

NCT01144247

  Cellular Immunotherapy Study for Brain Cancer
1

NCT01151670

  Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
1

NCT01201538

  A Study of Nilotinib in Growing Vestibular Schwannomas
1

NCT01209442

  Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
1

NCT01212237

  Dose Response of Functionally Critical Brain Regions for Brain Radiotherapy
1

NCT01212731

  Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
1

NCT01172912

  High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy
1

NCT01172964

  A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
1

NCT01180816

  Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA
1

NCT01181193

  Vitamin D for Treatment of Glioblastoma Multiforme
1

NCT00995007

  A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
1

NCT00998010

  Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
1

NCT00961090

  Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
1

NCT00968240

  Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)
1

NCT00981890

  Stereotactic Radiosurgery With Sunitinib for Brain Metastases
1

NCT01065805

  A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma
1

NCT01067469

  Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
1

NCT01083966

  Intraarterial Cerebral Infusion of Avastin for Vestibular Schwannoma (Acoustic Neuroma)
1

NCT01086345

  Radiosurgery Plus Bevacizumab in Glioblastoma
1

NCT01018836

  Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
1

NCT01024907

  Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas
1

NCT00897286

  Study of Stored Tumor Samples in Young Patients With Brain Tumors
1

NCT00890032

  Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme
1

NCT00893945

  Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors
1

NCT00943007

  Comparison of Standard Neuronavigation With Intraoperative Magnetic Resonance Imaging (MRI) for the Neurosurgical Treatment of Malignant Brain Tumors
1

NCT00946673

  Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
1

NCT00950001

  Resection Bed Post-Surgical Stereotactic Radiosurgery (SRS)
1

NCT00928226

  Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
1

NCT00935090

  3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
1

NCT00939315

  Multimodal Diagnostic Assessment of Cerebral Gliomas With FET & FCH PET/CT, and Magnetic Resonance Imaging/Spectroscopy
1

NCT00939523

  Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
1

NCT00308165

  Safety Study of Intracerebral Topotecan for Recurrent Brain Tumors
1

NCT00313599

  Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
1

NCT00323076

  Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
1

NCT00301418

  Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
1

NCT00330109

  Identification of Clinically Occult Glioma Cells and Characterization of Glioma Behavior Through Machine Learning Analysis of Advanced Imaging Technology
1

NCT00001595

  An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
1

NCT00001686

  Evaluation, Treatment, and Natural History of Children With Cancer
1

NCT00009035

  Natural History of Patients With Brain and Spinal Cord Tumors
1

NCT00054756

  Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
1

NCT00060541

  Evaluation and Treatment of Neurosurgical Disorders
1

NCT00075387

  Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
1

NCT00085202

  Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
1

NCT00103038

  Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
1

NCT00125710

  Comparative 2-D Tumor Analysis in Familial Gliomas
1

NCT00179907

  A Phase I/II Study of the Photon Radiosurgery System
1

NCT00267865

  Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
1

NCT00445965

  Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
1

NCT00390299

  Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
1

NCT00628940

  PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?
1

NCT00490334

  Assessment and Rehabilitation of Cognitive Impairments in Pediatric Survivors of Cancer
1

NCT00521183

  Cytochlor, Tetrahydrouridine, and External-Beam Radiation Therapy in Treating Patients With Cancer That Has Spread to the Brain
1

NCT00570908

  Brain Mets - Capecitabine and WBRT
1

NCT00598351

  Natural History Study of Patients With Neurofibromatosis Type 2
1

NCT00598949

  Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma
1

NCT00760409

  Prospective Study Differentiating Recurrent Brain Tumor Versus Radiation Injury Using Magnetic Resonance (MR) Spectroscopy, Diffusion Tensor Imaging and Diffusion Weighted Imaging on 3T(Tesla) MR Scanner
1

NCT00837928

  Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors
1

NCT00841555

  Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
1

NCT00857922

  Neurosciences Research Repository
1

NCT00880061

  An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma
1

NCT00883298

  Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
1

NCT00870129

  Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
1

NCT00876759

  Whole-Brain Radiotherapy (WBRT) Versus WBRT and Integrated Boost Using Helical Tomotherapy for Multiple Brain Metastases
1

NCT00876993

  Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
1

NCT00638898

  Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
1

NCT00724191

  Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)
1

NCT00660543

  Magnetic Resonance (MR) Imaging Study Using Ferumoxytol to Assess Early Tumor Response in Patients With Glioblastoma Multiforme
1

NCT00686387

  Establishment of a Brain and Spinal Tumor Tissue Bank
1

NCT00707343

  [F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
1

NCT00769093

  Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
1

NCT00798057

  Proton Radiation Therapy for Pituitary Adenoma
1

NCT00805103

  Perfexion Brain Metastasis
1

NCT00805376

  Delta-24-RGD for Recurrent Malignant Gliomas
1

NCT00811148

  Florida Center for Brain Tumor Research
1

NCT00813566

  Multi-Tracer PET Assessment of Primary Brain Tumors
1

NCT00813787

  Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-exponential T2 Components
1

NCT00823797

  Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
1

NCT01217996

  Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
1

NCT01222780

  To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
1

NCT01222728

  Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
1

NCT01228448

  In-Room PET in Proton Radiation Therapy
1

NCT01235793

  The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma
1

NCT01238237

  Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
1

NCT01240161

  Personalized Translational Platform for Biomarker Discovery in Brain Tumors
1

NCT01246869

  Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water
1

NCT01250470

  Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
1

NCT01252797

  Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases(RAD 1002)
1

NCT01272622

  Prospective Study of Children and Adolescents With Craniopharyngioma
1

NCT01276210

  Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases
1

NCT01263821

  Image Guided Therapy in the Treatment of Gliomas
1

NCT01266031

  Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
1

NCT01269853

  Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
1

NCT01301560

  Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain Metastasis
1

NCT01288235

  Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
1

NCT01303835

  Low-Dose Naltrexone for Glioma Patients
1

NCT01305941

  A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
1

NCT01419834

  Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors
1

NCT01430351

  Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)
1

NCT01434602

  Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
1

NCT01442220

  Genome-wide Association Study of Pituitary Tumors
1

NCT01445288

  Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
1

NCT01445483

  Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases
1

NCT01393912

  PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma
1

NCT01400672

  Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma
1

NCT01403610

  Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
1

NCT01410370

  Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases
1

NCT01414738

  Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases
1

NCT01332630

  TPI 287 in Breast Cancer Metastatic to the Brain
1

NCT01324635

  Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
1

NCT01351519

  A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors
1

NCT01358058

  Proton Radiation Therapy for Gliomas
1

NCT01363557

  Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis
1

NCT01368133

  The Observational Study of Growth Hormone-secreting Pituitary Tumors
1

NCT01386450

  AZD6244 in Children With Low-Grade Gliomas
1

NCT01342237

  Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors
1

NCT01377701

  The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor
1

NCT01378481

  High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma
1

NCT01479686

  iMRI Guided Resection in Cerebral Glioma Surgery
1

NCT01514877

  Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
1

NCT01516905

  PET/CT Imaging of Malignant Brain Tumors With 124I-NM404
1

NCT01526837

  Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
1

NCT01518621

  Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer
1

NCT01522820

  Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
1

NCT01499251

  Macitentan in Combo With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma
1

NCT01502280

  Fluorescence-guided Surgery for Low- and High-grade Gliomas
1

NCT01502917

  Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
1

NCT01508104

  Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
1

NCT01508117

  Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
1

NCT01508221

  Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis
1

NCT01464177

  Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
1

NCT01447810

  Constraint-Induced Movement Therapy in a Pediatric Oncology Population
1

NCT01454596

  CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
1

NCT01456455

  Gastric Cancer Metastasized to the Central Nervous System (CNS)
1

NCT01473485

  ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors
1

NCT01476878

  Frameless Stereotactic Radiosurgery for Brain Metastases
1

NCT01465672

  Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis
1

NCT01480583

  GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
1

NCT01484873

  Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor
1

NCT01491893

  PVSRIPO for Recurrent Glioblastoma (GBM)
1

NCT01574092

  Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas
1

NCT01577966

  Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma
1

NCT01578668

  Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
1

NCT01582152

  Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
1

NCT01582516

  Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma
1

NCT01586078

  Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Patients With Brain Tumors
1

NCT01591577

  Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme
1

NCT01592968

  A Prospective Phase III Trial to Compare Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy
1

NCT01595126

  Longitudinal Study of Biomarkers
1

NCT01601314

  Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients
1

NCT01556230

  Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
1

NCT01567202

  Study of DC Vaccination Against Glioblastoma
1

NCT01604590

  Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme
1

NCT01613417

  Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
1

NCT01538264

  Blood Flow MRI for Monitoring Brain Tumors
1

NCT01540175

  Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant
1

NCT01540513

  PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404
1

NCT01549392

  Imaging Study of Glioblastomas Treated With Avastin
1

NCT01528670

  Monitoring of Patients Treated With Particle Therapy Using Positron-Emission-Tomography (PET): The MIRANDA Study
1

NCT01534104

  MRI and Diffusion Imaging of Eloquent Brain Areas to Optimize Brain Tumor Resection Planning
1

NCT01535183

  Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents
1

NCT01535209

  Stereotactic Radiotherapy of Resection Cavity For Single Brain Metastasis Versus Whole-Brain Radiotherapy After Resection
1

NCT01535430

  Assessment of Eloquent Function in Brain Tumor Patients
1

NCT01535898

  Application of High Resolution Diffusion-weighted MR Imaging Pulse Sequence in Brain, Head and Neck, and Spine Cancer
1

NCT01535911

  Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors
1

NCT00822458

  GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
1

NCT00823459

  Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma
1

NCT01006044

  Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection
1

NCT01009307

  Study of Blood and Cheek Cell Samples From Patients With Glioma
1

NCT00555399

  Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
1

NCT00669669

  O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
1

NCT01756989

  ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors
1

NCT00089245

  Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
1

NCT00152659

  Developing Criteria for Cortical Resections
1

NCT00352599

  Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
1

NCT01088035

  Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma
1

NCT01102595

  Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma
1

NCT01140568

  Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
1

NCT01124240

  Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene
1

NCT01165671

  Carbon Ion Radiotherapy for Primary Glioblastoma
1

NCT01183663

  Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
1

NCT01204684

  Dendritic Cell Vaccine for Patients With Brain Tumors
1

NCT01208831

  An East Asian Study of LDE225
1

NCT01227434

  A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
1

NCT01716468

  Ketogenic Diet in Advanced Cancer
1

NCT01736722

  MRI-Guided LITT for Treatment Metastatic Brain Tumors
1

NCT00313729

  Temozolomide in Treating Patients With Low-Grade Glioma
1

NCT00831324

  Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma
1

NCT01119599

  RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
1

NCT01724801

  Icotinib Treat the Patient With Brain Metastasis Epidermal Growth Factor Receptor(EGFR) Mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy
1

NCT01727531

  IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy
1

NCT01729260

  Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide
1

NCT01736800

  Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
1

NCT01745081

  Comparison of 20% Mannitol and 3% Hypertonic Saline for Cerebral Relaxation During Elective Supratentorial Craniotomies
1

NCT01753713

  Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
1

NCT01620138

  Expression Profile of Somatostatin Receptors and Dopamine Receptor 2 in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vivo Response to Pasireotide and Cabergoline
1

NCT01635283

  Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
1

NCT01639612

  Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma
1

NCT01640509

  Synchrotron Radiation to the Treatment of Intracranial Tumors
1

NCT01644955

  Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
1

NCT01649830

  Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma
1

NCT01654497

  Dexanabinol in Patients With Brain Cancer
1

NCT01655927

  Efficacy of Tranexamic Acid in Brain Tumor Resections
1

NCT01663012

  Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
1

NCT01666600

  NOA-12: BIBF1120 and R-RT in Glioblastoma
1

NCT01667640

  Sector Irradiation Versus Whole Brain Irradiation for Brain Metastasis
1

NCT01668082

  An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
1

NCT01679743

  GRN1005 for Brain Metastases From Breast or Lung Cancer
1

NCT01688713

  Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer
1

NCT01689064

  Comparison of Surgical Approach to Endoscopic Pituitary Adenoma Resection
1

NCT01689402

  MRI for the Early Evaluation of Acute Intracerebral Hemorrhage
1

NCT01698437

  Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Brain Tumors
1

NCT01705548

  Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
1

NCT01706432

  Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
1

NCT01707836

  Genetic Influences on Pediatric Brain Tumor Development in Neurofibromatosis Type 1
1

NCT01498783

  Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma
1

NCT01517776

  Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents
1

NCT01542736

  Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)
1

NCT01562197

  A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma
1

NCT01473901

  A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
1

NCT01493219

  Biomarkers for Prognosis of Glioblastoma (GBM)
1

NCT01579253

  Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients
1

NCT01580969

  Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma
1

NCT01595139

  MicroRNAs in Patients With Neurofibromatosis Type 1
1

NCT01598454

  Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
1

NCT01637753

  Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma
1

NCT01642342

  Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors
1

NCT01644773

  Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
1

NCT01653834

  Lymphocyte Reinfusion
1

NCT01657734

  Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy
1

NCT01269424

  O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma
1

NCT01301430

  Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
1

NCT01331135

  Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
1

NCT01392352

  HYPAZ: Hypertension Induced by Pazopanib
1

NCT01403285

  Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
1

NCT01424839

  Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors
1

NCT01433991

  E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
1

NCT01443676

  Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma
1

NCT01347307

  Stereotactic Body Radiotherapy for Spine Tumors
1

NCT01721603

  A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases
1

NCT01661400

  Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
1

NCT01674582

  Treatment Effects Inclusive Cognitive Impact and Possibilities to Individually Adjusted Treatment in Patients With Intracranial Tumors With Clinical, Neuropsychological and Imaging Parameters
1

NCT01682746

  Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
1

NCT01450826

  Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
1

NCT01467986

  Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma
1

NCT01738646

  Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
1

NCT01740258

  Bevacizumab Beyond Progression (BBP)
1

NCT01619865

  Safety and Efficacy of 68Ga-DOTA-tyr3-Octreotide
1

NCT01672463

  Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
1

NCT01678352

  Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas
1

NCT01688401

  Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
1

NCT01702610

  Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
1

NCT01721577

  Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas
1

NCT01763385

  Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases
1

NCT01765088

  A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas
1

NCT01767415

  Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection
1

NCT01770626

  A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients
1

NCT01772771

  Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
1

NCT01779219

  iMRI-guided Brain Biopsies
1

NCT00207350

  Neurosurgical Use of Interstitial Laser Therapy (ILT)
1

NCT00852501

  Characterization of Receptors in Non-functioning Pituitary Macroadenomas
1

NCT00978562

  DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors
1

NCT01166308

  Carbon Ion Radiotherapy for Recurrent Gliomas
1

NCT01847235

  Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial
1

NCT01851733

  MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme
1

NCT01987830

  Bevacizumab w / Temozolomide PET & Vascular MRI For GBM
1

NCT01952769

  Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma
1

NCT01991977

  18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
1

NCT01999270

  Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
1

NCT02005614

  A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
1

NCT02006407

  A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors
1

NCT02006563

  Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors
1

NCT02007798

  Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia
1

NCT02010606

  Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
1

NCT01873469

  Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme
1

NCT01875601

  NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
1

NCT01972750

  Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma
1

NCT01974804

  Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
1

NCT01926171

  Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
1

NCT01811992

  Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma
1

NCT01619774

  An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
1

NCT01738880

  Effect of Goal-directed Fluid Therapy Based on Stroke Volume Variation on Metabolic Acidosis in Patients Undergoing Brain Tumor Surgery
1

NCT01985971

  F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer
1

NCT01987596

  Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
1

NCT01988675

  MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier
1

NCT01996527

  3T MRI Biomarkers of Glioma Treatment Response
1

NCT00626483

  Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia
1

NCT02029573

  Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma
1

NCT02031237

  MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
1

NCT02031965

  Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery
1

NCT02070380

  Crossover Comparison of MultiHance and Dotarem
1

NCT02076152

  FMISO PET Study of Glioblastoma
1

NCT02076477

  The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer(NSCLC)
1

NCT02077504

  Glial Tumors Electromagnetic Signature Study by MagnetoEncephaloGraphy (MEG) "CONDUCTOME"
1

NCT02054689

  Fractionated Stereotactic Radiosurgery for Large Brain Metastases
1

NCT02054819

  Treating NSCLC Minimal Stage IV With Curative Intent
1

NCT02060955

  Randomized Phase II Multicentre Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With Glioblastoma Multiforme Measured Compared to Avastin/Irinotecan
1

NCT02067156

  Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
1

NCT02069080

  Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor
1

NCT00147056

  MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors
1

NCT01903330

  ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
1

NCT01950195

  SRS (Stereotactic Radiosurgery) Plus Ipilimumab
1

NCT01986348

  A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
1

NCT02039778

  Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma
1

NCT02045368

  Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
1

NCT02045381

  Optimization of MRI for Radiation Therapy
1

NCT02046187

  Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma
1

NCT02034981

  Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
1

NCT02035852

  High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors
1

NCT02037945

  18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases
1

NCT02014545

  Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
1

NCT02020720

  18F-DOPA-PET in Planning Surgery in Patients With Gliomas
1

NCT02022384

  Immunophenotyping From Blood of Patients With Malignant Gliomas
1

NCT02022800

  Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography (PET)
1

NCT02023346

  Prognostic Awareness and Patient-Physician Communication in Malignant Glioma
1

NCT02025231

  Image Guided Reirradiation of High-grade Glioma
1

NCT02025881

  Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma
1

NCT01860638

  A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
1

NCT01861405

  Neurococognitive and Functioal Assessment of Patients With Brain Metastases
1

NCT01861717

  A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
1

NCT01865162

  Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study
1

NCT01869725

  Gallium Ga 68-Edotreotide PET/CT Compared With Indium In 111 Pentetreotide Plus Contrast-Enhanced CT (or MRI) in Diagnosing Patients With Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors
1

NCT01850563

  A Proof-of-principle Study of Hyperbaric Oxygen as a Radiosensitizer Prior to Stereotactic Radiosurgery for Brain Metastases
1

NCT01854554

  Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)
1

NCT01856933

  BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
1

NCT01880749

  Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
1

NCT01884740

  Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
1

NCT01884922

  Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults
1

NCT01887522

  Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults
1

NCT01887795

  Phase ? Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as ?rst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study
1

NCT01890278

  Phase II Trial of Conventional Versus IMRT Whole Brain Radiotherapy for Brain Metastases
1

NCT01891318

  Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
1

NCT01891747

  A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma
1

NCT01902420

  Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly
1

NCT01902771

  Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
1

NCT01903967

  Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH)
1

NCT01907165

  Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide
1

NCT01908179

  Markers of Prognosis and Response to Therapy in Patients With Metastatic Brain Tumors Undergoing Stereotactic Radiosurgery (SRS)
1

NCT01913067

  Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC
1

NCT01920191

  Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma
1

NCT01939483

  A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
1

NCT01939574

  A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma
1

NCT01942980

  Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer
1

NCT01944761

  The Neuro-protective Effects of Exercise in Children With Brain Tumors
1

NCT01951469

  Gefitinib With or Without Pemetrexed/Cisplatin in Brain Metastases From Non-small Cell Lung Cancer
1

NCT01951482

  Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer
1

NCT01954576

  NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
1

NCT01956734

  Virus DNX2401 and Temozolomide in Recurrent Glioblastoma
1

NCT01957735

  BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
1

NCT01967758

  Phase I Study of Safety and Immunogenicity of ADU-623
1

NCT01777633

  Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children
1

NCT01783756

  Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
1

NCT01731704

  Neurocognitive Outcomes In Patients Treated With Radiotherapy For Five Or More Brain Metastases
1

NCT01742260

  Cranial Reconstruction Using Mesenchymal Stromal Cells and Resorbable Biomaterials
1

NCT01754350

  Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma
1

NCT01756352

  FET-PET for Evaluation of Response of Recurrent GBM to Avastin
1

NCT01792505

  Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma
1

NCT01795313

  Immunotherapy for Recurrent Ependymomas in Children Treatment for Recurrent Ependymomas Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod
1

NCT01800032

  PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
1

NCT01801371

  68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma
1

NCT01801813

  Risk Factors of Complications Regarding Patients Undergoing Brain Tumour Neuro-surgery (Cranioscore).
1

NCT01801852

  Autologous Natural Killer T Cells Infusion for the Treatment of Cancer
1

NCT01813877

  Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
1

NCT01849484

  Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy
1

NCT01849549

  Neuropsychological and Brain Medical Imaging Study in Patients With Brain Damage
1

NCT01804634

  A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors
1

NCT01808820

  Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
1

NCT01810744

  Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma
1

NCT01811121

  MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS
1

NCT01811498

  Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
1

NCT01817751

  Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma
1

NCT01818713

  Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases
1

NCT01821443

  A Single Arm Study of Neurocognitive Outcomes in Patients With Brain Metastases Managed With Stereotactic Radiosurgery (SRS)
1

NCT01822275

  Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme
1

NCT01833273

  Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
1

NCT01843413

  Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases
1

NCT01846871

  Tivozanib for Recurrent Glioblastoma
1

NCT01847833

  Advanced MRI Applications Development
1

NCT02306135

  Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer
1

NCT02306278

  The Effects of Gabapentin Premedication on Neurosurgery
1

NCT02307877

  Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate
1

NCT02294994

  Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease
1

NCT02309567

  Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?
1

NCT02312934

  Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study
1

NCT02314377

  Bevacizumab Therapy for Brain Arteriovenous Malformation
1

NCT02315989

  Early-Phase Safety of Proton Therapy Equipment
1

NCT02316990

  China Survey of Stress Ulcer Bleeding in Critically Ill Neurosurgical Patients
1

NCT02317055

  Magnetic Resonance Imaging Evaluation of the Tissular Oxygen Saturation in Brain
1

NCT02317783

  Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
1

NCT02322853

  A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
1

NCT02322918

  The BC Psychosis Program Biobank and Database for Genetic Polymorphisms and Their Associations With Psychosis Disorder
1

NCT02323217

  I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers
1

NCT02292238

  Benfotiamine in Alzheimer's Disease: A Pilot Study
1

NCT02275416

  Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
1

NCT02281760

  Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease
1

NCT02296216

  Late Effects of Radiosurgery on Acromegaly Study
1

NCT02297893

  Improving Dexterous Skills in Parkinson's Disease
1

NCT02302534

  Pilot Study of Functional and Morphometric Brain Abnormalities Related to Adolescent Idiopathic Scoliosis (MOR-FO-SIA)
1

NCT02273635

  Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
1

NCT02243033

  Laser Interstitial Thermal Therapy of Prostate Cancer
1

NCT02284022

  Clinical Validation Protocol for BCI for the Communication of Patients Suffering From Neuromuscular Disorders.
1

NCT02285348

  Oxidative Stress, Low Grade Inflammation, Tissue Breakdown and Biomarkers in Cerebrospinal Fluid of A-T
1

NCT02288078

  Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)
1

NCT02330744

  The Neurobiology of Approach Avoidance Training in Depression
1

NCT02333006

  Anosognosia Evaluation After Cranocerebral Trauma Moderate to Severe
1

NCT02333838

  Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies
1

NCT02334904

  Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI
1

NCT02334969

  Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM
1

NCT02336282

  Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia
1

NCT02340715

  Advanced MRI Sequences for Radiation Therapy Treatment Planning
1

NCT02342587

  Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer
1

NCT02347579

  Neurophysiological Basis of Rehabilitation in Complex Regional Pain Syndrome, Type I and Chronic Low Back Pain
1

NCT02351518

  Cerebral Autoregulation and Vasospasm in Patients With TBI
1

NCT02354326

  Dual Energy Computed Tomography (CT) in Finding Bone Metastases in Patients With Cancer
1

NCT02326571

  Multimodal Monitoring in Patients With Spontaneous Intracerebral Hemorrhage
1

NCT02327442

  68Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and Applications in Glioma Patients or Breast Cancer Patients
1

NCT02327871

  Esophageal Temperature Management After Cardiac Arrest
1

NCT02379611

  Study of Neurologic Development of Temporal Voice Area (TVA) in Deaf Infant
1

NCT02383407

  Low Frequency Electrical Stimulation of the Fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)
1

NCT02383524

  Genetic Predictors of Responsiveness to Radiofrequency Denervation in Chronic Low Back Pain
1

NCT02384031

  Post-dural Puncture Headache - Needles and Biomarkers in CSF
1

NCT02386241

  Identification of Genomic Changes in Families Having Multiple Members With Tumors
1

NCT02387840

  Feasibility and Clinically Application of Magnetic Resonance Fingerprinting
1

NCT02388204

  Spinal Cord Stimulation for the Treatment of Motor and Nonmotor Symptoms of Parkinson's Disease
1

NCT02392975

  Fast MR for Young Children With Traumatic Brain Injury
1

NCT02394002

  SEP Changes During Deep Anesthesia
1

NCT02357875

  Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)
1

NCT02360527

  Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease
1

NCT02360917

  Emerging From the Haze™- Measuring the Impact of a Psycho-education Program on Perceived Cognition After Breast Cancer Treatment
1

NCT02361658

  Optic Nerve Sheath Diameter (ONSD) With the Raised PCO2 and Internal Jugular Venous Occlusion
1

NCT02162849

  Reward Sensitivity and Pharmacotherapy for Smoking Cessation
1

NCT02163330

  Normal Pressure Hydrocephalus Treatment by Acetazolamide
1

NCT02128373

  A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer
1

NCT02131688

  Phase I Study of Mitoxantrone Hydrochloride Liposome Injection
1

NCT02132884

  Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
1

NCT02134808

  Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
1

NCT02142335

  Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
1

NCT02142413

  HEart and BRain Interfaces in Acute Ischemic Stroke
1

NCT02145117

  Brain Biomarkers w/Mind-Body Tx in Veterans With Post Traumatic Headache (PTH)
1

NCT02146404

  The Effect of Hypoglycaemia on Brain Lactate Accumulation and Cerebral Blood Flow
1

NCT02146963

  Study of the BDNF-Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal
1

NCT02151448

  ?DC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
1

NCT02158988

  Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis
1

NCT02160535

  Treatment of Chronic Post-Traumatic Headache With OnabotulinumtoxinA
1

NCT02160730

  Treatment of Cushing's Disease With R-roscovitine
1

NCT02199795

  Functional Electrical Stimulation Mediated Neuroplasticity: Lower Extremity CCNMES in Stroke
1

NCT02192567

  Open Label Study of DS-5573a
1

NCT02192931

  A Feasibility Placebo-Controlled Study of Creatine in Depressed Meth-Using Females
1

NCT02180594

  Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients
1

NCT02180984

  The Effects of Repetitive Transcranial Magnetic Stimulation in Obese People With BED
1

NCT02184936

  Measuring Collaterals With Multi-phase CT Angiography in Patients With Ischemic Stroke
1

NCT02188550

  Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
1

NCT02167412

  EEG Characteristics in Youth POTS and/or Syncope
1

NCT02169739

  Remote Preconditioning Over Time To Empower Cerebral Tissue
1

NCT02170298

  Lisdexamfetamine's Effect In ADHD in the Brain and Cognition
1

NCT02172703

  Non-invasive Brain Pressure Monitoring After Trauma or Hemorrhage
1

NCT02178917

  Neurofeedback for Treatment of Central Neuropathic Pain (CNP) in Sub-acute Spinal Cord Injury (SCI)
1

NCT02179060

  Prehospital Resuscitation Intranasal Cooling Effects Seen in MRI of the Brain After Cardiac Arrest
1

NCT02179762

  Vigorous or Moderate Exercise in Enhancing Active Surveillance in Patients With Localized Prostate Cancer
1

NCT02252523

  Dexmedetomidine-based Sedation in Neurocritical Care Patients
1

NCT02253264

  A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
1

NCT02254759

  A Phase 1 Study in Healthy Volunteers to Investigate Possible Interactions Between RG1662 and Midazolam
1

NCT02254863

  UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
1

NCT02255929

  Gamma Knife Radiosurgery for Treatment of Essential Tremor
1

NCT02256137

  A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
1

NCT02261649

  Impact of Cerebellar Mass Resection on Pain Processing
1

NCT02263183

  Red Palm Olein and Cardiovascular Health
1

NCT02266121

  Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
1

NCT02266329

  Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin
1

NCT02268344

  Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection
1

NCT02269540

  A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)
1

NCT02246231

  Effect of Implant Position on Magnetic Resonance Image Distortion
1

NCT02246491

  Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia
1

NCT02248233

  Nimodipine for Treating Acute Massive Cerebral Infarction
1

NCT02248311

  "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
1

NCT02249676

  Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders
1

NCT02230267

  High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease
1

NCT02231073

  Exercise, Brain Imaging, Cognition, and Gait in Parkinsonism
1

NCT02232919

  Deep Brain Stimulation for Human Morbid Obesity
1

NCT02233348

  Neurocognitive and Psychosocial Outcome of Youths With Autism Spectrum Disorder
1

NCT02235441

  Effects of Chemoradiation and Surgery on Cardiopulmonary Fitness and Tumor Neoplastic Phenotype in Gastrointestinal Malignancies
1

NCT02237235

  Effect of Magnesium Threonate (MgT) on Cognitive Enhancement in Schizophrenia
1

NCT02238769

  18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular Carcinoma
1

NCT02223585

  Gut Microbiota and Proteins Intake
1

NCT02226042

  Investigating the Mechanisms of Mindfulness-based Cognitive Therapy (MBCT)
1

NCT02226848

  Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in People With Persistent Symptoms During the Subacute Period After Traumatic Brain Injury
1

NCT02203994

  Extracorporeal Shock Wave Therapy (ESWT) for the Treatment of Spasticity in Persons With Spinal Cord Injury
1

NCT02205268

  Near Infrared Spectroscopy Neurofeedback Training for ADHD
1

NCT02207075

  Measuring Active Microglia in Progressive Multiple Sclerosis
1

NCT02210130

  The Microvascular Brain Retina And Kidney Study
1

NCT02212496

  Identification the Cause of Cerebral Infarction in Patients With Cancer
1

NCT02559401

  Validation of Edema-invariant Multi-shell High Angular Resolution Diffusion Imaging (msHARDI)-Based Tractography With Intra-operative Cortical Stimulation
1

NCT02563691

  Stereotactic Radiotherapy for Oligometastatic Prostate Cancer
1

NCT02565927

  A Trail of a Novel Tracheal Radioactive Stent for the Malignant Airway Obstruction
1

NCT02567318

  Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia?
1

NCT02569918

  Use of Hand Prosthesis With Surface Electrical Stimulation for Treatment of Phantom Limb Pain
1

NCT02569957

  Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
1

NCT02573441

  KEYS to Succeed: Cognitive and Academic Intervention Program for Children and Adolescents Surviving Cancer
1

NCT02573766

  Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy
1

NCT02537080

  The Effect of Nimodipine on the Postoperative Cognitive Dysfunction
1

NCT02582528

  Cognitive Remediation in Youth at Risk of Serious Mental Illness
1

NCT02584647

  PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
1

NCT02553967

  Breast Reconstruction and Body Map : Assessment by Functional MRI (REMASCO)
1

NCT02554331

  Gait and REM Sleep Behavior Disorder
1

NCT02555982

  Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor
1

NCT02547168

  Determining the True Incidence of Atrial Fibrillation Before and After Lung Resection
1

NCT02549768

  Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery
1

NCT02551029

  fMRI and Visceral Perception Upon Capsaicin Infusion
1

NCT02544763

  A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex.
1

NCT02545803

  The Effect of High Frequency Percussive Ventilation on Cerebral Tissue Oxygenation
1

NCT02535325

  Methoxyamine, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
1

NCT02643914

  Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings
1

NCT02639325

  Tumor Related Epilepsy
1

NCT02635009

  Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer
1

NCT02635347

  Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study
1

NCT02636218

  Ketamine Infusion in Neurologic Deficit
1

NCT02605811

  Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
1

NCT02606591

  Houston Independent School District (HISD) Yoga Evaluation
1

NCT02608424

  Effects of Feet Mechanical Stimulation on Cardiovascular Autonomic Profile and Inflammation in Parkinson's Disease
1

NCT02611544

  Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors
1

NCT02632019

  Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract
1

NCT02615132

  TeleRehab for Stroke Patients Using Mobile Technology
1

NCT02624284

  tDCS Effects on Resisting Smoking: Dose Ranging Study
1

NCT02588638

  Next Generation Sequencing Diagnostics - On the Road to Rapid Diagnostics for Rare Diseases
1

NCT02590133

  A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC
1

NCT02591316

  Nutrition, Physical Activity, and Cognition in Breast Cancer Survivors
1

NCT02594800

  Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis
1

NCT02595190

  Treatment of the Symptomatic Sacral Perineurial Cysts
1

NCT02595723

  Phenytoin for Memory Impairment Secondary to Megestrol
1

NCT02595801

  Surgery in Early Life and Child Development at School-entry: A Population-based Study
1

NCT02602756

  Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas
1

NCT02586597

  Paired Associative Stimulation in Stroke
1

NCT02587715

  A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
1

NCT02598973

  Effect of Exercise in Parkinsonism
1

NCT02599168

  Effect of Dexmedetomidine on Propofol Requirement During Anesthesia
1

NCT02423044

  Spatial Context and Fear Learning
1

NCT02423239

  A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
1

NCT02423291

  A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL
1

NCT02424916

  Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study
1

NCT02428062

  Target Hemodynamics and Brain Injury During General Anesthesia in the Elderly
1

NCT02419131

  Cognitive-Behavior Therapy for Posttraumatic Headache
1

NCT02420067

  Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients
1

NCT02420639

  Prospective, Interventional Study Evaluating the Feasibility and Safety of the Esophageal Cooling Device
1

NCT02421744

  A Task-oriented Circuit Training in Multiple Sclerosis
1

NCT02432521

  Predictors of Treatment Response of Motor Sequels After a Stroke
1

NCT02434224

  Creative Music Therapy for Premature Infants
1

NCT02436746

  The Cognitive Variability in NF1 and TSC Monozygotic Twins
1

NCT02441491

  Treatment of Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation (ROHHAD )
1

NCT02443350

  Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area
1

NCT02446886

  Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS
1

NCT02448069

  Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke
1

NCT02448576

  PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy
1

NCT02406105

  An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson Disease
1

NCT02408016

  Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
1

NCT02409238

  Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study
1

NCT02412176

  Right Ventricular Apical Versus True Mid-septal Pacing
1

NCT02414269

  Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
1

NCT02399371

  Pembrolizumab in Treating Patients With Malignant Mesothelioma
1

NCT02397733

  Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)
1

NCT02363738

  12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression
1

NCT02364713

  MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
1

NCT02366741

  Neurocognitive Function After Prophylactic Cranial Irradiation & Hippocampal Sparing in LD SCLC Patients - a Pilot Study
1

NCT02369328

  Multimodal MRI Study of Ischemic Stroke
1

NCT02373605

  Spinal Manipulation and Dry Needling Versus Conventional Physical Therapy in Patients With Cervicogenic Headache
1

NCT02464696

  Early Non Invasive Ventilation and Hematological Malignancies
1

NCT02465346

  "Mobile Stroke Unit"-Concept for Delivery of Specialized Acute Stroke Care to Patients in Remote Areas
1

NCT02483130

  Effect of N-acetylcysteine on Brain Glutamate
1

NCT02483663

  Brain Regulation of Appetite in Twins
1

NCT02480803

  INfusion VErsus STimulation in Parkinson's Disease
1

NCT02457715

  Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
1

NCT02418325

  A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
1

NCT02451696

  A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
1

NCT02452216

  Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS
1

NCT02452502

  The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke
1

NCT02521818

  Dietary Treatments for Cognitive Impairment in Older Adults
1

NCT02524886

  Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia
1

NCT02514720

  Nicotine Metabolizers and [11C]-(+)-PHNO
1

NCT02515487

  An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors
1

NCT02530658

  Next Generation Sequencing of Tumor and Normal Tissues Prospectively in Pediatric Oncology Patients at St. Jude Children's Research Hospital
1

NCT02531581

  Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive
1

NCT02506608

  Use of Hand Prosthesis With Direct Nerve Stimulation for Treatment of Phantom Limb Pain
1

NCT02488668

  Surface Electrical Stimulation for Treatment of Phantom Limb Pain
1

NCT02491476

  Recording "Fast Ripples" Using Microelectrodes During Stereo-encephalography in Patients With Drug-resistant Partial Epilepsy
1

NCT02499302

  Mental Training for CFS Following EBV Infection in Adolescents
1

NCT02499835

  Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
1

NCT02500628

  Heart Rate Variability in Response to Metformin Challenge
1

NCT02502253

  BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes
1

NCT02504892

  Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
1

NCT02844608

  Feasibility of Quality of Life Assessment in Routine Clinical Oncology Practice at the University Hospital of Besancon
1

NCT02844868

  Evaluation of the Observance and the Tolerance of a Motor Training Program
1

NCT02845492

  Evaluating Qigong as a Clinical Intervention for Cancer Survivors' Fatigue
1

NCT02850666

  Social Skills in Children With ASD and Process Drama
1

NCT02853240

  Effect of Botulinum Toxin on Muscles of Children With Cerebral Palsy
1

NCT02854267

  Organ Procurement : Usefulness of a Guide for Meeting With the Next of Kin
1

NCT02855034

  Evaluation of Discriminating Power of Two Biomarkers in the Evaluation of Cerebral Lesions Due to Head Injuries in Infants and Children
1

NCT02855476

  HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
1

NCT02858466

  Structural and Functional Brain Reorganization in Neuropathic Pain: Basal State of Local Cerebral Blood Flow and Functional Connectivity
1

NCT02858479

  Structural and Functional Brain Reorganization in Neuropathic Pain. Influences of the Loss of Sensitivity and the Atrophy Cortical on Activations Due to Stimulation Allodynic
1

NCT02859389

  Neurocognitive and Psychosocial Outcomes in Survivors of Childhood Leukemia With Down Syndrome
1

NCT02859441

  A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
1

NCT02861742

  Impact of Emotional Skills of Young Women and Their Partner on Adjustment to Cancer
1

NCT02866240

  Safety and Therapeutic Measures of Tdcs in Patients With Refractory Focal Epilepsy
1

NCT02866981

  Observation for Patients With Asymptomatic CNS Metastatic Disease
1

NCT02868008

  Multimodal Imaging Techniques in Assessing the Surgical Risk for Eloquent Arteriovenous Malformations
1

NCT02874209

  Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
1

NCT02874820

  I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD
1

NCT02896504

  Chemotherapy Effect on Brain Structure, Neurophysiology and Psychomotor Behavior in Breast Cancer Patients
1

NCT02896881

  Interest of New MRI Sequences After Embolization of Brain Arteriovenous Malformations
1

NCT02899611

  A Dose Ranging Pilot Study to Assess Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures
1

NCT02900326

  Mindfulness-based Stress Reduction (MBSR) Program Combined With Endurance Exercise Training: a Help in Treatment for Breast Cancer?
1

NCT02881151

  Deep Brain Stimulation for the Treatment of Traumatic Brain Injury
1

NCT02886377

  The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset
1

NCT02887417

  Glioblastoma Platelet Activation Study
1

NCT02892877

  The French National Reference Centre of GTD
1

NCT02836340

  TIBOHCA: Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After OHCA
1

NCT02839720

  Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
1

NCT02843477

  Evaluation of Corrected Carotid Artery Flow Time as a Predictor of Fluid Responsiveness in Spontaneous Breathing Patients
1

NCT02877849

  Brain Functional Connectivity in Alcohol Use Disorder
1

NCT02879071

  Long Term Follow-up After Embolization of Brain Arteriovenous Malformations
1

NCT02880111

  Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa
1

NCT02812433

  Sildenafil Administration to Treat Neonatal Encephalopathy
1

NCT02813044

  Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor
1

NCT02820116

  The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
1

NCT02820454

  Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles
1

NCT02823158

  Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM
1

NCT02825472

  Exercise Training in Grown-up Congenital Heart Disease
1

NCT02826200

  Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC)
1

NCT02828787

  Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging.
1

NCT02829502

  The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke
1

NCT02833792

  Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease
1

NCT02777060

  Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures
1

NCT02778971

  Implications for Management of PET Amyloid Classification Technology
1

NCT02805400

  Neurocognitive Performance During Space Flight. Validation of a Test Battery
1

NCT02806778

  Monitoring of Cerebral Oxygenation Using Jugular Oximetry in Comatose Patients After Cardiac Arrest
1

NCT02809430

  Stroke and CPAP Outcome Study 2
1

NCT02809651

  Confounding Factors in the Detection of Intracranial Hemorrhage With the Infrascanner
1

NCT02810899

  Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy
1

NCT02791425

  Brain Computer Interface for Communication in Ventilated Patients
1

NCT02793921

  Exercise Program in Cancer and Cognition
1

NCT02795507

  Cross Education in Patients With Sensorimotor Impairment
1

NCT02796040

  Exploration of Mesocorticolimbic Pathway in Impulse Control Disorders in Parkinson's Disease: Study Using Tensor Diffusion Imaging and Tractography.
1

NCT02796495

  Use of Hand Prosthesis With Direct Nerve Stimulation for Treatment of Phantom Limb Pain
1

NCT02798003

  Food Reward in Cachexia Induced by Acute or Chronic Disease
1

NCT02801084

  Effects of Restricted Environmental Stimulation on Eating Disorders
1

NCT02803619

  A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis
1

NCT02761096

  Effect of Acupuncture on Inflammation and Immune Function After Craniotomy
1

NCT02762539

  Omega3 PUFA in Head Trauam
1

NCT02767154

  Dextran-based Priming vs. Crystalloid and Mannitol-based Priming Solution in Adult Cardiac Surgery
1

NCT02768571

  Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke
1

NCT02769000

  Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's
1

NCT02770300

  Effect of Personalized Robotic Therapy
1

NCT02771925

  Treatment for Alcohol Dependence With Gabapentin
1

NCT02649985

  Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease
1

NCT02650427

  A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection
1

NCT02650492

  Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma
1

NCT02654015

  INVEST: Minimally Invasive Endoscopic Surgery vs. Medical Management in Supratentorial Intraparenchymal Hemorrhage
1

NCT02654340

  Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex
1

NCT02657460

  Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion
1

NCT02661308

  Reducing Cancer Side-effects With Systematic Light Exposure
1

NCT02662504

  Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma
1

NCT02663557

  The Influence of Circadian and Long-term Blood Pressure Variation on the Recurrent Stroke
1

NCT02665104

  Middle Cerebral Artery Velocity and Oxygen Saturation of the Brain During Carotid Endarterectomy
1

NCT02665988

  Adjunctive Transcranial Direct Current Stimulation
1

NCT02666547

  68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis
1

NCT02667496

  Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
1

NCT02668172

  Pasireotide LAR and Pegvisomant Study in Acromegaly
1

NCT02668848

  The Fluid Therapy Strategy of the Non-dehydrated Patients With Acute Ischemic Stroke.
1

NCT02677077

  Clinical Disease Activity With Long Term Natalizumab Treatment
1

NCT02677987

  The "Light for the Brain" Study
1

NCT02680977

  Mucuna Pruriens Therapy in Parkinson's Disease
1

NCT02681822

  Multi-center Imaging Genetics Studies in China
1

NCT02682199

  Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation
1

NCT02682914

  Stroke in Korean Young Adults Study
1

NCT02683174

  Diagnostic Yield of an Ambulatory Patch Monitor in Unexplained Emergency Department Syncope: A Pilot Study (PATCH-ED)
1

NCT02683629

  Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease
1

NCT02690324

  The Development of Skin Adhesive Patches for the Monitoring and Prediction of Mental Disorders
1

NCT02697227

  Behavioral Activation Therapy for Smoking Cessation
1

NCT02672033

  Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma
1

NCT02674243

  Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion
1

NCT02674724

  The Effect of Resistance Training in Parkinson Disease: A Pilot Study
1

NCT02674945

  Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase
1

NCT02708810

  RAD 1501: A Trial of Virtual Cone Trigeminal Neuralgia Radiosurgery
1

NCT02708901

  Gut to Brain Interaction in Autism. Role of Probiotics on Clinical, Biochemical and Neurophysiological Parameters
1

NCT02708953

  Thoracic Spine Thrust Manipulation for Cervicogenic Headaches: A Randomized Clinical Trial
1

NCT02709629

  CCT for Older Diabetic Adults
1

NCT02727361

  Role of the Striatal Cholinergic System in the Pathophysiology of Dystonia
1

NCT02727686

  Post-Operative Water Load Following Transsphenoidal Pituitary Surgery
1

NCT02699918

  Impact of Obstructive Sleep Apnea Syndrome on Metastatic Potential of Cutaneous Melanoma: Prospective Study in Patients With High Risk Melanoma.
1

NCT02710253

  Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy
1

NCT02712385

  SPRITE - A Feasibility and Pilot Study
1

NCT02713984

  A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
1

NCT02717260

  Inhibition Transcranial Random Noise Stimulation
1

NCT02718404

  3 Tesla Magnetic Resonance Guided High Intensity Focused Ultrasound in the Treatment of Pain From Bone Metastases of Solid Tumors
1

NCT02723344

  Biological Signatures, Probiotic Among Those With mTBI and PTSD
1

NCT02723448

  Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy
1

NCT02752191

  Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease
1

NCT02754908

  Effectiveness of Musical Training in Children Surviving Brain Tumours
1

NCT02759536

  In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma
1

NCT02747576

  Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma
1

NCT02750059

  Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis
1

NCT02750371

  Effect of Irradiation of the Cavernous Sinus and the Sellar Region on Autobiographical Memory
1

NCT02751554

  PET Imaging of Patients Using 124I-PU-AD
1

NCT02752022

  Monitoring the Transition From Smoking to E-cigarettes
1

NCT02730858

  Palliative And Oncology Care Model In Breast Cancer
1

NCT02736916

  HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer
1

NCT02741193

  Presurgical Motor Mapping With Transcranial Magnetic Stimulation (TMS)
1

NCT02741440

  Natural History of Spinocerebellar Ataxia Type 7 (SCA7)
1

NCT02742883

  A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)
1

NCT02743052

  Anticoagulation in Cancer Related Stroke
1

NCT02743715

  Transcranial Direct Current Stimulation (tDCS) for Treatment-Resistant Obsessive-Compulsive Disorder (FRONT)
1

NCT03239418

  NMES to Improve Eyelid Functions in Cranial Nerve (CN) III and VII Palsy
1

NCT03239899

  PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
1

NCT03234309

  Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
1

NCT03218293

  Thrombolysis and RIPC in Acute Ischemic Stroke
1

NCT03219502

  Repetitive Transcranial Magnetic Stimulation (rTMS) for Neuropathy
1

NCT03209128

  Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala
1

NCT03214432

  Return to Work After Mild Traumatic Brain Injury
1

NCT03211884

  Evidence-Based Mental Health Services for Distressed Post-9/11 Military Family Caregivers
1

NCT03252912

  Study in Leptomeningeal Metastases of Breast Cancer
1

NCT03253354

  Neurostimulation for Dysphagia in Parkinson's Disease
1

NCT03254381

  The Effect of Exercise on Cognition in Older Adults At-risk for Diabetes: A Feasibility Pilot Study
1

NCT03255707

  A Comparative Study Between Dissociative Treatment and Binocular Interactive Treatment in Amblyopia
1

NCT03259438

  The Vitality Project for Fatigued Female Cancer Survivors
1

NCT03260153

  Deproteinised Calf Blood Serum Injection for the Treatment of Acute Intracerebral Hemorrhage
1

NCT03264300

  Development and Validation of Advanced MRI Methods for Clinical Applications
1

NCT03270059

  Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
1

NCT03272061

  Exercise and Brain Vascular Function
1

NCT03272594

  The Influence of Breastfeeding on Cortical Activity During Procedures
1

NCT03273712

  Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
1

NCT03273816

  Evaluation of the Benefit Provided by Sessions of Sophrology on the Per Operative Management of Parkinsonian Patients Planned for a Deep Brain Stimulation Surgery.
1

NCT03276676

  [18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
1

NCT03279224

  Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder
1

NCT03280485

  Validation of the Scandinavian Guidelines for Management of TBI in Adults
1

NCT03168880

  A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer
1

NCT03168893

  Deep Brain Stimulation for Patients With Chronic, Severe and Resistant Anorexia Nervosa
1

NCT03172104

  Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
1

NCT03141619

  Cerebral Oxygenation and Neurological Outcomes FOllowing CriticAL Illness-2
1

NCT03179449

  In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI
1

NCT03193567

  Study of High Efficient Killing Cell Therapy for Advanced NSCLC
1

NCT03196037

  Feasibility of an 8-week Tai Chi Chuan Intervention for Breast Cancer Survivors
1

NCT03196544

  Novel Behavioral Intervention to Enhance Social Connections in Anxiety and Depression
1

NCT03204604

  The Brain Ketone Body Challenge Imaging Study
1

NCT03187509

  Weight-Based Torsemide Dosing in Subjects With Heart Failure
1

NCT03189472

  Remotely-supervised Transcranial Direct Current Stimulation (tDCS) for At-home Treatment of Fatigue and Cognitive Slowing in Parkinson's Disease
1

NCT03128957

  Correlating Brain Tissue Oxygen and Regional Cerebral Oximetry
1

NCT03151447

  Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer
1

NCT03151772

  Bioavailability of Disulfiram and Metformin in Glioblastomas
1

NCT03154190

  Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
1

NCT03154801

  Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors (NEUROSEX)
1

NCT03159156

  Respiration and Applied Tension Strategies to Reduce Vasovagal Reactions to Blood Donation
1

NCT03164798

  Serum BDNF Role as a Biomarker for Stroke Rehabilitation
1

NCT03117829

  Study: Diet and Exercise Study to Improve Brain Blood Flow: Blood Flow Improvement Trial
1

NCT03119961

  Blood Brain Barrier Opening in Alzheimer' Disease
1

NCT03094910

  Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's Phenomenon
1

NCT03094988

  COgnitive and Physical Exercise (COPE) Prehabilitation Pilot Feasibility Study
1

NCT03095248

  Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
1

NCT03017209

  Locally Prepared Supplement to Support Growth and Brain Health
1

NCT03021174

  Exercise and Nutrition Interventions During Chemotherapy
1

NCT03026699

  Refining and Testing the Electronic Social Network Assessment Program (eSNAP)
1

NCT03028857

  Choline Supplementation During Pregnancy: Impact on Attention and Social Withdrawal
1

NCT03032302

  Micronutrient Supplement Effects on Cognitive Outcomes in Post-Acute TBI
1

NCT03050268

  Familial Investigations of Childhood Cancer Predisposition
1

NCT03052855

  Inflammatory Biomarkers and Brain Metabolites, a Study Based on Magnetic Resonance Spectroscopy
1

NCT03046693

  Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
1

NCT03046992

  Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC
1

NCT03032497

  Brain-Computer Interface (BCI)-Based Feedback for Chronic Pain Management
1

NCT03033693

  Study of the Depth of Anesthesia on Postoperative Clinical Outcome in Patients With Supratentorial Tumor
1

NCT03033706

  Intraoperative Goal Directed Fluid Management in Supratentorial Brain Tumor Craniotomy
1

NCT03035851

  Aerobic Exercise for Older Adults at Increased Risk of Alzheimer's Disease and Related Dementias
1

NCT03036254

  Hyperbaric Oxygen Therapy for Cognition in Diabetic Elderly at High Dementia Risk
1

NCT03038308

  Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
1

NCT03042156

  Immunotherapy And Palliative Radiotherapy Combined In Patients With Advanced Malignancy
1

NCT03042416

  18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
1

NCT03091270

  ZOOMit-fMRI Identifies Motor Functional Cortex
1

NCT03054285

  Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?
1

NCT03084211

  Prescribed Light Exercise for ED Patients With MTBI
1

NCT03086148

  Ketamine and Postoperative Depressive Symptom
1

NCT03086421

  Social Emotional Development in Young Children With Cancer
1

NCT03087591

  APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
1

NCT03089749

  Characterization of Human Autoantibody Titers After Central Nervous System Insult
1

NCT03062150

  Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
1

NCT03065218

  Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer Patients
1

NCT03068429

  Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline.
1

NCT03068793

  Reward Processing in Schizophrenia
1

NCT03068806

  Brain Imaging, Attention, and Auditory Processing in Schizophrenia
1

NCT03076099

  Dexmedetomidine on Post-operative Blood Pressure in Bain Arteriovenous Malformation Embolization
1

NCT03078816

  Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults
1

NCT03079713

  Handheld Vibrator Versus Topical Eye Drops as Anesthesia for Intravitreal Injections
1

NCT03080844

  Neuroimaging Studies of Practice and Smoking
1

NCT03082144

  Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid Tumors
1

NCT02939508

  Should Colon or Non-colon Originated Lesions be Distinguished?
1

NCT02941536

  Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Radiotherapy for Metastases of Breast Cancer
1

NCT02945826

  uPAR-PET/MRI in Glioblastoma Multiforme
1

NCT02989285

  Identification and Quantification of HIV CNS Latency Biomarkers
1

NCT02991365

  Effect of Weight Loss on Brain Insulin Sensitivity in Humans
1

NCT02992964

  Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
1

NCT02994576

  Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer
1

NCT02995902

  FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung Cancer
1

NCT03004976

  Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke
1

NCT03010943

  Brain Awake Surgery Using Virtual Reality Headset
1

NCT03012984

  Dexmedetomidine Supplemented Analgesia and Incidence of Postoperative Delirium
1

NCT03014518

  Biomarkers as Predictors of Suicidal Risk in Adolescents
1

NCT02947841

  The Effectiveness of Alternating Stimulation in Preventing Tolerance in Essential Tremor Patients
1

NCT02951273

  Cerebral Blood Flow During Propofol Anaesthesia
1

NCT02957591

  Probiotic Supplementation in Severe Depression
1

NCT02965027

  Prazosin for Post-Concussive Headaches
1

NCT02967250

  Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment
1

NCT02967484

  Acupuncture Lowering Blood Pressure for Secondary Prevention of Stroke
1

NCT02968433

  The Stanford Parkinson's Disease Plasma Study
1

NCT02968628

  Effect of Maternal Diabetes on Brain Development, as Measured by Neonatal Electroencephalogram (EEG)
1

NCT02972398

  N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders
1

NCT02977663

  Imaging Multiparametric/Multimodality for Lungcancer
1

NCT02978911

  Cranial Nerves Tractography
1

NCT02979782

  Neurological Outcome After Minimal Invasive Coronary Artery Bypass Graft
1

NCT02982304

  Multi-Target Pallidal and Thalamic Deep Brain Stimulation for Hemi-Dystonia
1

NCT02928926

  Cerebral Haemodynamics in Stroke Thrombolysis Study (CHIST)
1

NCT02931487

  Restoring Emotion Regulation Networks in Depression Vulnerability
1

NCT02932540

  Head Position on Cerebral Haemodynamics in Acute Ischemic Stroke and Controls
1

NCT02906384

  Memory and MRI Changes With Hippocampus Avoidance Prophylactic Cranial Irradiation(HA-PCI) for Small Cell Lung Cancer(SCLC)
1

NCT02906631

  Epidemiology and Prognosis of Encephalitis in Intensive Care
1

NCT02908113

  Visual Perception in Preterm Infants
1

NCT02908984

  Specific Neck Rehabilitation for Unilateral Neck Related Headache and Structural Changes in the Brain
1

NCT03348501

  Study and Follow-up of Multiple Endocrine Neoplasia Type 1
1

NCT03351283

  Effect of Sodium Intake on Brain Natriuretic Peptide Levels in Patients With Heart Failure
1

NCT03352739

  Fornix and NbM as Targets of Stimulation In Alzheimer's Disease
1

NCT03362346

  Signal Analysis for Neurocritical Patients
1

NCT03339505

  Effect of Antisecretory Factor, Given as a Food Supplement to Adult Patients With Severe Traumatic Brain Injury
1

NCT03341416

  Effects of Deep Brain Stimulation of the Dentate Nucleus on Cerebellar Ataxia
1

NCT03342612

  Multimodal Neuroimaging Analysis After Mild Traumatic Brain Injury
1

NCT03376373

  Neurotherapy to Promote Emotion Recognition in Autism
1

NCT03377504

  Clinical Evaluation of the Effects of Mirror Therapy in Patients With Complex Regional Pain Syndrome (CRPS) Type 1
1

NCT03382158

  International PPB Registry for PPB, DICER1 and Associated Conditions
1

NCT03386617

  AKY15-HK-301_NEPA Study
1

NCT03393442

  Evaluation of Gadolinium Deposits in Healthy Women Participating in a High Risk Screening Program for Early Breast Cancer Detection
1

NCT03394716

  Monitoring MRI Changes Before and During Radiotherapy Treatment of Brain Tumors
1

NCT03396939

  The Technology-assisted, High Intensive, Task-oriented Exercise Trial
1

NCT03399864

  Effectiveness of Musical Training in Hong Kong Chinese Childhood Brain Tumor Survivors
1

NCT03402425

  The Diagnostic Value of 18F-FET PET/MRI for CNS Tumors in Children and Adolescents
1

NCT03290326

  tACS for Amyloid-? Reduction in Alzheimer's Disease
1

NCT03291964

  Rapid MRI for Acute Pediatric Head Trauma
1

NCT03302026

  Real Time fMRI and Quitting Smoking
1

NCT03304665

  Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies
1

NCT03309917

  The Effect of Blood Pressure on Cerebral Blood Flow During Propofol Anesthesia
1

NCT03312608

  Cerebral Reorganization in Cervical Myelopathy Measured by Navigated Transcranial Magnetic Stimulation
1

NCT03285048

  Cognitive Remediation Therapy (CRT) for Adults Treated for Cancer
1

NCT03323450

  Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory
1

NCT03323580

  Effects of Intraoperative GDFT on the Postoperative Brain Edema
1

NCT03324360

  Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)
1

NCT03324945

  Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients
1

NCT03327714

  Mindfulness as a Method of Improving the Well-being, Quality of Life and Health of Primary School Pupils
1

NCT03430882

  TAK228 With Carbo and Taxol in Advanced Malignancies
1

NCT03474601

  Seoul National University Pituitary Disease Cohort Study
1

NCT03478527

  Probiotics, Brain Structure and Psychological Variables
1

NCT03371641

  In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions
1

NCT03406273

  Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma
1

NCT03417544

  Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
1

NCT03418961

  S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
1

NCT03419741

  Brain Stimulation For Cancer Smokers
1

NCT03424681

  Modafinil for the Treatment of Alcohol Use Disorders
1

NCT03440346

  Biomarker Research in ADHD: the Impact of Nutrition
1

NCT03444519

  The Therapeutic Time Window of Mannitol During Craniotomy for Optimal Brain Relaxation in Patients With Supratentorial Tumours
1

NCT03448315

  Role of Transcrainal Direct Current Brain Stimulation in Acute and Chronic Post-mastectomy Pain Management
1

NCT03452436

  Testosterone, Cognition, Ageing, and Cancer
1

NCT03458455

  Improved Therapy Response Assessment in Metastatic Brain Tumors
1

NCT03465618

  A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
1

NCT03469206

  Direct Intra-arterial Thrombectomy in Order to Revascularize AIS Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals
1

NCT01967823

  T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
0

NCT01931098

  Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM)
0

NCT01386710

  Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
0

NCT02655601

  Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
0

NCT03534128

  Combinated Cues and Virtual Spatial Navigation
0

NCT03322813

  ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Glioblastoma
0

NCT03404609

  Rapid Non-Invasive Brain Stimulation for OCD (oTMS)
0

NCT03191695

  Participation to Life of Children With Cerebral Palsy
0

NCT02362438

  Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy
0

NCT02359864

  Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's Disease
0

Brain Tumor News Articles About Metastatic Brain Tumor

  1. [07/19/2019] Study hints at why an aggressive form of brain cancer is hard to treat  Very important article.     It points out how the tumor is usually made up of at least 2-4 different subtypes of GBM, and most importantly, that the cells are able to change from one type to another.  This may account for how easily a tumor evades treatments. It also opens up a lot of possibilities such as targeting the mechanism that the cells use to change back and forth - perhaps have them all change to an easier cell to kill, Or just target the four subtypes with 4 different treatments and the cells would have no place to hide!  

  2. [07/17/2019] Electricity helps control man’s brain tumor  The doctor mentioned, Dr Peereboom, is one of the best neuro-oncologists in the world, and one of my favorites.  However, I disagree with what he says in the article. He talks about the average benefit is living 5 months longer with Optune than without.  That is true but I look at it in a different way. I would probably not choose something that only adds 5 months to the average survival (if there were any other choices).  I look at it as your chances of being alive in 5 years goes from about 4% without Optune, to 29% if you use Optune with at least a 90% compliance rate.  That is definitely worth choosing.

  3. [07/16/2019] GBM Awareness Day This Wednesday July 17th!  Please look for the hashtag #GBMDay on social media on Wednesday and retweet it so we can get it trending!

  4. [07/16/2019] Attend an Optune Open House.  From our friends at Novocure!   

  5. [07/06/2019] Insurance type impacts the economic burden and survival of patients with newly diagnosed glioblastoma.  As expected, the better insurance you have the better you will do.  This is very significant when we start talking about Medicare for all.  The most popular "medicare for all" plan really is Medicaid for all. It sounds good with no copayments or deductibles, but when you try to limit costs especially for complex cases like a brain tumor, quality has to suffer. One fault in the article- it says Medicare patients do not live as long as private insurance payments, but they did not correct for age.  Medicare patients are usually older than private insurance patients, especially at the time of the first surgery.  Older people in general do not do as well as younger people.    

  6. [06/24/2019] Musella Foundation awards 9 grants!  Our largest grant was a payment of $250,000 towards a $1 Million pledge we made to open the compassionate use program for the experimental drug ONC-201 in the USA, and to track the patients so we learn from every patient's experiences.   We are now saving for the next payment, due at the end of this year, as well as another $2 million to open the program in the rest of the world!    

  7. [06/22/2019] New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors  GammaTile is an fda approved treatment which is an implant that slowly releases radiation to the tumor bed.  See more details from our recent webinar on it at:  https://virtualtrials.com/video2019.cfm?video=201905

  8. [06/22/2019] Bayer’s regorafenib kicks off brain cancer platform trial  This is the opening of the GBM AGILE trial, which will allow drugs to be tested much faster and easier for GBM. New drugs can be added and underperforming drugs dropped to home in on the best treatment or combination of treatments quickly! I wish them luck!  

  9. [06/13/2019] Webinar: Personalized Approaches to Treating Cancer Explained in Plain Language  This is from our friends at Store My Tumor.Com   They provide services to store and freeze your tumor sample from surgery, as well as help you get access to the services that can use this tissue such as specialized testing and even the creation of custom made vaccines!

  10. [06/10/2019] Attend an Optune Open House.  These meeting are to learn about Optune and meet people who are using it!  One of them can be done online, the rest are real wolrd. Very much worth attending if you have a GBM or know someone who has one!

  11. [05/30/2019] NW Bio To Present Updates On DCVax® Clinical Programs In Industry Theater Presentation At ASCO  The presentation will be webcast live! See details below. 

  12. [05/26/2019] Brain Tumor Biotech Conference at Lenox Hill Hospital, NH June 7, 2019  This is mostly for health care professionals.   It will be at a much higher level than the type of conferences that we have that are targeting the patients and families.   However, it is one of my favorite conferences. We get to see a lot of new ideas and to meet the people doing this exciting work.

  13. [05/23/2019] No news is bad news for Tocagen

    The hysteria of the financial markets would be funny if it wasn't so serious.   Tocagen announced that the interim analysis result was that the trial will be allowed to continue to the final readout.  The money people took that as a failure and wiped out 1/3 of the value of the company in 1 day.  In reality, nothing changed and the chances of success are the same as they were the day before.  There are 3 possible outcomes to the analysis:

     

    1. The data for Toca 511 is worse than for the control group in which case the trial would be stopped and declared a failure.

     

    2. The data is so much better than expected that they stop the trial and try for FDA approval.

     

    3. The data is about what is expected in which case they allow the data to mature so we get a good reading on how well the treatment works.

     

    Keep in mind that we expect the immunotherapies (from experiences with other cancers) to work on a relatively small % of patients, but the benefit is that when they work, they usually work miracles and achieve long lasting benefits - something we just do not usually see with Glioblastomas.   I have already seen a few long term survivors from the early Toca 511 trials. 

    This can result in the median survivals for the treatment group to actually be the same as that for the control arm - but the real benefit is in the long arm of the survivors.  The median survival is defined as how long the middle person in the group survived. In this case with 403 patients enrolled it would be the average of the patients who died number 201 and 202. The analysis was based on 193 deaths, so the median was not even reached yet.   It would have taken an unexpectedly large improvement to trigger a stoppage of the trial at this point.

     

    In summary - this is NOT bad news. It is what was expected.  I still feel that the treatment is valuable and will get FDA approval.  Once it is approved, we can then easily experiment with ways to make it work better - in various combinations - so the majority of patients are helped. But before that happens, we still need to get each building block of the ultimate cocktail to get approved and be made available.

     

     

     

     

     

  14. [05/23/2019] Supporters Take Steps Toward Brain Tumor Research  A huge thanks to Bruce Blount for organizing this yearly event for us.     It was at a gorgeous winery - my wife and I participated and had a great time! The proceeds from the event will be used to help us fund a very special pediatric brain tumor research project!  

  15. [05/21/2019] Volunteers help raise over $100,000 for brain cancer research at St. Paul 5K  A huge thank you to the volunteers who organized all of our fundraisers.  Fantastic job. We are going through a bunch of grant applications and will give out all of the money raised within the next few weeks! Sad to say that due to a death in the family of the organizer, our Salt Lake City event set for this weekend has been cancelled and turned into a virtual event.  Visit the walk website for details.  Everyone who signed up for the event was notified by email, and anyone who wants a refund follow the directions in that email.

  16. [05/19/2019] Brain Tumor Awareness Month 2019 Webinar Series! Only 2 more webinars remaining this month!  These last 2 webinars are each focused on an individual treatment: Tonight: Tocagen - this is an experimental gene therapy. Absolutely fascinating. Dr Gruber will explain how it works and how it can kill cancer cells without hurting the normal cells.   Next Sunday: Gamma Tiles.  This is an FDA "cleared"  product - which means it is available now.  Very few people know about it yet.  This is a device that is implanted at the time of surgery into the cavity remaining after surgical removal of the tumor. It delivers radiation therapy to the tumor bed so it stops those cells from dividing.

  17. [05/19/2019] Latest ONC201 Clinical Efficacy to Be Presented in Oral Abstract Session at ASCO  Follow the links to see the 2 abstracts. Looks promising. When Oncoceutics had their webinar with us last week, they told me about the results but were not allowed to disclose them publicly until these abstracts were published.. so here they are!

  18. [05/17/2019] AbbVie brain cancer drug fails late-stage study in another oncology setback  So sad to hear of another clinical trial failure of a gbm drug.  They did not release the details yetso we do not know if it is worth trying it in some other way or in combinations with other drugs yet.

  19. [05/16/2019] Optune Open Houses  These meetings are for anyone who uses or is thinking of using Optune.  Most of these are live but there are some broadcast on the web!  

  20. [05/15/2019] New edition of the "Brain Tumor Guide For The Newly Diagnosed" is now available!  Our new edition is finally available!   Please let me know what you think of it.  Every chapter has been updated and we added about 15 pages.

  21. [05/14/2019] Study touts new method to reduce cognitive side effects of brain cancer radiation treatment  This would be a huge breakthrough if it works. I love research like this and wish them well.

  22. [05/13/2019] New edition of the Brain Tumor Guide For The Newly Diagnosed will soon be out! The new edition will arrive sometime this week! 

  23. [05/13/2019] Brain Tumor Awareness Month 2019 Webinar Series! 2 more webinars in the next few days! The first 2 webinars in the series went very well and you can view them at virtualtrials.com/video.cfm  

  24. [05/13/2019] BMS’ Opdivo fails late-stage brain cancer test   There are many ways to use the checkpoint inhibitors.  This study shows that using Opdivo instead of Temodar during radiation for newly diagnosed is not helping.  This doesn't mean the drug is bad - just that it isn't being used correctly.  There are other trials going on that hopefully will show us how best to use this class of drug!

  25. [05/09/2019] Brain Tumor Awareness Month 2019 Webinar Series! 2 webinars in the next few days!  We have one this Sunday and Wednesday!  Both have excellent speakers.  Sunday is on Immunotherapies, Wednesday is on Onc-201 for DIPG and H3K27M mutant gliomas.

  26. [05/09/2019] The EndBrainCancer Initiative to Feature Renowned Brain Cancer and Modified Poliovirus Duke Researcher, Dr. Annick Desjardins, as its Keynote Speaker for the 2019 Annual May "Brains Matter" ACTION Dinner  From our good friends at the End Brain Cancer Initiative, Should be interesting.

  27. [05/09/2019] New Treatment Could Become First Targeted Therapy Designed For ‘Untreatable’ Childhood Brain Cancer  This is very early but it is an exciting new type of treatment for dipg.   The Musella Foundation is part of the DIPG Collaborative and helped fund this project!

  28. [05/05/2019] Reminder: Webinar tonight Sunday 5/5/19 7PM Eastern!  Dr Ashley will be speaking about immunotherapies and specifically the Polio Vaccine and CMV vaccines at Duke!

  29. [05/03/2019] Tmunity signs licensing deal for pediatric brain cancer immunotherapy There is a desperate need for this. I wish them luck and will be watching closely.  Dr Okada is on our medical advisory board and is one of the world experts on this topic.

  30. [04/30/2019] Brain Tumor Awareness Month 2019 Webinar Series! (Schedule Change)  We added another webinar to our lineup:   5/15/2019: WEDNESDAY Topic: Onc-201 for DIPG and H3K27M mutant gliomas!   

  31. [04/29/2019] Optune Open House  Here is an updated list of the Optune Open Houses.   These meetings are interesting and a lot of fun for everyone who has  a brain tumor.

  32. [04/27/2019] Brain Tumor Awareness Month 2019 Webinar Series!  This is a good opportunity to meet the experts and ask questions!  We may extend this year's series a few weeks if there is interest as there are lots of topics to cover!

  33. [04/27/2019] Correlation of Tumor Treating Fields dosimetry to survival outcomes in newly diagnosed glioblastoma: A large-scale numerical simulation-based analysis of data from the Phase 3 EF-14 randomized trial.  This is a very technical article but basically it boils down to showing that there is a dose-response curve.  The higher the dose the better the patient does.  The dose is determined by the arrangement of the arrays around the tumor, as well as the average compliance time - which is the % of time the machine is turned on! The differences in survival are pretty significant.  The doctor has to determine the positioning of the arrays (and articles like this will help optimize that), but the patients can work on the second part: compliance.   I find that most patients do not understand the importance of high compliance. The doctors usually say to try for about 70% compliance, but the evidence says if you can get to 90% or better, there is a big improvement.  Unlike drugs which work for days or weeks after you take them, Optune stops working the second you turn the machine off - and starts again when you turn it on.  

  34. [04/27/2019] National Walk To End Brain Tumors  We are trying to raise money for several very important projects.  I have many brain tumor research grant applications sitting on my desk right now - we will use the proceeds from our walks to fund these projects.  

  35. [04/20/2019] Cancer and the dopamine D2 receptor: a pharmacological perspective.  Interesting article.  They are correct that the D2R receptor family (also known as  DRD2) is very important in many types of cancers, including brain tumors – especially in tumors of the midline and brainstem.

    However, they are incorrect when they say there is no useful way to target this. The drug Onc201 is a very selective antagonist to DRD2 and is now in clinical trials for brain tumors.    Although it is too early to tell how well it works, I have seen a few remarkable responses to it already. This article talks about trying to repurpose older drugs that are NOT selective.

     

    Disclaimer:  The Musella Foundation was an early supporter of Onc201 and we are involved in funding the compassionate use program for this treatment.

  36. [04/15/2019] Successful treatment of brain radiation necrosis resulting from triple-negative breast cancer with Endostar and short-term hyperbaric oxygen therapy: a case report  This is just one case report so of course you can not say how it well it works but it opens the door for another treatment possibility for those who have symptomatic radiation necrosis that did not respond to current treatment options.

  37. [04/11/2019] `I Love What I Do` - Internationally Renowned Brain Surgeon Dr. Linda Liau  This is one of my all time favorite brain tumor doctors and proud to say she is a friend. Also an advisor to the Musella Foundation.  She just spent a lot of time helping us update our Guide for the Newly Diagnosed - which should come out next month!

  38. [04/09/2019] National Walk To End Brain Tumors   We are having a series of 5k fundraisers - visit the Walktoendbraintumors.org website to see Where and When.  If you can't participate in the event, you can still make a donation!  

  39. [04/09/2019] Optune Open Houses

    This is a chance to learn about Optune - or for those of you using it - to meet others using it and swap tips and ask the experts any questions you have!  Most are live but the last one is a webinar.

  40. [03/15/2019] First-Of-Its-Kind Treatment Beats Back Notorious Brain Tumor  I love articles like this.  Diffuse midlines gliomas are among the worst of the worst brain tumors.     Of course you can not make decisions based on a handful of case reports but they do give some hope where there really wasn't much before. Your donations have helped fund this - we gave 3 grants to help get this developed and it is in clinical trials, and there is a compassionate use program open.  Ask your doctors about this if you have the  H3K27M mutation (sometimes reported as H3F3A), or a brainstem tumor.  It is most common in younger people with tumors near the midline of the brain.    We will be dedicating part of the proceeds from our National Walk To End Brain Tumors 5k events to this project!

  41. [03/14/2019] Optune Open Houses
    These are informative and fun meetings. Some of them are webinars available online for those not close to a live meeting.  All are free.  They are sponsored by Novocure and the Musella Foundation is not involved - I am just letting you know about them because they are important!  


  42. [03/12/2019] Northwell neurosurgeons remove “glowing” brain tumor using breakthrough technology in Long Island first  Gleolan is FDA approved - it helps the neurosurgeon know what is tumor and what is not while operating.   Good work to my friend Dr Schulder!

  43. [03/10/2019] Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study.  This looks good for recurrent GBM.  It is too small of a study to tell for sure but the survivals compare very well to historical survivals.  We need to follow all patients who use Optune to see which combinations are the best, and this opens the door for more research on using Optune for recurrent GBM.

  44. [03/09/2019] National Walk To End Brain Tumors  We are having a series of 5k fundraisers - visit the Walktoendbraintumors.org website to see Where and When. 

  45. [03/09/2019] Update on Medicare CAC meeting  Stay tuned - I will send out another news blast about this issue when the proposed rule is released! Thanks to those who watched the video on Youtube.  I think that helped. Nobody wants to be viewed as advocating for a 2 tiered health system in the USA where 95% of private insurances pay for Optune but our elderly and disabled won't be able to get it.  Things like that can happen behind closed doors but not when everything is out in the open. Medicare did the right thing with this process. This was the first ever public CAC meeting for a device - they used to do these things behind closed doors.

  46. [03/09/2019] Optune Open House These are nice meetings if you are using Optune or are considering it!  

  47. [03/05/2019] Brain Tumor Advocacy Alert - we need you to watch this video Wednesday Morning 3/6/19 at 9am Eastern Time!   I need everyone to watch this video.  Ask your friends to watch it as well - all on separate devices so each person gets counted. You will probably see a lot of negative things being said about Optune. Take that with a grain of salt. The committee is trying to find an excuse not to pay for it and I doubt if any of the committee members have much experience with using Optune. We will point out the good things in our follow up letters!

  48. [03/02/2019] The sneaky way estrogen drives brain metastasis in non-estrogen-dependent breast cancers

    This may explain why using Tamoxifen for glioblastomas helped some patients.  An old research paper  (see https://virtualtrials.com/Tam1.cfm)   from 1996 showed pretty good results using high dose tamoxifen for recurrent glioblastomas.

     

    I had a relative who did well with high dose tamoxifen for over 5 years with her GBM, but it's use fell out of favor when Temodar arrived on the scene.  Maybe it is time to go back and test this again in new combinations!

  49. [02/27/2019] Medicare meeting about Optune! Tune in this Wednesday March 6, 2019

     On a different issue, a few years ago, the medical director of Medicare told me that we will never get what we want from Medicare because the brain tumor community is not organized enough to apply pressure.  We have to show them that is no longer true.  We finally have a big step forward in the treatment of brain tumors and Medicare doesn't want to pay for it.   This is the most important advocacy issue we face now.   Trying to get additional funding for research is futile if we lose this battle because any new treatments will be expensive and if Medicare doesn't pay we won't have access anyway.



  50. [02/23/2019] Improved survival of glioblastoma patients treated at academic and high-volume facilities: a hospital-based study from the National Cancer Database.  This shows what we already assumed:  getting treated in a academic center with a high volume of brain tumor patients will result in a better outcome.

  51. [02/21/2019] Malaria drug successfully treats 26-year-old brain cancer patient  We have been watching Chloroquine for a while. Some of our long term survivors have been taking it.  My thoughts are it might help some other treatments, such as Optune, work better but there have been no trials to prove that. The next best thing is to watch patients in our registry..  If you are going to try this, please register with us before you start so we can see how it works out!     Virtualtrials.com/brain

  52. [02/21/2019] Major Advocacy Issue: Optune  

     We can not let Medicare deny access to FDA and NCCN approved brain tumor patients. It sets a dangerous precedent.   

  53. [02/17/2019] Confirmation of high therapeutic effect in doctor-led clinical trials of viral therapy for brain tumor - Application for approval for the manufacture and marketing of the first cancer treatment viral drug in Japan - This was written in Japanese and the link takes you to a google translation of it so it is a little hard to understand but it looks like they are reporting 1 year survival rate for recurrent GBM of 92% compared with historical controls of 15%.  If that is true, this is amazing.  It was a small study but may lead to approval in Japan.

  54. [02/17/2019] why some brain tumors respond to immunotherapy  This is the type of research that will lead to the cure.    We need to know WHY things work and do not work in order to put together an intelligent combination of treatments.  

  55. [02/15/2019] Statins, NSAIDS Have No Apparent Survival Benefit for Grade IV Glioma  There have been other trials that show statins and NSAIDS have helped brain tumors. This study says no (except Aspirin for grade 3 gliomas).  It is hard to prove one way or another with such conflicting information.  A randomized blinded trial would be the best way but that will never happen due to cost. The next best thing is for the registry to track these drugs - but record the dosage and length of time the drugs are used, then evaluate it over a large number of patients. 

  56. [02/14/2019] Contractor Advisory Committee (CAC) Meeting Information - Tumor Treatment Field Therapy (L34823)  Medicare is going to reconsider it's decision to not cover Optune.  The meeting is going to be streamed online but you have to register (free) soon. You can not comment at this meeting but they will have a follow up meeting where you can tell Medicare how you feel on this topic. It is important to watch this to show the support of the brain tumor community.

  57. [02/14/2019] University of Minnesota First in U.S. to Offer New Targeted Therapy for Recurrent Brain Tumors  This refers to the Gamma Tiles that I wrote about a few weeks ago. They are implantable wafers that slowly release radiation to the tumor bed and were recently approved by the FDA.  We will have a webinar on this treatment in May during brain tumor awareness month!  Watch for the announcement as it gets closer.  

  58. [02/13/2019] Suppression of HMGB1 Released in the Glioblastoma Tumor Microenvironment Reduces Tumoral Edema.  This is another way to beat the edema from a brain tumor without using steroids. These researchers used an antibody that blocks the protein that causes the swelling in the first place!  Again - too early but this is something to keep an eye on!

  59. [02/13/2019] Progesterone is more effective than dexamethasone in prolonging overall survival and preserving neurologic functions in experimental animals with orthotopic glioblastoma allografts.  An alternative to dexamethasone is badly needed, especially when using immunotherapies or Optune.  This may be one such alternative but the experiment was done in rats.  Need to wait until it is tested in people before using it.  

  60. [02/13/2019] Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation
    Interesting experiment. Of course it is too early to tell if it will help people with a GBM, but something like this should be easy to pick up in our virtual trial.   For those of you who are participating, and take aspirin on a regular basis,  go back in and enter it!
     
    Warning:  Talk to your doctor before taking Aspirin.  It can also increase the chances of bleeding. It might also help prevent blood clots - but this is a delicate balance.
     


  61. [02/13/2019] Oncotelic Reports that It`s Proprietary In-Situ Cancer Vaccine Improved Survival over Standard Chemotherapy in Patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma  Impressive results in the article but the underlying poster (http://oncotelic.com/wp-content/uploads/AACR-JCA-Glioma-Finalv3.pdf) is a little on the confusing side.  They talk about "chemo naive recurrent glioma" but I would assume most patients would get Temodar as newly diagnosed. Where do they find those patients who did not use Temodar? There might be something special about them.  Then they go on to show survivals with and without previous Temodar and with and without subsequent Temodar.  The best group appears to be the control group and the conclusion is that this treatment is not inferior to Temodar.  This might just be that the amount of text on a poster is limited and we have to wait for the published results to completely dissect the trial.

  62. [02/12/2019] Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review

    This article intended to be a balanced article on the plusses and minuses of Optune.  Unfortunately it is loaded with errors and bias.  For example,

     

    1. They say:   They did a survey between January 2015 and July 2015 and found only 41% of doctors had access to the device.  Optune was approved for newly diagnosed in July 2015.  So they did the survey before the device was available for newly diagnosed. (The recurrent data was not great). This article was published in 2019.  Optune is now available at just about every major medical center in the USA. Their website, optune.com says there are 700 certified treatment centers that offer Optune in the USA.  They should have repeated the survey but instead used an old one that made Optune look bad.

     

    2. They harp on the fact that there was no sham device in the control group.  That would have been ridiculous.  Imagine having to shave your head twice a week and carry around the old version of the device (which was twice as heavy and bulky as the current version), and risk getting skin problems without a chance to benefit from it? I would not want to do that.  The endpoint was overall survival. Placebos cannot show such an increase in overall survival.  The Temodar studies did not use a placebo and nobody faulted the study for that. The Avastin trials did use a placebo but the placebo group did not do better than the treatment group (which means placebos do not help  glioblastomas). This is absolutely not an issue.

     

    3. They say Optune is not covered by Medicare or many other insurance companies. The second part of that statement is not true.  Over 90% of non-medicare insurance companies pay for Optune. They go on to say Medicare has now agreed to reconsider coverage – which only happened a few weeks ago so there is no reason to be so far behind on the statistics. That statement was true in 2015 but not in 2019. Hopefully by the end of this year all insurances including Medicare will be paying for it.  In the meantime, Novocure has said they would not let a patient not get access to this treatment due to being unable to afford it. They very generously gave it for free or at a very reduced rate to those on Medicare or who did not have insurance that covered it. 

     

    4. They keep talking about patients being reluctant to wear the device and shave their heads. This is too subjective. Of course patients would prefer not to shave heads or have to wear a device that constantly reminds them of the disease.   However, having to use a wheelchair, or being unable to speak, at a much sooner time are not great alternatives. It is a personal decision that the patient has to make.

     

    5. Finally – they complain about the price. At least they do point out that other new treatments are way more expensive.  I doubt we will ever see a new brain tumor treatment priced less than Optune.  Optune is about half of the price of Avastin, and the trials showed a big increase in survival for Optune, and no increase in survival for Avastin (although they did show a nice improvement in progression free survival and patients feel better on it). I never heard the complaint that Avastin was too expensive.  Hopefully we will have a few new treatments approved in the next year or 2.  We have no idea what they will cost but to put it in perspective:  The cheapest gene therapy on the market (for other diseases) is $373,000 for the one treatment. Most expensive now is over $1 million for the one treatment. A new one that is under review might be $4 million for the 1 dose. As for vaccines, the only one approved in the USA (for prostate cancer) cost about $93,000 for a 6 week course of treatment.    The only way to bring these prices down to earth is a major change in regulatory policy – but that is for another day.

     

  63. [02/11/2019] Ziopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer Trial  This is a fascinating gene therapy. Follow the link in the article to the video explaining how it works. They have the ability to insert a gene into the cancer cells which can be controlled by an oral drug - which turns on the production of IL-12 in the infected cells.  Stopping the oral drug turns off the production of IL-12 and they can fine tune the amount of IL-12 produced by adjusting the oral dose of the drug.  IL-12 turns on the immune system and helps your body fight the cancer.  The next step is to add a checkpoint inhibitor, which have not worked that great with brain tumors but this gene therapy might be able to make the checkpoint inhibitors work for brain tumors!

  64. [02/06/2019] Brain Tumor `Pied Piper` Device Gains Breakthrough Status  This is an amazing concept. They trick the tumor cells into leaving the brain. It was never tried in people yet but it did work in mice! Will be keeping an eye on this.

  65. [02/05/2019] Moleculin Biotech (MBRX) Announces FDA Orphan Drug Designation for its Brain Tumor Drug  This drug is a new class called "immune transduction modifiers" and targets 3 important markers: STAT3, HIF1-a and c-Myc as well as JAK2..  Will keep an eye on this one. There is a clinical trial in Texas:   https://clinicaltrials.gov/ct2/show/NCT01904123

  66. [01/31/2019] GT Medical Technologies Announces Publication of Data Showing Company’s Targeted Therapy is Effective for Treating Recurrences of Common Type of Brain Tumor  This is a new type of radiation therapy which is implanted at the time of surgery. It is made up of biodegradable wafers. It has FDA clearance so it can be used now.  The current article talks about using it for recurrent meningiomas, but it can also be used for any primary or metastatic recurrent brain tumors.  Interesting concept. Check their website for more details.

  67. [01/30/2019] Musella Foundation awards a pediatric brain tumor research grant!  There is a drug in clinical trials that targets this marker in other cancers. This project will do preclinical testing which, if successful, will lead to a clinical trial of this drug in pediatric DIPG.   

  68. [01/26/2019] Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial This is probably the most important article about Optune.  It updates the data reported the prior year and shows a little better results.  If you can maintain over 90% compliance, the  % of patients alive at 5 years was 29.3% compared to 4.5% in the control group which was Temodar and whatever else the doctor and patient wanted to use.  This is the best survival rate ever reported in a large brain tumor trial and should finally put to rest any resistance to it's use.  At this point, Optune (plus Temodar)  should be considered the new standard of care.

  69. [01/25/2019] New Liquid Biopsy Test Detects Brain Cancer, But It Doesn`t Use Blood  This is still experimental but very interesting.  Hopefully you can get the same information as a biopsy in a much easier way. Very useful for inoperable tumors, or to see how a tumor is responding to treatment over time.

  70. [01/19/2019] Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma.  This article talks about the role of DRD2 in GBMs.  Looks like it may play an important role.   Onc-201 is an experimental drug in clinical trials for brain tumors. It is a DRD2 antagonist. This may explain it's method of action.

  71. [01/18/2019] Optune Open House, Newton, MA  These are great get togethers for any brain tumor patient or anyone who knows a brain tumor patient!  

  72. [01/14/2019] Copay assistance program is now open!  Thanks to generous donations, we are able to reopen our copay assistance program!  We have a lookback period of 3 months from when the completed application arrives so if you are approved, and have paid for a covered treatment in the last 3 months we can reimburse you!  

  73. [01/11/2019] Publication Reports Role of Dopamine Receptors in Cancer and ONC201 Response  The article they mention is at http://clincancerres.aacrjournals.org/content/early/2018/12/19/1078-0432.CCR-18-2572.long but it is not free. It shows that the DRD2 is overexpressed in many types of cancer.  Onc-201 blocks that receptor, but they also found that high levels of DRD5 make the cells resistant to the Onc-201.  So for this drug to work, we need high DRD2 and low DRD5.  That happens in most brainstem gliomas, and high grade gliomas that are in the midline of the brain - especially those in the thalamus, and in younger patients.   There are about 14 clinical trials going on for Onc201 in various cancers, including brain.  For those who do not qualify for the clinical trials, there is a compassionate use program available – contact us (the Musella Foundation)  for details 888-295-4740  

     

  74. [01/09/2019] Musella Foundation awards 2 grants! The first grant is for the development of a new type of vaccine for the treatment of brain tumors.  The second is a project to try to make it easier to find the correct clinical trials.  It is not just a matching service - it is a system where clinical trials will be explained and reviewed so we have more information to go on when selecting a clinical trial!  

  75. [01/07/2019] Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.

    They should have done this a long time ago. I hope this becomes available for patients soon.  The delivery method should be approved separately from the drugs used - so we can mix and match drugs based on a patients' genetic profile.

  76. [12/24/2018] Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells This study identifies a few promising combinations of readily available drugs.  However, it also shows that it is hard to predict which combinations will work in an individual.  Different cell lines reacted different ways, and sometimes made the tumor grow faster instead of helping.  More research needs to be done but I think this is a step in the right direction.  They may be able to find readily available (and sometimes cheap) drugs that can be added to the standard treatments to make them work much better.

  77. [12/24/2018] Tumour treating fields in a combinational therapeutic approach
    Good review of how Optune works and talks about  how it may work better in combinations.
    Our virtual trial is trying to identify combinations that work well.  If you are using combinations, make sure to register with our virtual trial project  virtualtrials.com/  click on virtual trial.  We will be able to identify good combinations faster than any trial can because patients are doing these combinations now and nobody is tracking it. When the researchers propose a trial of combinations, it takes about 3 years and lots of money to do one combination.  There are many possible combinations out there. It is impossible to do a formal trial of each.  
     


  78. [12/20/2018] Penn Medicine Launching Telemedicine Platform for Brain Tumor Consults  Dr Brem is another one of my favorites.  They offer proton beamm radiation and immunotherapy trials including CAR-T cell which is one of the most promising new treatments.

  79. [12/19/2018] Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. I have written a lot about this drug (Onc-201) lately - I am excited about it and we (the Musella Foundation) have a special interest in it because we gave grants to help them get this far!  This study shows that it may also be good to treat many other types of tumors that overexpress the target!  Right now for brain tumors it is in clinical trials for DIPG and high grade gliomas that have the H3 K27M mutation - which usually occurs in younger people with tumors in the midline of the brain.

  80. [12/15/2018] Finding Hope in the Face of Brain Cancer  This is a nice story about a patient with  an H3 K27M mutant glioma, which is one of the worst types of brain tumors.  This involves the drug Onc-201, which the Musella Foundation has given a few grants to help develop!

  81. [12/15/2018] An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US. Voyager is an experimental  device that is worn on the head and is used to treat the brain tumor.  This small study shows that the device is safe, but we can't tell if it helps yet.  They have a very impressive list of authors on the paper, so I know the research will be done correctly.

  82. [12/13/2018] Tumor treating fields increases membrane permeability in glioblastoma cells.  This show a different possible method of action for Optune.

  83. [12/10/2018] Musella Foundation awards 2 more pediatric brain tumor research grants! Both of the grants we gave out today are urgent projects that needed to be done.  Thanks to the generosity of our donors, we were able to quickly approve them - both applications were received within the last 4 days and our dedicated medical advisory board were able to evaluate and approve them quickly!

  84. [12/05/2018] Cancer therapy shows promise for some brain tumors

    This is the experimental drug Onc-201.    When the article says that it was largely ineffective in a pilot study for GBM, they did not point out that that study included mostly GBM patients who did not have the H3 K27M mutation, and they have since realized that this mutation makes the tumor more sensitive to this drug.

     The current clinical trials (and compassionate use program) requires the H3 K27M mutation be present. (DIPGs do not require a biopsy – it is assumed that most will have the mutation).

     

    The mutation H3 K27M is a marker of the worst of the worst brain tumors.  Most DIPGs have it, and it is found in the midline and spinal cord gliomas usually of younger adults and kids.  Until now, there really was no hope for these tumors.  This drug gives some hope. It is not a miracle cure for everyone but it is a huge step in the right direction.  It is an oral drug with minimal side effects.  Look at your pathology reports and see if you have this mutation. If you do, ask your doctor about Onc-201.

    The Musella Foundation has been a supporter of it's development since they started.

  85. [12/03/2018] Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.  I am a big fan of Optune, and think almost all GBM patients should be on it. It is the best treatment currently available, but it is not good enough by itself.  We need to find what to add to it so that it works for everyone.  This article presents one such combination.   There are hundreds of other combinations that also need to be tested and the only way we are going to find the best combination is for us to track the outcomes of every patient who uses Optune.  We are now tracking patients in our virtual trial project. Go to virtualtrials.com and click on virtual trial to learn about it and join. It is free - but you need to commit to posting update monthly for as long as needed.  All brain tumor patients should be participating, but especially if you are considering Optune.

  86. [11/22/2018] Giving Tuesday! Donate to Musella Foundation

  87. [11/20/2018] Musella Foundation 2018 Highlights  As the year comes to a close, we reflect back on what was accomplished.  This was a really exciting year for brain tumors.  We feel that we are on the cusp of a major breakthrough. Everything is coming together - many clinical trials are reporting long term survivors in a small % of patients.  Our goal is to speed up the approvals for these treatments so doctors can combine them in cocktails and get long term survivors for most  brain tumor patients!

  88. [11/20/2018] SNO Highlights

    SNO is an amazing meeting. Aside from all of the presentations, I got to meet and talk with many brain tumor researchers and physicians and discuss what they think are the best treatments, what is needed to advance the field, what is slowing down progress and much more.

    We also were able to interact with many other brain tumor nonprofits. There was some resistance in the past to working together but I think the last barriers were recently removed and you are going to see a lot more collaboration now.   We are all about collaboration.  Working together we will be able to accomplish much more than any of us could individually.  

  89. [11/11/2018] Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.  Mebendazole is an old, cheap, easily available drug approved for  treating worm infestations.  This paper (and many others) suggest it might be useful for treatments brain tumors, especially when combined with radiation. This article is about meningiomas but other articles mention GBM and Medulloblastomas!  

  90. [11/10/2018] The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma.  In the case presented, the patient had a GBM but was allergic to Temodar so they had to try something different.   They tried erltinib and Optune, which has resulted in stable disease for at least 9 months after radiation.  It is only 1 case but shows brilliant thinking on the part of this patient's team. They chose Optune, which is the obvious choice, but since the patient overexpressed EGFR, they also added erlotinib.  More research needs to be done on such combinations of Optune and therapies personalized to the patient!

  91. [11/08/2018] Hebrew U Researchers Discover Promising Treatment Against Aggressive Brain Tumors  This is just in mice at this point but it is an exciting new approach. I wish them luck and will be following this!

  92. [10/17/2018] PVSRIPO (Polio Vaccine) clinical trial now open in 4 brain tumor centers!  This is one of my favorite trials and has just opened up in CA, MA and FL in addition to NC. The pediatric version is still only in NC. Disclaimer: I am on the advisory board of the Preston Robert Tisch Brain Tumor Center at Duke University, and have given grants towards these projects.

  93. [10/12/2018] Checkpoint Blockade Reverses Anergy in IL-13Ra2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas.  This type of treatment worked miracles in other types of cancer. The first attempt in human glioblastoma wasn't spectacular but these researchers may have found a way to make it work at least in dogs and rats.  Lets hope it translates to people! 

  94. [10/04/2018] Novocure Announces 55 Presentations at European Association of Neuro-Oncology Meeting 2018

    This shows that Optune has finally hit the mainstream.  55 presentations at the major European brain tumor conference.  Many of these are looking at ways to improve the outcomes, including new types of arrays, new placement of arrays for tumors lower in the skill and for pediatric patients.

  95. [09/20/2018] Experimental drug `nothing short of miraculous` for father of 4 with super-rare brain tumor  This is the drug that we recently gave a million dollar grant to help support and speed up it's development!  The mutation (H3K27 M)  is very common in DIPG, and common in midline and thalmic malignant gliomas, more so in younger GBM patients.  This experimental drug is in clinical trials. Check your pathology report to see if you have this mutation.  If you do, contact us and we can help you find a trial. (It is so common in DIPG that  no biopsy is needed to get into the trials for that tumor type - it is assumed they all have this)

  96. [09/17/2018] Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs.  I love this type of research.  Invadopoia are small projections from the edges of tumnor cells that help allow them to move.  Without the ability to move, the tumor is much less dangerous and more sensitive to normal treatments. This is a highly underappreciated target and they found 2 existing drugs which may target this.  Of course, it is just theory now and needs to be tested but it is a promising approach!

  97. [09/14/2018] Brain Tumor Webinar Series: Gamma Knife Radiosurgery Sunday, 9/16/18  Dr Schulder will be speaking about the new version of the Gamma Knife, but will also answer questions on any brain tumor related topic!

  98. [09/14/2018] Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition.  I am a big fan of Optune. It is the most effective approved treatment for gbms,  but it is not good enough by itself. We need to find ways to make it work better.  There are about 16 clinical trials going on now that involve Optune and ways to make it work better.   Any of these trials are worthwhile to try.  Experiments like this are needed to identify candidates for the trials. 

  99. [09/13/2018] Researchers make breakthrough in understanding aggressive brain cancer  Researchers at Duke identified why brain tumor patients have such low t cell counts - as low as that of AIDs patients.  Now we just need to figure out how to use this information!

  100. [09/13/2018] Moleculin’s Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson  This is a new STAT3 inhibitor. STAT3 has been known as a good target for brain tumors but until now we did not have a good drug to target it. This was just the first in human doses of the drug so it is way too early to tell if it will work, but it may become an important tool in the ultimate cocktail.

  101. [09/10/2018] Patient Foundation Collaboration to Advance ONC201 in DIPG and other H3 K27M-mutant Gliomas

     This project will speed up the development of a drug (Onc-201) that has shown promise in early trials for DIPG as well as high grade gliomas that have a specific mutation called H3 K27m. If you have DIPG or a high grade glioma with that mutation, give us a call.

     This is a one million dollar grant, to be paid in 4 equal payments over the next 3 years. We gave the first $250,000 payment today!  I am going to need help raising the rest of the money!  This is one of the most important projects that we have ever worked on and we need to raise the money for the next payment in a few months.  Contact us for details.  

  102. [09/10/2018] NCI and Musella Foundation Award Grants for ONC201 Trials in Adult and Pediatric Brain Tumors  I would like to emphasis that this is a collaboration between the Musella Foundation, the Cure Starts Now Foundation, and the Michael Mosier Defeat DIPG Foundation! we couldn't have done this without them. 

     

  103. [09/01/2018] This brain cancer drug stock has been on a tear  I usually do not report on financial stuff, but this is good news for the brain tumor community.  It shows that a brain tumor treatment can be a financial success and this will encourage other companies to enter this space!

  104. [08/29/2018] Optune open house Seattle, WA  These are always very interesting and worth going for anyone dealing with a brain tumor.

  105. [08/27/2018] Aspirin affects tumor angiogenesis and sensitizes human glioblastoma endothelial cells to temozolomide, bevacizumab, and sunitinib impairing VEGF-related signaling.  Interesting study - but it is only in the test tube. We follow Aspirin in the virtual trial but nobody has recorded it - I know many people must be taking it long term for heart protection - they just aren't recording it. If you are in the virtual trial and take long term Aspirin , please go back and post an update so we can see if it helps!

  106. [08/24/2018] Tocagen`s Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned First Interim Analysis Good news.. We expected there would be no problems, and this confirms it. 

  107. [08/23/2018] CLINICAL TRIAL TO DISRUPT THE BLOOD-BRAIN BARRIER FOR BRAIN TUMOR TREATMENT LAUNCHED AT UNIVERSITY OF MARYLAND  This is a way to open the blood brain barrier to allow more of the drug to get to the tumor.  They are looking for people with suspected Glioblastoma Multiforme before they have the surgery.

  108. [08/23/2018] Importance of electrode position for the distribution of tumor treating fields (TTFields) in a human brain. Identification of effective layouts through systematic analysis of array positions for multiple tumor locations This may be a way to improve the results of Optune.

  109. [08/23/2018] Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.  This drug has a strange past - it did very good in early trials for breast cancer but failied in the large phase 3 trial.  It seems to have lottle toxcicity and the early brain tumor trial showed good results so it is worth a try again

  110. [08/22/2018] Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients This is another type of analysis of the latest Optune trial for newly diagnosed GBM. Unlike most results that are published, this is for an evaluation of the health economics where they use a mathematical model to predict how long patients will live in each arm of the trial if they were observed over the course of 15 years instead of about the 5 years covered by the trial. This reports the average survivals, not the median survivals that were already presented.  The main difference is the median survival is the point at which the person at the midpoint of the trial dies. For example, if there were 500 patients, it is the point at which patient number 250 dies.  This allows them to report the information in a reasonable amount of time, but it doesn't give any insight into the long tail - patients who live for a long time. The average adds up all of the survival times and divides by the number of patients. This is impossible to do when patients live for a long time, so this study is using a model to estimate it.   This takes into account the long term survivors.   There are a few amazing numbers presented here.  IF you survive the first 2 years on Optune, you will have about a 17% chance of living to 15 years.  In the temodar group, that number is 8.7%.   The average life expectancy for the Optune group was 4.2 years vs. the control arm of temodar alone at 2.4 years.  An increase of 1.8 years!

  111. [08/16/2018] 5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas.  This is a dye used at the time of surgery to allow the surgeon to better setermine the difference between tumor and non tumor, allowing for a better chance at a total resection.   A total resectionn is associated with longer survival times.  It is now FDA approved and readily available!

  112. [08/01/2018] Tumor Treating Fields Utilization in a Glioblastoma Patient with a Preexisting Cardiac Pacemaker: The First Reported Case.  At least we now know you do not have to physically remove the pacemaker to use Optune.  Unfortunately you still have to turn it off.  Hopefully there will be more testing done so that we can keep it turned on.

  113. [07/27/2018] Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells. This study shows that Metformin MIGHT be useful to help other treatments work better. We know that by itself it is not going to cure a brain tumor, but the evidence shows it inhibits motility and invasion at least in the test tube.  Might be good to watch how it interacts with other treatments in the virtual trial

  114. [07/25/2018] The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in the patients with glioblastoma and anaplastic astrocytoma.  This study says that for a small group of patients (we have to be careful trusting results in small groups), overall survival was doubled by adding Avastin during or right after radiation ends for gbm patients who progress through radiation.

  115. [07/21/2018] Webinar on brain cancer vaccines Sunday July 22, 2018!  These clinical trials are for both newly diagnosed  GBM and recurrent GBM and Anaplastic Astrocytoma (and variants) . You will be able to ask any brain tumor related questions.  

  116. [07/16/2018] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling.  About 1/2 of the USA population has high blood pressure - so it may be worthwhile to consider this drug if you have a gbm, are taking Temodar and also have high blood pressure.  This is a perfect combination to observe in the virtual trial!  

  117. [07/10/2018] Brain Tumor Webinar Series continues...  These events allow you to ask the experts any questions about brain tumor treatments.  Dr Rahman is the co-principal investigator for a promising vaccine clinical trial  https://clinicaltrials.gov/ct2/show/NCT02465268  She will tell us the theory behind the vaccine and why she thinks it will help, as well as the results of an earlier trial..  This is a simple shot in the skin - not into the brain. Dr Schulder is the director of the Brain Tumor Center at Northwell Health's Neuroscience Institute and they recently  acquired the new version of the Gamma Knife. Dr. Schulder is past president of the American Society for Stereotactic and Functional Neurosurgery and is vice president of the World Society for Stereotactic and Functional Neurosurgery.  He is one of the rare neurosurgeons who can and does treat brain tumors both with surgery and / or  radiation.  

  118. [07/09/2018] IsoRay Announces FDA Clearance of GammaTile™ Therapy for the Treatment of Recurrent Brain Neoplasms  This gives another option for recurrent brain tumor treatment. They did not say what the results have been.  An FDA 510 K clearance is not a high hurdle - the treatment just needs to be as safe and effective as a similiar treatment that is already being marketed.  

  119. [06/26/2018] Recurrent Glioblastoma Treated with Recombinant Poliovirus  See my editorial under the link to the full text of the article!  This is a major breakthrough and must read article!

  120. [06/22/2018] Seattle Children’s aims to cure terminal brain cancer using immunotherapy with new BrainChild initiative  This is a CAR-T cell trial. It is accepting children with any type of recurrent brain tumor that expresses the HER-2 receptor.  

  121. [06/21/2018] Musella Foundation awards another pediatric brain tumor research grant!  This is an exciting project that could quickly lead to a new clinical trial for DIPG!

  122. [06/14/2018] Gamma Knife, immunotherapy combo shows promise in managing certain brain tumors  This is an interesting combination. Will keep an eye on it.  BTW: Northwell Health (Northshore Medical Center) on Long Island, NY just got the new version of the gamma knife.

  123. [06/13/2018] Musella Foundation awards 7 brain tumor research grants!  A big thank you to our amazing volunteers and participants in the National Walk To End Brain Tumors!  These projects are going to make a difference fast!

  124. [05/31/2018] FDA-approved drug for lymphoma and leukemia may help treat common type of brain tumor  This is too early to say if it helps or not, but is another treatment that is available if you have the right target.

  125. [05/31/2018] Brain Tumor Awareness Month Webinar Series are now available free on demand!  Let us know what you think of this format, and if you have ideas for speakers or topics for future webinars!

  126. [05/30/2018] Trump signs `Right to Try Act` aimed at helping terminally ill patients seek drug treatments  This is a big step forward!  I am now working on how to use this to the advantage of brain tumor patients.  If anyone wants to try to get a drug through this pathway, please join our online support group at https://virtualtrials.com/braintumor-treatments.cfm and discuss it there!

  127. [05/29/2018] First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
    This article is so important that I am placing my editorial comments into the full text part of this entry so more people see it, along with a link to the full article.


  128. [05/28/2018] Minute Particles could Assist Battling Brain Cancer  Great concept. Probably wrong drug but they are working on it.  Maybe they should try 06bg  

  129. [05/27/2018] Brain Tumor Awareness Month Webinar Series: Special Guest Dr. Eric T. Wong, Co-Director, Brain Tumor Center, Beth Israel Deaconess Medical Center: Tonight (Sunday 5/27/18) 7pm Eastern Time!   Just a reminder that it is tonight! Please join us!

  130. [05/25/2018] Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma.  This is only 1 case report but it shows great results using an old drug in a new way.

  131. [05/25/2018] Midatech Pharma Commences First In-Human Study Of Brain Cancer Drug  This is a new way to get drugs to the tumor!

  132. [05/24/2018] Brain Tumor Awareness Month Webinar Series: Special Guest Dr Eric T. Wong, MD, Co-Director, Brain Tumor Center, Beth Israel Deaconess Medical Center (Sunday 5/27/18) 7pm Eastern Time!  This is the final speaker in our Brain Tumor Awareness Month Webinar Series!  Dr. Wong was in charge of the USA trials for Optune and will discuss all aspects of the use of Optune for brain tumors!

  133. [05/24/2018] Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial.  Pretty good results, but it is in a small trial.   

  134. [05/20/2018] URGENT ACTIVISM ALERT: Right To Try Bill up for vote this Tuesday!  We need lots of emails and calls!  

  135. [05/20/2018] Brain Tumor Awareness Month Webinar Series: Special Guest Dr Henry Friedman Tonight (Sunday 5/20/18) 7pm Eastern Time!  Just a reminder that it is tonight! Please join us!

  136. [05/18/2018] Brain Tumor Awareness Month Weminar Series: Special Guest Dr Henry Friedman  This is an opportunity to talk to Dr Henry Friedman and ask questions on any brain tumor related topics!

  137. [05/18/2018] Webinar: Navigating the New Normal After a Brain Cancer Diagnosis  From our friends at Tocagen.  Dr. Lovely earned her PhD at the University of California San Francisco (UCSF) School of Nursing focusing on symptom management and brain tumor patient care.

  138. [05/17/2018] Support for Legislation Increasing Awareness for DIPG  This is from our friends at Oncoceutics and Jack's Angels Foundation.  Please contact your representatives and ask them to support this bill to create a national DIPG awareness day. (DIPG is a devestating brain tumor usually found in children)

  139. [05/16/2018] Duane A. Mitchell, M.D., Ph.D., World-Renowned Immunotherapy Expert to Speak at Seattle “Brains Matter” Dinner  From our good friends at the End Brain Cancer Initiative! 

  140. [05/13/2018] When did the glioblastoma start growing, and how much time can be gained from surgical resection? A model based on the pattern of glioblastoma growth in vivo.  Fascinating. We get this question all of the time. The answer is it takes about a year for the gbm to grow to the size where it causes symptoms and you notice it.   And there is a big gain from removing 99% of the tumor compared to 95%.  If they only remove 50% of the tumor, it will grow back before the surgery heals.

  141. [05/12/2018] Brain Tumor Awareness Week 2018 Webinar Series - Tonight! 7pm Eastern  Just a reminder!  

  142. [05/03/2018] Durham firm with innovative brain cancer treatment lights up $642K equity round  I did not see research results but the methodology looks very interesting

  143. [04/25/2018] Brain Tumor Awareness Week 2018 Webinar Series

  144. [04/24/2018] Needed context absent from release on “less toxic way to treat brain tumors”  This brings up a very important point.  Every day we see an article claiming a breakthrough. Us old pros know it is just hyperbole - not really meant to be taken literally.  They are just trying to get their treatment noticed and if they told the truth in the headline, nobody would look at it.  But for the new people here, who are desperately looking for anything to help their loved one with a brain tumor, it is very dangerous.  The website noted below digs into these stories and exposes the truth.  I like to think that is what we do here also with these editorials about the articles.  It gives perspective. Same with our online support groups: https://virtualtrials.com/lists.cfm   If you find something online that looks interesting for brain tumor patients, share it with one of the online groups.  

  145. [04/19/2018] A Shock to the System: Tumor-Treating Fields Plus Temozolomide for Glioblastoma  Nothing we did not know before, but now this impressive journal has an article that says Optune should be the standard of care for GBMs.  This should help get insurance coverage for those few plans that still deny it.

  146. [04/18/2018] New Technology Crosses Blood-Brain Barrier To Fight Glioblastoma Cells Directly Interesting new drug - apparently did well in phase 1 testing.

  147. [04/18/2018] Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

    This study definitively proves what we already knew, that you do better if the entire tumor is removed. At a recent FDA advisory committee meeting I attended, the FDA said they did not believe that is the case.  Next time they will believe this study.  

  148. [04/18/2018] Musella Foundation Copay assistance program is now closed to new and renewal patients  We just awarded our 1,000th grant (of $5,000 each) to a brain tumor  patient in need of help today!   I know most people would rather donate to brain tumor research, but there is a huge need for this type of help also.    We give you a choice when making a donation - you can pick where your donation goes!  

  149. [04/17/2018] Study Reports Possible Novel Method for Stopping Untreatable Pediatric Brain Cancer  It is way too early to say it stops these pediatric brain tumors but this is a new idea that hopefully will start human clinical trials soon!

  150. [04/14/2018] WEALTH: All the money in the world: A couple whose child was diagnosed with a brain tumor is hoping an influx of funding will help find a cure. This man asked my opinon, and I told him: The Virtual Trial.  We are expanding our virtual trial concept, collaborating with other organizations, and now have a team of experts who can help find the best treatments, track the outcomes, and learn from every patient..  Go to virtualtrials.com/ask for details.  

  151. [04/12/2018] Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.  This is a very important article.  Although a small sample, it opens the door to using a BRAF inhibitor for brain tumors that have the BRAF V-600 mutation. Note that this shouldn't be used in other mutations of BRAF, only the V-600 mutation. They found that using these drugs may actually speed up the tumor if they do not have the V-600 mutation.

  152. [04/06/2018] The Musella Foundation For Brain Tumor Research & Information, Inc awarded a brain tumor research grant today! This is an interesting project.  This is  a preclinical experiment that may quickly lead to a human trial!  

  153. [04/04/2018] Apexigen to Recruit Children with Brain Tumors for Phase 1 Trial of Immunotherapy  This is a phase 1 trial, which means we do not yet have results but may sounds logical.

  154. [03/31/2018] The Musella Foundation For Brain Tumor Research & Information, Inc awarded a brain tumor research grant today!  This is an important project because the drug being studied is approved for Lung Cancer. so if they find it useful for glioblastomas, it can immediately be used off label!

  155. [03/25/2018] About ONC-201 - a new class of oral treatments for brain tumors  ONC-201 is a new class of treatment for brain tumors -  it is in clinical trials now for recurrent GBMs and any type of glioma that has the H3 K27M mutation!

  156. [03/24/2018] UCLA 18th Annual Brain Tumor Conference  Always a worthwhile experience from our good  friends at UCLA!

  157. [03/23/2018] FDA issues Class I recall for Minnesota-made brain probe  This is a rare occurence - happening about 12 times out of 1,800.  The cause was identified and they are fixing the problem, and letting the doctors know about it so they can watch for it and prevent problems.  I feel it is still a good treatment as this device is used for "inoperable" tumors that will most likely kill the patient without the treatment, so it is still worth the small risk.

  158. [03/20/2018] NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma  This is great news.  The NCCN basically sets the standard of care for cancer treatments. The NCCN treatments classification is:

    NCCN Categories of Evidence and Consensus

    • Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
    • Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
    • Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
    • Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
    Not only does this set the standard of care as including Optune, but it should make it impossible for insurance companies to deny it.

  159. [03/15/2018] Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018 That is an impressive number of presentations, and means that Optune has finally been accepted by the research community.  

  160. [03/13/2018] OURBRAINBANK: PEOPLE-POWERED, TECH-ENABLED START-UP TO TACKLE BRAIN CANCER  This is from our friends at "OurB Brain Bank".  It is an app that records your information to be used in research and helps match you with clinical trials.   We have similar projects going - the brain tumor virtual trial, and our clinical trials matcher, but it is good to get other points of view

  161. [03/09/2018] Optune Open House  This is from the people at Novocure.  It is a facebook event where you can learn about and ask questions about Optune!

  162. [03/09/2018] New Ammo In The War On Brain Cancer  This is a tv news segment about an exciting new clinical trial for recurrent glioblastoma of: EGFR(V)-EDV-Dox.   See  https://clinicaltrials.gov/ct2/show/NCT02766699 for details on the trial. and click HERE for details on this new treatment. Disclaimer: Dr. Boockvar is a member of our medical advisory board.

  163. [03/08/2018] Failure in pivotal PhIII brain cancer trial drags Israel’s VBL Therapeutics down  This is so sad. I had high hopes for this trial. The earlier phase 2 trial reported very good results.  The details have not been released yet - would love to see how the 2 trials differed and why the phase 3 trial did not show a benefit when the phase 2 showed such a large benefit. 

  164. [03/07/2018] Novel Combo Explored for Rare Brain Tumor  This is a clinical trial for recurrent Anaplastic Astrocytomas.  Looks promising. Disclosure: Orbus Therapeutics is a sponsor of our organization.  

  165. [03/03/2018] Secretive Mexican brain cancer clinic to be investigated by Australian expert  It doesn't sound like they are going to be open to investigations.  They are currently treating 70 patients at a cost of $300,000 per patient.  If the treatment worked, they would have  published and patented it and make a fortune helping patients all over the world.   If they are not sure it works, then they need to keep it secret so they can scam rich foreigners.  As a reminder, some drugs, like Avastin, can make a tumor disappear from a scan even though it is still there.  So I am not that impressed with the scan results. However, the article does say there is some evidence of living longer, which would impress me. I hope they let the expert investigate.

  166. [02/24/2018] Tumor microenvironment after biodegradable BCNU wafer implantation: special consideration of immune system.  Very interesting.   If this is true,  this may lead to big gains in immunotherapies.  One of the problems was the lack of CD8+ Killer T Cells in the area of the tumor. Apparently, Gliadel wafer may attract these cells to the tumor bed.  So we need to watch combinations of Gliadel with immunotherapies! Very exciting!

  167. [02/16/2018] Shared cancer neoantigens: Making private matters public  This is for a new treatment for pediatric brain tumors that have a certain mutation. Almost all DIPG patients have it and some high grade glioma patients have it, especially those near the midline of the brain.  Fascinating but highly technical article.  Bottom line is that it led to a clinical trial for kids with this mutation.

  168. [02/14/2018] A cold virus could extend lives of some brain cancer patients, MD Anderson study finds  This is impressive.  After a single injection, they had a complete response to a recurrent gbm, and 20% of the patients did much better than expected - although unfortunately they all died.  This is a step forward - it has to be fined tuned:  optimize the delivery and schedule of it and see which drugs can make it work better.

  169. [02/14/2018] Thoughts on "Right To Try"  These are my thoughts on the right to try law. The Senate passed it already and the House is considering it.   

  170. [02/01/2018] Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma A Secondary Analysis of a Randomized Clinical Trial  JAMA is one of the most respected journals. The  conclusion: Considering the net clinical benefit, our HRQoL (healthcare related quality of life)  data support the addition of TTFields to standard therapy in patients with glioblastoma

  171. [02/01/2018] BTB Foundation Expands Giving with Academic Scholarship Opportunity (Chicago Area Only)  This scholarship is for students in the Chicago area affected by a brain tumor.

  172. [02/01/2018] Cancer ‘vaccine’ eliminates tumors in mice  This is not in brain tumors yet, but this may be the most exciting news in years. This team has previously invented Rituximab, which is one of the most important cancer drugs ever invented, so they have the experience  to do this correctly and quickly..  I am trying to see if we can get it tested on GBMs and/or DIPG.   

  173. [01/31/2018] ONC201 Trial Begins at NYU for Children with H3 K27M Mutant Glioma  This is an important trial for patients who have this mutation. Check your pathology report for the H3 K27M mutation, or if your child has a DIPG and did not have a biopsy - they most likely have this mutation.

  174. [01/29/2018] Optune Open House, Santa Anna, CA  This is from the people at Novocure. These meetings are a perfect introduction to Optune for brain tumor patients thinking about trying it or those who are using it!  

  175. [01/28/2018] Tiny implant opens way to deliver drugs deep into the brain  This may be groundbreaking.. We just need a good drug to use.

  176. [01/21/2018] Lessons Learned Using a High-definition Three-dimensional Exoscope for Brain Tumor Surgery  Very cool video of a new tool for brain tumor surgery. Warning - very graphic.

  177. [01/17/2018] Long Island resident with recurrent brain cancer receives novel experimental treatment at Lenox Hill Hospital  This is an exciting new type of treatment. I will be watching it closely!

  178. [01/17/2018] High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy.  Very interesting.  In our virtual trial, we have 10 glioblastoma patients who tried the combination and they did a lot better, on average, than those who took Temozolomide without Metformin.

  179. [01/08/2018] Study Finds Growing Socioeconomic and Racial Disparities in Management of Brain Metastases  It is very sad if true. 

  180. [01/05/2018] Bettye J. Wiley Hooks shares lessons of own battle with cancer

     One of our members wrote a nice book about her experiences with a brain tumor

  181. [12/29/2017] Musella Foundation awards brain tumor research grant! We gave this researcher a grant previously - that project came out very well.  She now needs just a little more money to follow up on it to get enough data to apply for big government grants.  Our relatively small investment in her work can lead to a big grant that can take this new treatment into the clinic!  

  182. [12/28/2017] Foundation Aims For Virtual Trial Registry To Help Patients With Brain Cancer Get Drugs Sooner Of course I am biased, but I think this is the fastest way to finding the cure for brain tumors!

  183. [12/23/2017] Musella Foundation awards brain tumor research grant!  This project will hopefully allow the researcher to apply for a large NIH grant to get the clinical trial going! I thank all of our end of year donors for making this possible. We have 3 other worthy projects waiting for funding. If you would like to help fund them, make a donation at:  Virtualtrials.com As a reminder, the tax laws have changed significantly for next year.  For most people, it is going to be better to donate in 2017 than 2018.  Ask your accountant! As always, it is best to donate appreciated stocks than to donate cash. This works best for stock that you own for over a year.  Click HERE for details on why it is better.  We make it simple to donate stock. Just call us at 888-295-4740 and we will explain how to do it.

  184. [12/19/2017] JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma  This is the final report of the Optune trial for newly diagnosed GBM.  It should set the new standard of care for GBM to include Optune.

  185. [12/06/2017] FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer  This is great news.  I was worried that they would remove the approval based on the study mentioned.  The study showed "no significant increase in overall survival".   That study did not take into account how Avastin is used in the real world.  In the real world it is used in combination with many other things and is a very useful drug.  Our virtual trial is tracking the combinations.  One that looks exceptionally good (although only 4 patients used the combination) is Avastin plus Optune.  2 of the 4 patients died, but they survived an average of 30 months. The other 2 are alive - one for 22 months so far and the other an amazing over 8 years.

  186. [12/04/2017] A novel immuno-oncology approach to treating a rare childhood brain cancer  This is a very exciting new treatment for one of the worst diseases that could happen to kids.

  187. [12/03/2017] Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma.  This was only in mice, but it shows that using morphine might make temodar work better.  

  188. [12/02/2017] SNO 2017: No Unexpected Safety Issues Arise With Tumor Treating Fields in Glioblastoma Patients With Shunts, Pacemakers, or Defibrillators  The package inserts warns against using Optune if you have an implanted defibrillator  or a programmable shunt.  However, they looked at patients in the trials who had these devices implanted and used Optune anyway, and found that there were no safety problems.

  189. [12/02/2017] Promising target for treating brain tumors in children  This is a press release about the research I mentioned in a previous news blast article!

  190. [12/02/2017] Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma  This research found a new target for these devastating pediatric brain tumors - and there are drugs available that can hit these targets so it may offer hope for these patients.  This project was funded by the Musella Foundation.     We are saving up for the next step in this research.

  191. [11/24/2017] Ziopharm says its brain cancer drug helped trial patients live more than a year  This is a gene therapy that is showing some impressive results in an early trial!

  192. [11/21/2017] Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit.  This showed no benefit of adding Gliadel when 5-ALA was used to guide the surgery. Surprising results. 

  193. [11/16/2017] National Cancer Institute designates UCLA brain cancer program a site of research excellence  I am proud to say that I am the patient advocate on the board for this program!  This is a brilliant group of researchers who deserve this recognition and will put the grant money to great use to speed up the search for the cure!

  194. [10/24/2017] Incidental findings abound on brain scans of the general pediatric population  Very scary - 1/4 of all children had a brain abnormality on MRI. Only 1/2 of 1% had something serious.   I am not sure what this means for the concept of routine screening for brain tumors.  The vast majority of abnormalities is nothing serious but might cause unnecessary surgery and worry.

  195. [10/18/2017] Clinical trial targets the most common form of brain cancer  This is an interesting video about the trial of MDNA55. This is a new approach to treatment and did well in earlier studies.  (Medicenna is a sponsor of the Musella Foundation)

  196. [10/18/2017] Diffusion Sprints on FDA Nod for Brain Cancer Treatment  This clinical trial should be considered by anyone with an inoperable gbm. Early results looked very good.

  197. [10/18/2017] Arsenic identified as a potential treatment for brain cancer  These researchers looked back at a failed trial and found that for a specific subtype of gbm, it actually doubles or triples average survival.  They are running a trial on that subtype now.  

  198. [10/11/2017] Areas of glioblastoma tumors correlate with separate subtypes of glioma stem cells  This is the type of research and thinking that can lead to major breakthroughs. Figuring out why treatments fail, and putting together intelligent combinations is the path to breakthroughs.  This research is in mice, hope they try it on people soon.

  199. [10/11/2017] Mustang CAR-T brain tumor trial gets funds to expand  This is one of the most promising treatments in the pipeline.

  200. [10/10/2017] New resources for children affected by brain tumors in the family!  We partnered with the Pediatric Brain Tumor Foundation to distribute these animated films for any kids who either have a tumor or know someone with a tumor. Makes it easy to explain to kids what is going on.  

  201. [10/09/2017] Combination Treatment Targeting Glucose in Advanced Brain Cancer Shows Promising Results in Preclinical Study  Interesting approach.  Works in mouse model, hope it works in human trials!

  202. [09/29/2017] I’m dying of brain cancer. I prepared to end my life. Then I kept living.  This is a common topic of conversation.  My views are that assisted suicide has a place - but most consider it way too early, just like this man.  You get diagnosed, read about the horrors of the diagnosis on the internet and give up.  But what is missed is that some people do beat this. There is progress every week. Just this week, we published 2 articles showing major gains:  adding CCNU to Temodar upped the average survival to 46 months.. which means half of the people lived longer than that!  And the long term results of the Optune trial showing that the 5 year survival rate, which was stuck at 5% for the last 100 years or so, is now 13%.  (Still bad, but a lot better than 5%)

  203. [09/29/2017] Biologists identify possible new strategy for halting brain tumors  Interesting research.

  204. [09/27/2017] Amazing increase in survival for newly diagnosed GBM by adding CCNU  This study shows an amazing increase in survival by adding ccnu to Temozolomide.  These treatments are already available and may be worth asking your doctors about now. 

  205. [09/24/2017] Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients  The 5 year results for Optune just came out and they were unbelievably good.  This is a large study in newly diagnosed GBM patients so the results are significant. Bottom line: 5 year survival rate was 13% for the Optune (plus Temodar) group and only 5% for the Temodar alone group.  That is a major step forward.

  206. [09/19/2017] New math developments lead to more improved brain cancer treatment  I agree completely.  Advanced math is going to be the key to finding the cure.  I think the path to the cure is having all patients tracked in the virtual trial registry, and analyzing the data to find the best combinations.  (Along with getting early access to experimental treatments)

  207. [09/10/2017] How a Dallas reporter pushed the FDA for a new approach to treating brain cancer  This is about our proposal to speed up the search for the cure.  They mention there is a legal problem  we are working on that and it appears that will not be an issue at all - our proposal could be implemented under current laws.    If interested, we are discussing it in the braintumor treatments online support group at https://virtualtrials.com/braintumor-treatments.cfm  

  208. [09/07/2017] Curtana Pharmaceuticals Successfully Completes Pre-IND Submission for CT-179 for the Treatment of Malignant Gliomas  This sounds exciting - it is a new target which is not usually found on normal brain but is found in GBM cells - especially cancer stem cells

  209. [09/06/2017] Brain Cancer Survivor Strives to Increase Public Awareness Around Disease  People have no idea what our brain tumor patients and their loved ones are going through.

  210. [09/06/2017] Zika Virus Kills Brain Tumor Cells, Researchers Find
     I wasn't going to write about this but so many people asked about it already.  My thoughts are that it is way too early to tell if this will help patients. It is getting huge media coverage because of the association with Zika, when there are many other treatments that patients can get access to which have shown some good results in people.
     It is better to focus on the treatments that are available now or will be available soon.


  211. [09/01/2017] Lymphoma Patient’s Brain Tumor Disappeared After She Received JCAR017, Study Reports  This is only in 1 patient but worth keeping in mind if you have a CNS lymphoma that is not responding to standard treatments.  Hopefully they will eventually be able to use this technology for the more common brain tumors! 

  212. [09/01/2017] Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields  This looks interesting and needs further study.

  213. [08/18/2017] Reengineering Immune System Cells to Fight Glioblastoma  This may lead to a breakthrough in the treatment of most cancers!

  214. [08/16/2017] CHOP to lead new pediatric data resource center for research in childhood cancer, birth defects  This is the type of effort needed to make headway in the fight against cancer (and birth defects).   The Musella Foundation funded early work for this project which led to the big NIH grant which is making it a reality!

  215. [08/16/2017] VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme  This vaccine showed very good results in early trials!

  216. [08/15/2017] Curtana Pharmaceuticals Granted FDA Orphan Drug Designation for CT-179 for the Treatment of Gliomas  This targets Oligo2, which sounds like it might be a great target 

  217. [08/14/2017] Options to Treat a Glioblastoma  I was asked for my opinion on what I would do if I had a newly diagnosed gbm.. here is my response.  We can discuss it in the braintumor-treatments online group https://virtualtrials.org/braintumor-treatments.cfm  

  218. [07/29/2017] Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.  Very interesting study. It says that starting radiation therapy earlier than we usual do actually is worse for the patient. The study was performed just by looking at billing records.  I would like to see more research on this. Perhaps look at the reasons radiation was started earlier. Maybe those patients had a lot of residual tumor so they were rushed into radiation as there was less space for recurrence? Or had some other medical reasons.

  219. [07/23/2017] Glioblastoma: New tools against brain cancer This is one of my favorite new treatments. It is too early to tell how well it works, but it looks promising.  Disclaimer: I am on the patient advisory board at the Brain Tumor Center at Duke (but have no financial involvement in this treatment)

  220. [07/22/2017] The Musella Foundation has awarded a pediatric brain tumor research grant

  221. [07/20/2017] Camp Jinka is a free summer program for kids and teens whose lives have been impacted by the diagnosis of a brain tumor .  I have heard excellent things about this camp  

  222. [07/19/2017] The Cedars-Sinai Department of Neurosurgery Presents Outsmarting Brain Tumors: A Conference on Brain Tumors for Patients, Families and Caregivers  This is an excellent conference for patients and anyone interested in brain tumors.

  223. [06/24/2017] No measurable gadolinium in children’s brains even after multiple doses  One less thing to worry about!

  224. [06/21/2017] Cash-strapped ImmunoCellular halts brain cancer vaccine trial, eyes `strategic alternatives`  This is a shame. There were long term survivors from the trials, and there were basically no side effects. Even if it helps 20% of the people, it is worth using. I hope they find a way to continue.

  225. [06/12/2017] First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma  Interesting combination.  I would guess the concept they are going after is that Avastin, when it fails, doesn't just stop working - it just doesn't work enough but still is slowing down the tumor.  If you add Optune, perhaps the combination could be strong enough to stop the tumor.  Hate to say, but it may make more sense to just start Optune at the start - right after radiation - on newly diagnosed people.  For those that missed that opportunity, this trial makes sense. [Disclaimer: Novocure is a sponor of our organizaiton]

  226. [06/07/2017] Estimating the annual frequency of synchronous brain metastasis in the United States 2010–2013: a population-based study  Not enough attention is being paid to metastatic brain tumors.  They are much more common than the primary brain tumors.   The Musella Foundation is listed as a sponsor of this research!  Good work!

  227. [06/07/2017] New Target Found to Attack an Incurable Brain Tumor in Children  75% of pediatric DIPG patients have this - and there is a drug available against it which can be used off label. Hope they quickly start trials on DIPG kids.

  228. [06/07/2017] Five years before brain cancer diagnosis, changes detectable in blood  This is a major find.  It may lead to a simple blood test to predict risk of developing a brain tumor - and perhaps even lead to research on how to stop the formation of the brain tumor if you know it is coming!

  229. [06/07/2017] Medicenna’s Immunotherapy Phase 2b Trial Underway Using Brainlab Drug Delivery Technology  [Disclosure - this company is a sponsor of the Musella Foundation|    It looks like the technology to get the drug in the correct spot at the right concentration is finally here. Follow the link in the press release to the background info on the delivery system.  And this may be the right drug to use. In an earlier study, in recurrent GBM patients, they had a few complete responders, with some still  alive 4 years later.  

  230. [06/01/2017] Musella Foundation awards 7 brain tumor research grants!  I would like to thanks all of the volunteers and participants in our "Natioanl Walk To End Brain Tumors" who made this possible, as well as the donors to our organization and the families that named us for memorial donations.

  231. [05/30/2017] Efficacy Results for ONC201 in Recurrent Glioblastoma Published
     Impressive results in a few patients. Interesting about the  histone H3 tumor mutations - it has been shown that brainstem gliomas commonly have that mutation. Unfortunately only adults are getting access to this compationate use program now. Maybe they will expand it to children after a few adults do well.
    The Musella Foundation funded the early work on this new treatment!
     


  232. [05/25/2017] Four Neuro-Oncology Experts to Lead New Glioblastoma Research Center at NewYork-Presbyterian  These are some of the brightest minds in the field. Great to see them working together!

  233. [05/25/2017] Study provides better understanding of how brain tumors `feed`  This is the type of basic research that can lead to major advances!

  234. [05/14/2017] Tumor treating fields in pediatric high-grade glioma.  This is proof of concept - that kids (aged 10-20) can at least tolerate the treatment. 

  235. [05/14/2017] Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.  This is a different way to give Avastin - directly into an artery.  One case doesn't prove anything but it is very nice to see.

  236. [05/11/2017] First spherical nucleic acid drug injected into humans targets brain cancer  A completely new approach. I wish them luck. Looks very interesting!

  237. [05/11/2017] Inovio, Regeneron Plan Clinical Trial of Triple-Combo Immunotherapy for Brain Tumors  I love this kind of combination - tries to cover all of the bases.  I wish them luck.  However, I am trying to change the system - it should be legal for a doctor to try this type of combination outside of trials.  What happens if they determine that a different drug might do better if they switch it out for the one they chose now?  It is back to the drawing board - design and set up another trial - waste a year or 2, and loads of money.  There is a better way.

  238. [05/05/2017] Duke researchers develop treatment that triples survival time of brain cancer patients  Impressive results, but it is on a small group of patients. We need more research on this. Disclosure: I am on the patient advisory board at Duke.

  239. [05/04/2017] Research Reveals Non-coding RNA SPRIGHTLY Plays Important Role in Tumour Growth, Spread  May be a new target!

  240. [05/02/2017] Using CRISPR to Find Treatments For Aggressive Pediatric Brain Cancers Interesting research found a new target in one of the worst forms of pediatric brain cancer, and luckily, found an existing drug that can be used against it.  This researcher submitted a grant application to us in our current grant cycle to work on this project. Our National Walk To End Brain Tumors will be raising money for us to give out - If we raise enough money, hopefully we can fund her project and other very promising projects.  Go to walktoendbraintumors.org for details on our event!

  241. [05/01/2017] Brain Tumor BioTech Conference June 2, 2017 in NY  This is one of my favorite conferences. It is targeted at doctors, researchers and the people who invest in biotech.  Not really for patients and families.

  242. [05/01/2017] Breakthrough brain tumour visualisation drug Gliolan to be listed on NZ hospital medicines list from 1 June  This treatment is being considered for approval by the USA  FDA next week.. I will be speaking  there as a patient advocate. Impressive results:  Six-month progression-free survival was achieved in 41% of patients receiving GLIOLAN compared to 21% of patients who were operated on without the use of the drug   p=0·0003  

  243. [04/26/2017] New Tupperware Fundraiser!  This fundraiser gives us 40% of your purchases!   Please remember to use this link if you buy Tupperware!

  244. [04/26/2017] Surgical success in previously “inoperable” brain cancers  This may be an option when you are told a tumor is inoperable. Disclosure: this company is a sponsor of the Musella Foundation

  245. [04/26/2017] TARGETED THERAPY BEING TESTED IN SOCAL GIVES BRAIN CANCER PATIENTS HOPE  This is an exciting trial. An early pilot study showed pretty good results. Disclaimer:  This company is a sponsor of the Musella Foundation

  246. [04/22/2017] Brains Matter Awareness Fundraiser and Celebration Luncheon / Now Accepting Nomination for our 2017 National Hope Award  2 announcements from our good friends at the End Brain Cancer Initiative. I have seen Fran Drescher speak at events like this and she is hilarious!

  247. [04/21/2017] Pediatric Brain Tumor Mutations are Detectable in Cerebrospinal Fluid  This is a huge advance, although it is a small study and needs to be validated. The concept of a liquid biopsy is that instead of trying to get tumor tissue directly, you get it from blood, or in this case, cerebral spinal fluid, which is a lot easier than brain surgery. You can usually only get a biopsy once or twice of the actual tumor. In some cases, it is dangerous to do a biopsy at all.  However, with a liquid biopsy, you can repeat it over time, and see how the tumor is responding to treatment.  We are funding the development of a new drug that targets the exact marker this researcher is testing for.  I can envision a day when you do this test, and personalize treatment based on it.  Then repeat to see how the tumor is trying to mutate around the drug and be able to change the treatment plan.

  248. [04/19/2017] Cloud Over Pediatric Oncologist and Brain Cancer Vaccine  This is a dificult article to interpret. I have met this doctor and we went over his research in detail. The results he showed me were pretty good - but nowhere near claiming to be a cure.  It was in line with the vaccine trials here in the USA. Some people do very well - others aren't helped at all.  I know of a few people doing well on his vaccine. I also know people who weren't heped by it.  We recently started tracking his treatment in our virtual trial project but don't have enough data to make a judegement on it yet.  

  249. [04/18/2017] FDA Okays Clinical Trial of Injectable Brain Cancer Drug - See more at: https://www.specialtypharmacytimes.com/news/fda-okays-clinical-trial-of-injectable-brain-cancer-drug  Interesting trial, but it looks like it will only be available in Austrailia for newly diagnosed gbm

  250. [04/17/2017] Survey on the use of animals in brain cancer research  We know this is a a controversial and emotional issue but we need to know your thoughts on the matter. Please fill out the survey.

  251. [04/17/2017] CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence  This study shows that Optune should be continued after the first recurrence, and use it in addition to a second line therapy.  Patients who had a recurrence and remained on Optune therapy did 31% better than those that discontinued Optune.

  252. [04/14/2017] Medicenna Treats First Patient in Phase 2b Recurrent Glioblastoma Trial  This is an exciting trial.  Early (small)  trials had a few complete responses after a single treatment. Disclaimer: Medicenna is a sponsor of our organization

  253. [04/12/2017] Feinstein Institute examines use of antiparasitic drug as new treatment for brain tumors  Brilliant work.  If they are correct, this drug may be able to replace the Vincristine in PCV, making it more effective and much less toxic! Disclosure: I am on the patient advisory board of the Feinstein Institute.

  254. [04/06/2017] Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity Toca 511 is an experimental gene therapy being tested for recurrent glioblastoma.  This study shows long lasting immunity - actually a cure - in mice.  Even when they tried to inject a new tumor into these mice, the mice rejected the tumor. 

  255. [04/05/2017] DelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting  This is one of my favorites. It may become a drop in replacement for Temodar in patients who have unmethylated MGMT, and it might also do better in other situations.

  256. [04/03/2017] "Sci-fi" cancer therapy fights brain tumors, study finds  This is the final results of the Optune trial.  Survival rates were 43 percent versus 31 percent at two years; 26 percent versus 16 percent at three years, and 13 percent versus 5 percent at five years. These results are impressive.  The survival advantage has improved since the last report as there are now more 5 year survivors.   All subgroups of patients had a benefit - methylated or unmethylated, young or old, gross total resection and biopsy only.  They also clarified their position of letting every patient who wants to use it get it regardless of ability to pay.

  257. [03/29/2017] MGH/Dana Farber Initiate Expansion of ONC201 Glioblastoma Trial  Exciting news- the trial was expanded.   We (the Musella Foundation) gave a grant to help with the early development of this new drug!

  258. [03/20/2017] Is it time for "Conditional Approvals"?  I have been working on this plan for a while, but I think now is the time for it to actually be approved. Everything is coming together - like the perfect storm: 1. We finally have a few experimental treatments in the pipeline that look really good. 2. The new president is slashing regulations and calling for faster FDA approvals and for slashing drug prices. 3. Computer technology  and biostatistics have reached the point where our plan for a registry trial can be just as reliable - maybe more so - than traditional phase 3 trials. IF this plan is put into effect, I predict we would have an immediate breakthrough in the treatment of brain tumors, and the possibility of a cure in a few years, instead of the decades it would take on the current path. I need the support of other organizations now, and in a few weeks I may need everyone to be writing letters and making phone calls.  I will send out details when it is time!

  259. [03/17/2017] Antibody treats pediatric brain tumors safely and effectively in mice  Let's hope this gets into human trials quickly

  260. [03/17/2017] Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.  This article says that using more than 6 months of Temozolomide is not better than using 6 months of it as far as survival goes. That is counter-intuitive.  I would like to see larger studies to confirm it.

  261. [03/10/2017] Ependymoma Awareness Day.  From our good friends at the CERN foundation!

  262. [03/10/2017] 4th ANNUAL HOOPS FOR HANNAH FUNDRAISER FOR BRAIN TUMOR RESEARCH  This is a fun way to raise money for brain tumor research. Part of the proceeds goes to the Musella Foundation!

  263. [03/10/2017] Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.  Good project, but I disagree with their conclusion.  They found that 25% of the time, the methylation status changes between the first and second surgery.   They conclude that it is insignificant and we shouldn't bother testing the second time as it provides no useful information.  They are correct for now, but  that should change very shortly as there is now a drug in clinical trials that can work on unmethylated patients. This makes the methylation status very important to determine, and for those 25% of patients with the changed status, it can be a life altering test.

  264. [03/08/2017] Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.  General consensus is that Optune is now the standard of care for newly diagnosed GBM patients, and a good option for recurrent GBM patients!

  265. [02/23/2017] Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade Glioma  This is very exciting news. I have always felt that it is almost criminal that most patients do not have access to treatments like this.  They have shown that the treatment is safe, and early results show impressive results - at least a doubling of average survival with some patients still doing perfectly for a long time.  This breakthrough therapy designation will speed up the process of approval.  It opens the possibility  that FDA approval could come based on the phase 2 trial which has completely enrollment and results should be available within a year, which means that FDA approval might be possible by the end of next year.  Unfortunately not soon enough for anyone who has a brain tumor now. We still have to work on ways to make it available now to people who need it - possibly using compassionate use or the right to try laws.  

  266. [02/06/2017] NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA There is no mention of why there was a hold in the first place. It makes no sense to me that they have to wait for 233 people to die before they can analyze the data.  If we ever have a cure, these methods insure that we will never see it because the trials would never end.

  267. [02/04/2017] New Brain Cancer Coalition Announces Precision Medicine Study During CHOP Event  I love collaborations like this. It will help speed up the search for the cure. An interesting part of this is that Independent Blue Cross will pay for the genomic testing of the patients for their patients.  Cost was a big stumbling block for some similar projects. The Musella Foundation helped fund some of the early work on this!

  268. [02/04/2017] Researchers at Yale have taken steps toward a ‘completely unexpected’ new way to treat brain cancer  Interesting use of an already approved drug for brain tumors with IDH mutations. It hasn't been tried in clinical trials yet.

  269. [02/04/2017] Northwell Health is First on Long Island to Acquire Synaptive Medical’s BrightMatter™ Technology for Complex Brain Tumor and Spinal Surgery  This technology will help make braintumor surgery safer, and may also make some tumors that were thought inoperable, operable! Disclosure: I am on the patient advisory board of this medical center!

  270. [02/04/2017] FDA Grants New Clearance for Brain Surgery Technology  These 2 new approvals should help make brain tumor surgery safer, and also may turn some inoperable tumors into operable ones!

  271. [02/04/2017] 17th Annual UCLA Brain Tumor Conference  This is an excellent conference. Worth going to!  

  272. [01/28/2017] The Musella Foundation announced that it has awarded a $25,000 brain tumor research grant This project involves a new material that can be 3-d printed into the shape of a bone flap, which can be inserted when the original bone flap created during a brain tumor surgery, can't be used (such as for infections or necrosis).  This new material quickly transforms into real bone.

  273. [01/26/2017] Out of Warburg Effect: an effective cancer treatment targeting the tumor specific metabolism and dysregulated pH.  I like the approach. We had a few articles recently on this approach. Maybe combining some would make sense.

  274. [01/25/2017] ‘Tumor Shrinking’ Drug Shows Promise In Dogs Before Clinical Trials On Humans Sounds promising. Might not be a cure by itself - but may be another tool that we have to use in combinational therapies.

  275. [01/25/2017] DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)  This is one of the more promising trials.  Val-083 is a new chemotherapy that works similar to the way Temozolomide works, except at a different location, so the MGMT repair enzyme can not undo the damage.  If there is a lot of MGMT repair enzyme around, (sometimes pathology reports call this unmethylated MGMT genes)  temozolomide has a much smaller chance of helping, so something else is needed.  

  276. [01/25/2017] Correction to: Brain Surgery Made Safer With New Smart Needle  Sorry - the link I posted yesterday had a space in it and didn't work. It is now fixed.

  277. [01/24/2017] Brain Surgery Made Safer With New Smart Needle  Amazing technology.  Hope it becomes available soon!

  278. [01/23/2017] Musella Foundation Request for Brain Tumor Research Grant Proposals  We raise money through our National Walk To End Brain Tumors  in May.  We request research grant proposals with a deadline of April 15, 2017, so they can be reviewed and the grants awarded as soon as our events are completed!

  279. [01/23/2017] The Musella Foundation announced that it has awarded a $10,000 brain tumor research grant  We are always open to collaborating with other organizations to help fund brain tumor research!

  280. [01/19/2017] Novocure’s Optune® Now Available at 500 Cancer Treatment Centers in the U.S.  That is amazing, as doctors have to take a course to get certified in the use of Optune. This means that practically every major brain tumor center in the USA can offer Optune to their patients.    There was a 70 percent increase in the survival rate at 4 years for newly diagnosed GBM patients, and Optune is now considered the standard of care for newly diagnosed gbms!

  281. [01/19/2017] Glioblastoma Treatment Breakthrough: `Untreatable` Brain Cancer Tumor Stabilized With Malaria Drug  Chloroquine is a cheap drug approved for treatment of Malaria, and is now being tested against many types of cancer.  This article talks about success with 3 patients, and all 3 benefitted.   In our brain tumor virtual trial registry, we have 8 patients who tried it.  5 out of the 8 lived over 2 years, and 3 went on to become long term survivors.  Note that they also took many other treatments besides Chloroquine, so it is impossible for us to tell if it was due to the Chloroquine, but it may be worth looking at closely

  282. [01/19/2017] New Study Aims to Extend TTFields Beyond Grade IV Brain Cancer Domain  It would make sense to use Optune with grade 3 brain tumors - would be nice to see the proof. Good luck with the trial!

  283. [01/19/2017] Agenus announces collaboration with the National Cancer Institute to evaluate the combination of Pembrolizumab (Keytruda®, Merck & Co., Inc.) with Prophage™ (Agenus Inc.) autologous vaccine  This is an exciting trial. I love the combination. Hope it works!

  284. [01/15/2017] Immunotherapies for GBM: Tumor Vaccines by Linda Liau, M.D., Ph.D., M.B.A.  This is a video about the DCVax trial, given by one of my all time favorite brain tumor doctors, Dr. Liau.  This looks very promising. We are hoping to hear the results of the big phase 3 trial soon.  In the earlier trials and in the early progressors which were excluded from this trial but were followed as they took the vaccine,  about 25% of the patients went on to be long term survivors, with many alive and progression free 5-10 years later.  That is unheard of with the standard treatments. Some other immunotherapies have also reported similiar results (although not as long follow up).    We are hoping this large phase 3 trial shows something close to that so it can be approved quickly and all patients can benefit from it.  Best of all it had no serious side effects. Dr. Liau is on the Musella Foundation Medical Advisory Board.  The Musella Foundation has supported Dr Liau's immunotherapy research with $375,000 in grants and we have never received any financial  support from the company developing this treatment, Northwest Biotherapeutics.

  285. [01/14/2017] National Walk To End Brain Tumors – Volunteers needed  We desperately need to fund more brain tumor research. We have many research proposals on our desk that are just waiting to be funded. Any of them might lead to advances.  If you have the energy - please volunteer. (And when the time comes - donate!)

  286. [01/13/2017] Salmonella Has Been Genetically Engineered to Consume Brain Tumors  This is way too early to tell if it will work on people but I like the thinking behind it. Good luck to the researchers.

  287. [12/31/2016] Top Brain Tumor News Stories for 2016  2016 was an exciting year - but I think 2017 will be the year we see big steps forward! Happy New Year! BTW: The copay program will open again very soon - maybe Monday or Tuesday. Will announce it as soon as it opens!  

  288. [12/31/2016] A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastomas.  We (the Musella Foundation) are partially funding this work!  Good luck to them.

  289. [12/31/2016] Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.  This suggests that stereotactc radiosurgery may be worth consdering for recurrent gbm. This is another controversial issue in the field.  Some doctors I talk with never use it, and others use it a lot.  This is why it is so important to get second opinions.

  290. [12/31/2016] Pathway linked to slower aging also fuels brain cancer  They need to find a way to target only the tumor cells and not have the side effects on the normal cells.  There is a lot of research going on to accomplish this with other treatments, such as antibody drug conjugates, convection enhanced delivery, super selective intraarterial intracranial infusion, gene therapies such as used by Tocagen and a few others.

  291. [12/31/2016] Florescent light helps surgeons target brain tumors  This is approved and a standard treatment in Europe. It is not yet approved in the USA so it is only available in clinical trials. Hopefully the new administration will relax some FDA rules and allow potentially life saving treatments to be approved sooner rather than later.

  292. [12/29/2016] Novel Type of Immunotherapy Helps Man Fight Brain Cancer  Of course it is too early to tell how it will work but great sign that they were able to get rid of all of the tumors for a while, and that they have shown it is safe to use multiple times.

  293. [12/25/2016] Some glioblastoma patients benefit from `ineffective` treatment, Stanford researchers say  This is the problem with clinical trials.. if the average patients doesn't benefit, they call it a failure.  They do not identify the patients who do benefit. In this case, they identified a group of patients who would benefit from Avastin, even though an average patient doesn't. I have seen many patients with a huge benefit from it, which makes no sense when you look at the trial results. This may explain why. They should go back to the original Avastion trials,  and see if this group of patients did better,

  294. [12/25/2016] ONC201 Glioblastoma Trial to Expand Based on Promising Initial Results  It's a great sign that they expanded the trial to include more patients and has shown signs of helping patients as well as of not hurting them.

  295. [12/25/2016] First patient enrolled in brain tumor trial combining 9 repurposed drugs - CUSP9v3 project  This is the 3rd version of CUSP9... it appears that they are only taking patients from Germany at this time, however, since all of the treatments are already approved and readily available, it can be done outside of that trial. If you try it, please register for our virtual trial project first at virtualtrials.com. That way we can track results. 

  296. [12/19/2016] Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.  Aside from the mechanism of action these authors proposed, perhaps the theories about cytomegalovirus playing a role in GBMs are valid, and this drug also fights the CMV, just like Valcyte does.

  297. [12/13/2016] Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to Israel  We have a lot of members from Israel asking about coming to the US for clinical trials - now they have one of my favorite trials available there!

  298. [12/13/2016] Medicenna Announces Initiation of Phase 2 Clinical Trial of MDNA55 for the Treatment of Recurrent Glioblastoma  (Disclosure: Medicenna is a new sponsor of the Musella Foundation).   This immunotherapy had some very impressive results in a small early trial. Of course we have to be careful when there are small numbers involved - sometimes that doesn't pan out when the large trials are done, but it is a good sign.  In a group of patient with recurrent gbm who did not have a resection at the time of recurrence, just one infusion of this new treatment, they had 20% complete response rate.  That means the tumor disappeared after just one infusion.  The response rate was 56% and if you include stable disease, the benefit rate (Stable + partial response + complete response) was 68%.   They were no serious safety problems. This treatment is a fusion protein which targets Interleukin-4 which is overexpressed on 3/4 of GBMs, and 100% of brainstem gliomas. It carries along a toxin that can kill the cells which overexpress IL-4. Normal cells have a low level of IL-4. Delivery is via convection enhanced delivery.  Prior trials involving CED have failed, mainly because the early versions of CED were not accurate - they couldn't get the drug to the target.  The Tocagen trials proved that CED is now at a point where they can routinely get the treatment 

  299. [12/09/2016] NW Bio Provides Update About Phase 3 Trial Of DCVax®-L for Newly Diagnosed Glioblastoma Multiforme Brain Cancer

    Very exciting news.  Nobody knows why the trial was placed on hold. Usually that is a bad sign but there are many reasons a trial can be placed on hold that have nothing to do with how good a treatment is.  See www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm .  I doubt it is for safety reasons, as there were no safety issues at all in the first few trials and in similar trials. That is the one we would worry about if it were true.  There are many other reasons. One possibility is that the FDA thinks that the trial will not prove anything.  There has been arguments back and forth about appropriate endpoints. At one time the FDA allowed progression free survival as an endpoint, but then the Avastin trial showed excellent progression free survival but no increase in overall survival, so the FDA changed its stance and said it wanted overall survival as an endpoint and that progression free survival is not enough. This happened after the trial was designed. The primary endpoint is progression free survival.  This trial allows patients in the control group to cross over and get the vaccine when they have a recurrence.  This messes up the endpoint of overall survival because you will be comparing people who get the vaccine to people who get the vaccine.  The FDA may think it is futile to try with the current design and may want the trial redesigned and done over again, which would probably be too expensive and lead to abandoning of the treatment.  I would protest that it is unethical to not allow cross over for the control group. (Let alone that it is unethical to have a control group in the first place).

       

    Anyway - this press release says they have stopped enrollment in the trial and will just analyze the results they have.  They already enrolled 331 patients, which should be enough to tell how it looks. IF it shows a progression free survival benefit, we will be fighting to get it approved based on this trial and hopefully not have to go through another phase 3 trial.

  300. [12/07/2016] First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report.  The FDA approval for Optune limited it to use in patients 22 and old because that was the youngest patient in the trial and it hasn't been tested on younger patients. Obviously, it should help younger people.  It can be prescribed for pediatric patients, off label, but insurance companies might try to reject it based on that FDA label restricting age.  Reports like this help us fight the insurance companies! I think the only real limit is the size of the head - the arrays are large and won't fit on a young child.

  301. [12/01/2016] New edition of the "Brain Tumor Guide for the Newly Diagnosed"  Pleased to announce a new version of the guide!  The big change is the inclusion of a section on Optune. There were many smaller changes - worth taking a look at again even if you read it before.

  302. [11/25/2016] ZIOPHARM Announces Clinical Data on Ad-RTS-hIL-12 Demonstrates Survival Benefits in Patients with Recurrent Brain Cancer  Very impressive results for a new type of gene therapy.  

  303. [11/24/2016] Dr. Reardon on the KEYNOTE-028 Trial of Pembrolizumab for GBM Pembrolizumab (Keytruda) is approved for other types of cancer and can be used off label for GBMs.  This shows pretty good results, but it is a small trial and more research needs to be done.

  304. [11/18/2016] Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates  This is what we have been waiting for. The final results of the Optune trial for newly diagnosed GBM.  There was some resistance to accepting Optune as the standard of care because the results presented 2 years ago were "just preliminary". The final results are actually better than the preliminary results! Now the next step is getting insurance to pay for it. Already most non-Medicare plans do pay for it, but Medicare has been hesitating. We had a petition a while ago to help nudge Medicare toward paying for it.  I presented it to them and we did come close and I think it did help - but we had that problem of results being preliminary.  We are going to try again. I resurrected the survey - and updated it to show current results.  Please sign it and have your friends and family members sign it.  IF you already signed it last time - you do not need to sign it again - it is still valid.  If you aren't sure, email me your name and address and I will check it for you.  Go to https://virtualtrials.com/activism.cfm for details and to sign! 

  305. [11/09/2016] Musella Foundation Co-payment Assistance Program is now closed to new patients   I am sorry to say, the program is now closed to new applicants.  I am trying to raise more money - and will reopen it as soon as we can. We have awarded $4,025,000.00 to over 800 patients so far with this program!

  306. [11/09/2016] DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA  This is an exciting combination.  The immunotherapies have had some impressive results in some patients, but not everyone was helped.  Adding a checkpoint inhibitor may allow more - or all - patients to be helped!

  307. [11/09/2016] New vaccine for brain cancer brings hope to those fighting the disease  This is a new vaccine for GBM patients.  Nice video - they say "Doctors say for many of the patients, there is no evidence of recurrence and those newly diagnosed with glioblastoma may be the best candidates for this treatment."  Of course, there aren't enough patients treated yet to prove it works, but it is fantastic to have patients respond for long periods of time.

  308. [11/08/2016] Posttranslational Regulation of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers.  This is another interesting way to enhance the ability of Temodar to work on patients who have unmethylated mgmt.

  309. [11/07/2016] United Healthcare Issues Positive Coverage Decision for Optune This has been a big battle to get insurance to pay for Optune.  United Healthcare was basically the last private insurance that didn't pay - now almost all do.  Next up is the Medicare battle.  I have been working on that one for a while and getting closer. I may need your help soon - we are thinking of another petition campaign!

  310. [11/07/2016] Novocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of the Society of Neuro-Oncology  It looks like Optune is finally getting the respect that it deserves. When it was first introduced, I would say most neuro-oncologists dismissed it without looking at data, based solely on preconceived notions that it couldn't possible work.  Now, most seem to at least allow their patients to try it, if not encourage them to try it.  The holdouts tell me that the data is preliminary and they will wait for the full report. Well - that will come out next week!  I did not see it yet, but I assume from this press release that it is favorable.  Hopefully that will remove the last doubt that this should be part of the standard of care for newly diagnosed Glioblastomas. It is very significant that most of the presentations are from researchers not associated with the company.  That shows broad acceptance in the field. 

  311. [10/25/2016] Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and Review of the Literature. This is a reminder that we have to be careful of the treatments we use. If you think an alternative treatment is strong enough to stop a glioblastoma, then it may be strong enough to cause other severe problems.

  312. [10/23/2016] The Musella Foundation announced that it has awarded a $25,000 brain tumor research grant to Dr. Robert Prins of UCLA.  In keeping with our efforts to collaborate with other organizations to speed up brain tumor research, we partnered with Voices Against Brain Cancer to fund this $50,000 grant request.  Each organization paid ½ of the total amount.  This is a very special project, which I think has the potential to make a big impact. It will combine a checkpoint inhibitor with a custom made vaccine.  The vaccine by itself has had remarkable success in a few patients - with some GBM patients alive and doing well after 6 years, but it didn't help other patients. This project will try to figure out how to make the vaccine help more - or all - of the patients.

  313. [10/22/2016] Patient-Tailored Immunotherapy Shows Promise in Treating Brain Cancer  Pretty good results in a large phase 3 trial.

  314. [10/20/2016] An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.  This may be a new target for GBM treatment, which may use a few drugs already approved for other diseases. Should be quick and easy to prove... Might be a perfect project for our brain tumor virtual trial registry.

  315. [10/09/2016] Last chance for NY Islanders Home Opener Fundraiser!  It's getting close!  One week away to the start of an exciting season!  Get your tickets now and help us fund some really important brain tumor research!

  316. [10/09/2016] CIK Treatment Extends Progression-free Survival of Glioblastoma Patients by 1.5 Times  Impressive results in a large controlled trial.

  317. [10/09/2016] Darren Daulton Battling Brain Cancer Through Charitable Foundation  This organization offers brain tumor (and brain injury) patients up to $5,000 per year to help with expenses! Great work!

  318. [10/09/2016] Exclusive: Interview With DelMar Pharmaceutical CEO Jeffrey Bacha This drug, Val-083, might just be the next big step forward.  Late stage trials are about to start. It already had been approved in China for other diseases, and over 1,000 patients took it and have shown that toxicity is not a problem. It might especially be useful for gbm patients who have unmethylated MGMT.   The article may have missed a little on the statistics. I doubt if 200,000 GBMs are diagnosed a year. They say "less than 200,000" but it is more like 20,000.  

  319. [10/09/2016] High response rate in phase I/II paediatric brain cancer trial  Luckily, the drug they used, dabrafenib, is already approved for other types of cancer so it can be used off label immediately. Unfortunately, in melanoma, it was found that most patients become resistant to it quickly.  There is work going on now using another drug, Trametinib, combined with the dabrafenib, which may prevent that resistance. The FDA approved this combination for melanoma. Maybe it would work in brain tumors also!

  320. [10/06/2016] Veteran With Terminal Brain Cancer Explains Why He’s Against Assisted Suicide  This is a hot topic now.  I would like your thoughts on it. Click HERE to take a quick 1 question survey!

  321. [10/05/2016] Tocagen Presents Updated Tumor Response Data for its Cancer-Selective Gene Therapy  Pretty good results.  20% of the patients in the trial responded, but those that responded  remain alive at 21-42 months. This means that the median survival they reported,  14.3 months, will go up as time goes on - assuming these patients continue to do well for a while! In the past, I have seen numbers reported of about 8 to 9 months average survival for recurrent gbms.. (this press release doesn't break down the % with anaplastic astrocytoma), but that is with everyone dead at the end of the trial. And they mention the Musella Foundation as funding part of the work.  Your donations at work! :) We are starting a new fundraiser to raise money specifically to speed up approval for this treatment. For details, go to https://virtualtrials.com/toca_fund.cfm

  322. [10/01/2016] Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.  Excellent results.. in a small group of patients.  Average survival of 30.5 months for newly diagnosed GBM patients is pretty good. More research needs to be done.

  323. [10/01/2016] Pioneering Studies Apply New Immunologic Insights to Glioblastoma  This is a completely new way of trying to treat brain tumors by suppressing cells in the blood that travel to the brain tumor and inhibit the immune system.  We (The Musella Foundation) funded part of the project!  This is YOUR donations hard at work! Thanks  

  324. [10/01/2016] Injecting live virus in brain tumors may fight cancer, study suggests  This video is about the Tocagen trial.  They said that so far, it has doubled overall survival compared to historical survival times. We are launching a new fundraiser to help speed up this trial and collect more data on how it works and how to make it work better. See virtualtrials.com/toca_fund.cfm for details.  And for the first time ever, we are offering t-shirts, hats and jackets with the Tocagen motto: "No One Should Die Of Cancer" for donations!

  325. [09/30/2016] Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Glioblastoma Multiforme  It is a shame that the connection to illegal marijuana has severely delayed research and acceptance of a promising treatment for brain tumors.  It is great that this drug company is taking it on even though it isn't politically correct to do so.

  326. [09/28/2016] The Musella Foundation For Brain Tumor Research and Information, Inc is proud to announce that we partnered with the DIPG Collaborative to award a $100,000 pediatric brain tumor research grant to Dr. Adrian Krainer, of the Cold Spring Harbor Laboratory in NY.  This is the 90th brain tumor research grant that the Musella Foundation has funded, and it may be one of the most important.  IF it works, the approach can be modified to treat many other types of tumors. The researchers asked me for the grant right after our scheduled round of granting for the year.  Our medical advisory board quickly approved it, giving it one of the highest scores we ever had, but we did not have the money to fund it.  I approached the DIPG Collaborative and asked them to split the cost with us.  The DIPG Collaborative quickly had their medical advisory board evaluate it and had over 20 independent foundations vote on it, with amazing speed!  They understand the importance of not only finding and funding the best research, but doing it quickly. It was a pleasure to work with them.

  327. [09/28/2016] Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy  Explains how Optune works. 

  328. [09/28/2016] Glioblastoma: Overview of Disease and Treatment.  This is a good overview of the basics of what a glioblastoma is and how it is treated.  

  329. [09/26/2016] Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer  Interesting drug. It is approved for uses other than cancer, so if this trial shows it works, access will be easy. I am not sure about the statistics they use.. they say anaplastic astrocytoma was the largest subset of anaplastic glioma, but Glioblastoma multiforme is.  They say 75% of the 20,000 cases of anaplastic glioma are 2,700 anaplastic astrocytomas..  but 75% of 20,000 is 15,000.. 

  330. [09/21/2016] The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR.  Excellent article. Apparently, when the MGMT methylation status test results show inconsistent methylation, it really should be thought of as being unmethylated.  For background:  MGMT is a gene that codes for an enzyme that repairs damage to the DNA caused by Temodar.  If your MGMT genes are methylated, that means they are inactive and can not produce the repair enzyme.  This makes Temodar work much better.  However, if your MGMT is unmethylated  (or apparently now - even inconclusive), the repair enzyme is produced which reverses the damage caused by Temodar, making it not really work. This really didn't matter much until recently when a new drug, Val-083, was created which works similar to Temodar but on a different part of the DNA so that this repair enzyme can not reverse the damage. This drug is about to start phase 3 clinical trials. Worth considering for those whose test show unmethylated MGMT. 

  331. [09/19/2016] Brain cancer replaces leukemia as deadliest cancer for kids, study shows  Luckily, this is a result of better treatments for Leukemia, not a rise in the number of pediatric brain tumors.  This underlines the need for more research. We need YOUR help to enable us to fund more research. The ideas are there - just not the money.

  332. [09/19/2016] CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma This should make the treatment work better - especially for those offices that do not have a lot of experience with using Optune

  333. [09/08/2016] Human cytomegalovirus encoded chemokine receptor US28 activates the HIF-1?/PKM2 axis in glioblastoma cells.  The concept of cytomegalovirus being associated with GBMs is controversial.  Some researchers say 100% of GBM samples have it, others say none of them have it. I tend to agree with the ones that say it is very common in GBM samples.  IF that is true, this study may show how CMV can promote the formation of tumors. And that opens the door for treatments. There is already an approved drug that fights CMV, and there is a brain tumor vaccine under development that targets the CMV. Preliminary results look good. This study also identifies other downstream targets which may be exploited.

  334. [09/08/2016] Monteris Medical Receives IDE Approval From FDA To Evaluate NeuroBlate® In Patients Newly Diagnosed With Glioblastoma Multiforme  This trial will be for patients with newly diagnosed GBM who are told the tumor is inoperable. This is a form of laser surgery where a small hole is made in the skull and a special probe is inserted to destroy the tumor. It can sometimes be done in locations that were though impossible to treat using regular surgery. The Neuroblate system is already available all over the USA.  You can find a doctor near you at http://mybrainsurgeryoptions.com/directory/locations/    [Disclosure: Monteris is a sponsor of the Musella Foundation]

  335. [09/07/2016] DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer  Val-083 is an experimental treatment (actually it is approved in China for other types of cancer) for brain tumors. It is similar  to Temodar, but works at a different site which is not affected by the MGMT status of the patient.  The VAL-083  trial for recurrent GBM should be considered for patients who have unmethylated MGMT.  This press release talks about combining VAL-083 with Temodar or BCNU, and implanting it at the time of surgery to increase the dosage of the drugs at the site of the tumor. Sounds exciting.

  336. [09/07/2016] The fourth weapon in the battle against cancer  Nice story about one of the members of our online support group (Brain-novocure)! To join the group, go to https://virtualtrials.com/lists.cfm and select brain-Novocure

  337. [09/07/2016] NY Islanders fundraiser for Brain Tumor Research!  It's getting close!  One month away to the start of an exciting season!  Get your tickets now and help us fund some really important brain tumor research!

  338. [09/01/2016] Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis.  Another abstract on Optune showing a good effect in the test tube.

  339. [09/01/2016] Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation.  This brings up an exciting possibility. Optune is not used during radiation now, for theoretical reasons - the radiation can irritate the skin and cause delayed healing, which may make the irritation from the electrodes worse. As far as I know it was never tried. Might be worth trying.

  340. [08/31/2016] Kadmon launches mid-stage study of lead oncology candidate in brain cancer  This oral treatment crosses the blood brain barrier. 

  341. [08/31/2016] Immunotherapy, Vaccines Offer Promise in Glioblastoma, But Data is Still Preliminary  This is exciting but going too slow!  I am trying to speed up the process! I am saving up to fund a brain tumor research project that combines a checkpoint inhibitor with a vaccine in a human trial!

  342. [08/25/2016] NY Islanders fundraiser for Brain Tumor Research!  This is your chance to meet and hang out with me and other families dealing with brain tumors while enjoying the first game of the season at Barclays! Always a fun event!

  343. [08/23/2016] Curcumin Changes the Polarity of Tumor-Associated Microglia and Eliminates Glioblastoma.  This is only in mice now but looks exciting.

  344. [08/18/2016] Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.  There has always been the fear that using Avastin would cause the tumor to become more invasive as the blood supply to the tumor gets cut off.  This article shows in a large number of patients that this fear is not justified.

  345. [08/18/2016] Tamoxifen Induces Cytotoxic Autophagy in Glioblastoma.  I had a relative do great for over 5 years with high dose tamoxifen for her gbm.  It was relatively popular before Temodar came into use. Studies showed that it helped a small % of patients, but when it helped, it helped a lot. And it had minimal side effects.  This article  might explain why it helps some patients and not others. More research needs to be done.

  346. [08/16/2016] Novocure Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA Approval on July 13 This should make the Optune system easier to use.

  347. [08/10/2016] Call for chefs to enter Flo’s Chili Cook-Off  From our friends. Sounds like a great event.

  348. [08/10/2016] Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.  This may be why the vaccines do not work in some patients.  Worth further study.

  349. [07/26/2016] Musella Foundation Co-payment Assistance Program is now closed to new patients  I am sorry to say, the program is now closed to new applicants.  I am trying to raise more money - and will reopen it as soon as we can.

  350. [07/26/2016] Musella Foundation awards $149,992 in 3 brain tumor research grants.  These 3 projects can make a big impact in this disease, quickly.   The first project is a pilot human trial for kids with brain tumors using the polio virus vaccine made famous on a recent 60 minutes episode. This is the first time it will be tried on children and if successful, will lead quickly to a larger trial, then hopefully FDA approval so all kids would be able to get access to this promising treatment.  The second project involves a new way to get drugs to the tumor at a higher concentration and for a longer period of time. This is a mouse experiment to see if this new delivery method can make a significant difference in outcome. If it does, it will lead quickly to a human trial.  The third project combines an immunotherapy that is already approved for other types of cancers with stereotactic radiosurgery in a mouse model. Since both parts are easily available today, this can lead to immediate use in patients if successful.  I would like to thank all of the volunteers and donors who made it possible for us to give these grants out!  

  351. [07/26/2016] International Study Finds Effective, Less Toxic Way to Treat Brain Tumors  I love this type of research. They took into account the patient's quality of life as well as survival time to determine that for 1 to 3 brain metastases, stereotactic radiosurgery is better used alone rather than in combination with whole brain radiation.  The survival times were about the same either way, but quality of life was better with radiosurgery alone. Not to mention a lot cheaper and more convenient.

  352. [07/26/2016] NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma  I sent a story about this in a recent news blast but this is the press release from Novocure and their take on the topic!

  353. [07/25/2016] Musella Foundation Co-payment Assistance Program about to close to new patients  If you think you qualify and may need help paying for one of the covered treatments (Optune, Gliadel, Temodar or Avastin), send in the application as soon as possible. We have enough funding for only a few more patients. 

  354. [07/23/2016] Local Biotech Company Develops Therapy to Treat Brain Cancer for Extended Survival  Although it was only a small phase 1 trial, they reported that the overall survival doubled compared to historical controls.  This is now in a large phase 2/3 trial throughout the USA.  We are working on raising funds to help speed up the approval process so all brain tumor patients could get access.  Eventually, this may work for not only brain but most other types of cancer. 

  355. [07/13/2016] Musella Foundation Request for Donations!  Most of the funds for this round of granting come from our National Walk To End Brain Tumors.  I would like to thank all of the volunteers who made it possible!

  356. [07/13/2016] Novocure Receives FDA Approval for Second Generation Optune System  I have seen the new system, and it is much nicer. Smaller, lighter, looks much more modern, and is easier to use.  

  357. [07/06/2016] New microfluidic device offers means for studying electric field cancer therapy Great proof of principle that TTFs can interfere with tumor growth and spreading.   Maybe they could use this type of device to personalize the Optune treatment based on a biopsy from each patient and make it work better.  

  358. [07/05/2016] FDA Grants Accurexa Pre-IND Meeting for its ACX-31 Program in the Treatment of Brain Cancer  This is a new platform for delivering treatments into the brain tumor directly. Higher dosages can be achieved in the tumor, with less or no exposure to the rest of the body. Work in mice showed that Temozolomide and BCNU given directly into the tumor work a lot better than the standard ways of giving it. Hopefully this will translate into patients quickly.

  359. [07/04/2016] Scientists just discovered we`ve been looking at cancer growth all wrong. This could change everything.  This is still preliminary work, but raises an important point: that we should recheck everything that we thought we knew about these tumors.  The technology we have now is amazing compared to what was available in the 1950s when it was decided that brain tumors use glucose as the main energy source. This article points out that by culturing the tumor cells in blood, you change the tumor cells to use what is most common in the blood, which is different than what is in the brain. On the other hand, they also mention that PET scans show where glucose is being used - and the tumors do use a lot more glucose than non tumor brain.

  360. [06/29/2016] Rapid regression of glioblastoma following carmustine wafer implantation: A case report.  You can never make decisions based on individual case reports but they are nice to see.  Gliadel has been neglected by some medical centers.  On average, it adds a little extra time before the tumor progresses, sometimes allowing time for other treatments to have a chance at working. It was never meant to be a cure by itself.  We do not have enough patients in our brain tumor virtual trial (virtualtrials.com) to make a statistically significant statement about it, but taking a look at just our  long term (over 5 year) GBM survivors,  5 out of the 21 (24%) have used Gliadel as part of the plan. Looking at all GBM patients, 36 out of 469 (8%) have used Gliadel. To me this means that if Gliadel had no effect, you would expect the same % of patients who used it as the % of long term survivors who use it. But we see a tripling of the %, which means Gliadel does have a big increase (possibly tripling) in the chances of becoming a long term survivor, and it should be studied more in depth.  

  361. [06/29/2016] Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain.  This is amazing.  I never heard of patients in the USA being tested or treated for this, and they say a significant % of patients who are CMV positive will have a reactivation of the CMV infection in the brain when the immune system is depressed with steroids and radiation.  Treating it may reduce symptoms and hopefully prolong life.

  362. [06/29/2016] Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials.  This study shows that it might be OK to avoid radiation therapy for high grade gliomas in young children, or at least delay it until they are older.  Radiation in young children can cause permanent problems like a lower IQ.  These results are still not good enough but are similar to the treatments that do include radiation, so the lucky few who survive are presumably in better condition. A better way needs to be found.

  363. [06/24/2016] Cortice Biosciences Announces Presentation of Results from a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma at the Annual Meeting of the American Society of Clinical Oncology  Impressive results.

  364. [06/24/2016] Extended Survival Reported in Brain Cancer Patients Treated With Viral Gene Therapy  This treatment is now in a phase 2/3 trial for recurrent gbm, available in over 35 centers across the USA and Canada!  Go to https://clinicaltrials.gov/ct2/show/study/NCT02414165 for details!

  365. [06/23/2016] Study: New Vaccine Helps Prevent Brain Tumors From Coming Back  This is another of my favorite treatments.  The video explains how the Toca 5 trial works! We are planning on launching a fundraising campaign to help speed up development of this exciting treatment!

  366. [06/23/2016] ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma  Great news!  This is one of my favorite trials, and they are now open! This is a stock vaccine - which means you do not need fresh tumor tissue to make the vaccine.  It is a relatively simple blood draw and shot in the arm.

  367. [06/21/2016] Musella Foundation issues request for proposals for brain tumor research grants.  Our National Walk To End Brain Tumors was a big success! Thanks to all of our volunteers!   We will be sending out a mailing introducing our new Immunotherapy research fund soon! Watch for it or go to https://virtualtrials.com/immunotherapy_fund.cfm for details!

  368. [06/16/2016] Camp Jinka - NJ From our friends at the Zocchi Brain Tumor Center

  369. [06/01/2016] Study Published in Science Translational Medicine Reports Favorable Safety and Extended Survival for Brain Cancer Patients Treated with Tocagen’s Cancer-Selective Viral Gene Therapy  This is impressive results from a small study.  There is a large multicenter trial going on now for recurrent high grade glioma and they will soon start one for newly diagnosed. And they acknowledge the Musella Foundation (and other brain tumor foundation)  grant support for this project!  This is your generous donations at work!

  370. [06/01/2016] Musella Foundation Copay Assistance Program reopens!  It might not be open long, so if you are thinking of applying, do it quickly!

  371. [05/31/2016] Novocure Receives IDE Approval to Initiate METIS Trial  This sounds like a great combination. Radiosurgery can usually control an individual brain met over 90% of the time, however the patient usually still develops new mets in the brain - because the radiosurgery doesn't do anything for the little islands of tumor cells that you can't yet see on the scans.  The TTFields might be able to stop those islands from developing into new tumors.  

  372. [05/31/2016] The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary  There is a new classification of brain tumors!  This will allow better comparisons among patients. For example, glioblastoma is now separated into IDH mutant and IDH wild type glioblastomas.  In some studies, the difference in survival between these 2 groups is actually more than the difference that the treatment being studied makes.

  373. [05/28/2016] ZIOPHARM Highlightx Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer  Pretty good results in early testing. The great part of this is they can turn the immune response on and off and possibly control the intensity by varying the oral component.

  374. [05/25/2016] Histone mutation linked to fatal pediatric brain tumor  Very important research!  Finding a single point mutation that may be responsible for DIPG and other types of cancer is amazing because it presents a target that can be attacked. 

  375. [05/24/2016] Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment.  I thought that Avastin crossed the blood brain barrier but this experiment, in mice, shows that opening up the blood brain barrier using a relatively simple application of focused ultrasound leads to vastly improved outcomes and much higher concentration of Avastin in the brain.  There is a trial in humans now of administering Avastin via intra-arterial infusion directly into the tumor. We do not have the results yet, but this experiment gives hope that the principle of increasing the dosage to the tumor may work in people!

  376. [05/19/2016] Walking for charity  A big thank you to the students (and teachers) of the Middlebrook School in Wilton, CT. Great job!

  377. [05/16/2016] BiCNU (carmustine for injection): FDA Alert - Counterfeit Product Discovered in Some Foreign Countries  Another thing to worry about...  the link shows the difference between the real medication and the fake one..  the real one has a blue top (the fake has a white top), and the NDC number ends in -31 for the real one and -41 for the fake.  

  378. [05/12/2016] Promising brain cancer trial given breakthrough status by FDA  This may be one of the most important news articles of the year.  This will give the trial the green light to start all over the country - and if successful, may  quickly lead to FDA approval. There will be a story about this treatment on "60 Minutes" on Sunday.   Disclaimer - I am on the patient advisory board of The Brain Tumor Center at Duke, but have no financial interest in it.

  379. [05/10/2016] Time to Sign up for Camp Jinka 2016  This is a great program for kids and teens to interact with other kids going through the same thing in their families.

  380. [05/10/2016] The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.  This is the new classification for brain tumors. They now recognize that GBMs with and without the IDH mutations are very different tumors - they were lumped together before, but they behave so differently that you can't compare them. All trials from now on should seperate out the data by IDH status. For more details see iap-ad.org/lectures/ESPC/Day2/08.30%20-%2009.15%20-%20WHO-Dubai%202015.pdf

  381. [05/08/2016] Tocagen Presents Intravenous Toca 511 Clinical Data at the 84th AANS Annual Scientific Meeting Very good results. An article at http://neuro-oncology.oxfordjournals.org/content/9/1/29.abstract says average 12 month survival for recurrent gbm is 14%. This trial is reporting 61%. This project was supported, in part, by the Musella Foundation (as well as the other organizations listed in the article!).  Thanks to those whose donations allowed us to help get this project going!

  382. [05/08/2016] Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Unfortunately, this treatment did worse than the control group - which was the standard of care.

  383. [05/08/2016] Long Beach Woman, Wendy Santana, Recovers from Brain Tumor, Writes Book  Nice story - and I am honored that she chose the Musella Foundation as the beneficiary of the book sales! Thanks!

  384. [05/08/2016] Entrectinib Achieves High Response Rate Across Solid Tumors  This is an experimental treatment of a new targeted drug which hits 3 targets: NTRK, ROS-1 and ALK.  Might be worth trying this trial (or trying to get it on compassionate use if you do not fit the trial) if your genomic report mentions you have 2 or 3 of these targets overexpressed. Go to https://clinicaltrials.gov/ct2/results?term=Entrectinib+&Search=Search for the current trials with this drug.

  385. [05/08/2016] NeuroBlate therapy brings hope to brain cancer patients  Neuroblate is now available in a lot of centers across the USA. Go to mybrainsurgeryoptions.com/ for details on the procedure and where it is available! (Monteris - the maker of Neuroblate - is one of the sponsors of our organization)

  386. [05/06/2016] Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Support and Inspire Those Affected by Glioblastoma  They did a nice jobe with the website. Take a look at the stories there. I never heard of ThunderClap before but it also looks like it can be very useful to raise funds for research and awareness for brain tumors. This is a perfect way to try it out. Follow the instructions below.  You will have to give your permission for the Thunderclap program to post a one time message to your facebook page.  It is safe to allow that. They can't see your username or password.  You do that now and then at the specified time, Thunderclap posts a message supporting brain tumors to everyones' facebook (and other social media) pages. By everyone sending it at same time, a huge number of people will see it and it might trend on twitter.

  387. [05/05/2016] Innovative Hypofractionated Stereotactic Regimen Achieves Excellent Local Control with No Radiation Necrosis: Promising Results in the Management of Patients with Small Recurrent Inoperable GBM.  This sounds like an ideal treatment for small recurrent gbms. They had local control (of the treated tumor) in over 90% of the tumors, although most people eventually died of tumors growing outside of the treated areas.   None had radiation necrosis which happens frequently with single fraction sterotactic radiosurgery.  This may work well in combinations with other treatments to give them time to work.

  388. [05/04/2016] 11th SURVIVING BRAIN TUMORS AWARENESS EVENT— MAY 23 & 24, 2016—AT CLEVELAND CLINIC  We are honored to be one of the beneficiaries  of this event.

  389. [05/02/2016] Valley Stream (NY) Navy recruit gets new brain cancer treatment  I am on the advisory board of the brain tumor biotech center at Northwell Health Foundation. This fundraiser is going to a great cause!

  390. [05/01/2016] NCI opens online platform to submit ideas about research for Cancer Moonshot [Correction] [This is a correction - the link was incorrect]  The Moonshot program is looking for ideas.. I submitted one on the Virtual Trial concept.   Would be nice if everyone helped by commenting on it - which will bring it to their attention! Go to https://cancerresearchideas.cancer.gov/a/dtd/Virtual-Trial/177937-39827  

  391. [04/28/2016] Nate Brundage continues the fight against brain cancer  This patient's insurance company initially rejected the claim for Optune because of the patient's age.  The FDA approval was for ages 22 and up.   That is a strange age for them to pick. I assume it was because the youngest patient in the trial must have been 22 even though the trial accepted patients 18 and older. Anyway - I am happy the insurance company backed down and approved it.   If anyone else has this problem, contact me and I can try to help fight it.

  392. [04/28/2016] The Musella Foundation has created a brain tumor immunotherapy fund to raise money for immunotherapies.  I have never been as optimistic as now that major advances are near! We have the power to speed it up!

  393. [04/27/2016] Experimental therapy for brain cancer developed by UCLA and Caltech could prevent drug resistance  Brilliant work...  this lays the groundwork to find the combinations of drug needed to prevent resistance

  394. [04/27/2016] NCI opens online platform to submit ideas about research for Cancer Moonshot  The Moonshot program is looking for ideas.. I submitted one on the Virtual Trial concept.   Would be nice if everyone helped by commenting on it - which will bring it to their attention! Go to https://cancerresearchideas.cancer.gov/a/dtd/Virtual-Trial/177937-39827  

  395. [04/27/2016] Research findings could lead to treatment for deadly brain cancer  Sounds like an exciting new approach

  396. [04/27/2016] Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S.  Looks like Optune should now be available to just about everyone.

  397. [04/05/2016] National Brain Tumor Society`s CEO Named to Cancer Moonshot Initiative`s Blue Ribbon Panel of Experts /h3>

    David Arons is the perfect person for them to pick for this panel. One thing that makes him uniquely qualified to be the patient advocate for the Cancer Moonshot Initiative is his experience in bringing together all of the important groups of people needed to make the project a success.  Finding the cure for cancer isn't going to happen by just getting a few of the best cancer researchers in the world together. We need input from ALL of the researchers, as well as the patient advocates, device manufacturers, pharmaceutical companies, FDA, nonprofits and of course the patients themselves.

       

    We are lucky to have David representing us!  Good luck to him!

  398. [04/04/2016] 11th SURVIVING BRAIN TUMORS AWARENESS EVENT— MAY 23 & 24, 2016—AT CLEVELAND CLINIC  Sounds like a nice event!

  399. [04/04/2016] Brain Cancers Reveal Novel Genetic Disruption in DNA  This needs to get into trials quickly.. however, caution (and a clinical trial) is needed because we do not know what else would be affected. For example, when the MGMT gene is methylated, the tumor is more sensitive to temodar and you live longer. Unmethylating it might put you into the worse prognosis group.

  400. [03/18/2016] LIVE Youtube Streaming TONIGHT! @ 5:30PM PST (8:30 PM Eastern) Patient Education Event for Brain Tumor Patients & Families  I mentioned this conference in the last news blast. Just found out it will be streamed live tonight.  3 of my favorite brain tumor doctors will be speaking: Dr Cobbs, Dr Liau and Dr Prados.

  401. [03/17/2016] Ependymoma Awareness Day  From our good friends at the CERN Foundation

  402. [03/17/2016] Tocagen to Present at Three Oncology Conferences  It is impressive that so many of the brain tumor foundation (including the Musella Foundation:) have come together to support this promising research.

  403. [03/14/2016] March Madness Brain Cancer Fundraiser in Memory of Wilton Woman’s Sister  This is a fun fundraiser where you can win $1,000 by picking the winning teams in the NCAA basketball tournament!  It benefits the American Brain Tumor Association, Accelerate Brain Cancer Cure and the Musella Foundation!

  404. [03/05/2016] The Curcumin Analog C-150, Influencing NF-?B, UPR and Akt/Notch Pathways Has Potent Anticancer Activity In Vitro and In Vivo.  I would love to see human trials of this.

  405. [03/04/2016] Dbait: An innovative concept to inhibit DNA repair and treat cancer  This was not in brain tumors but the same mechanism may cause resistance to Temodar in brain tumors - so perhaps this would help.

  406. [03/03/2016] Humana Issues Positive Coverage Decision For Optune  Humana insures 10 million people in the USA, and now all of these people have access to Optune if they need it!    

  407. [02/27/2016] Pediatrics Data Platform Announced at White House Precision Medicine Initiative  This is one of the more important projects of the year. I went to a seminar last week where Dr Resnick demonstrated it. The system has amazing capabilities  already. You can have the child's brain tumor sample analyzed and uploaded into the system and it will figure out which are the most important mutations driving the tumor growth and which drugs are available or in trials which may be useful against this tumor.   You can see how your tumor compares to all of the other samples with your tumor type.   The Musella Foundation gave Dr Resnick a grant last year to help add and analyze DIPG samples with this system!

  408. [02/23/2016] Two forms of radiosurgery for brain metastases are equally effective  This is a tiny study, but it shows that a linear accelerator is just as effective as the Gamma Knife - which is what we knew all along.  

  409. [02/21/2016] Photodynamic Therapy for Malignant Brain Tumors. Photodynamic therapy for malignant brain tumors involves giving the patient a dye right before surgery and then shining a laser light at the tumor at the time of surgery.  It has been approved in Japan and this article shows that it may increase the time to progression, at least in the treated area, but a lot. There was no control group so we don't know for sure but compared to historic controls, it looks pretty good. As far as I know, the clinical trials for photodynamic therapy of brain tumors in the USA are completed and we are waiting for the results.

  410. [02/21/2016] Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series.  I do not think this was the best way to set up the study.  The better way of doing it would have been to start Optune a few weeks  after radiation is over, and perhaps try Avastin in a pulse dosing form  - either as newly diagnosed at the same time you start the optune, or at the time of recurrence.  Withholding Optune from a newly diagnosed patient for the purpose of entering a trial like this sounds unethical to me. It shows a lack of understanding of how Optune works. It is a slow, gentle treatment. The time to start it is not when you have a recurrence as it needs a few months to kick in.  The effect of slowing tumor growth starts immediately but it takes time before the tumor starts to shrink.   The trial using it for newly diagnosed patients did much better than the one that started at recurrence. Having said that, the results show that Optune does help when used this way, but I would like to see more trials using it the correct way. For those that missed out on the opportunity to use it when newly diagnosed, this shows that it is worth trying at the time of recurrence.

  411. [02/18/2016] UCLA 16th Annual Brain Tumor Conference  This is always an excellent conference!

  412. [02/14/2016] ABT-414, an Antibody Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.  This is very exciting. They found a way to target the EGFR in tumors and not in normal tissue. There are a few trials going on now for this treatment. Check virtualtrials.com for details.

  413. [02/14/2016] Anthem Inc. Issues Positive Coverage Decision For Optune in Newly Diagnosed Glioblastoma

     Great news.   

    Now that the 3 largest private health insurance carriers in the USA cover Optune, the rest should follow suit soon!  This is a major victory in the fight against brain tumors. We thought the hard part was going to be getting FDA approval because it is a completely new type of treatment, but that actually was easy since the data supported it.  Once that happened, I assumed patients would be able to just get it but the timing was terrible. Insurance companies have just started fighting back against expensive treatments and started denying all new treatments as a way of saving money until they are forced to pay for them. It was a long, hard battle but the people at Novocure persevered and won the battle with the private insurers.

    Next up is Medicare. I had multiple meetings with Medicare and they are getting close to approving payment. The people I met with at Medicare understand that brain tumor patients need this treatment and they are trying to find a way to pay for it. Having the majority of private insurance companies paying for Optune, along with the recent publication of data in the Journal of the American Medical Association, should allow patients to appeal Medicare rejections successfully. IF you have a problem with a Medicare rejection, call me at 888-295-4740 and maybe I can write a letter for you to help with the appeal.

  414. [02/12/2016] Washington State members - Immediate Action Requested!  Please help with this if you live in Washingotn State. The "Right To Try" movement is taking over the country. It started 2 years ago and already about 21 states passed this bill. Discuss it in the braintumor-treatments online group!  (virtualtrials.com)

  415. [02/10/2016] Brain tumor movie - looking for volunteers!  These people are trying to create a movie about brain tumors and are asking for help - they need patients and doctors to volunteer to be interviewed..  

  416. [01/23/2016] The Musella Foundation announced that it has awarded a $5,000 Brain Tumor research grant to Ninh Doan, MD, PhD, of the Medical College of Wisconsin.  We gave a $50,000 grant last year to this researcher and the project is looking good. He wanted to expand it to include Medulloblastomas, which is a mostly pediatric brain tumor type.  Hopefully, if succesful, it should also help many other tumor types.

  417. [01/21/2016] My fight against brain cancer: Greg’s story  This talks about a patient's experiences with the Toca 511 clinical trial

  418. [01/21/2016] Oncoceutics Begins Fifth Clinical Trial for ONC201  This is a new clinical trial for recurrent GBMs.  This is a new approach, with a new target. It is an oral medication. See oncoceutics.com/therapeutic-approach/ for details on the mechanism.   I will be watching this closely - as the Musella Foundation gave them a research grant a few years ago to help do the preclinical work on this new drug - which came out pretty good!    

  419. [01/21/2016] FDA Approves NextSource`s Brain Tumor Treatment  This is an old drug - CCNU - but a new capsule size was just approved by the FDA.  It is commonly used in combination with Avastin.  The standard dose is 130mg/m2 which for a 200 pound 6' tall person works out to about 275 mg... They already had capsules of 100mg, 40 mg and 10mg.  SO I guess this allows for finer control of the dose - however, some insurance companies charge a copay on each capsule size.

  420. [01/19/2016] Neurosurgeons Evaluate Precision Laser Treatment Of Brain Tumors at UC San Diego Health  This trial is available at many locations. See clinicaltrials.gov/ct2/show/NCT02392078 for details

  421. [01/07/2016] Oncurious NV Announces FDA Acceptance of Investigational New Drug (IND) Application for a Phase I/IIa Study with TB-403 for the Treatment of Pediatric Brain Tumors  New trial for Medulloblastoma.  Also may be another tool to use if a path report for any tumor shows a high overexpression of the target, PIGF

  422. [01/06/2016] Novocure Files Premarket Approval Supplement Application With FDA for Second Generation Optune System  I saw the new system, and it looks like it will make using the system a lot easier!

  423. [01/05/2016] Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies.  Looks like we need more research on this. Very interesting

  424. [01/05/2016] Association between human cytomegalovirus infection and histone acetylation level in various histological types of glioma.  This is a controversial topic in the brain tumor world. Studies have shown that most or all gbm samples contain this virus. However, other studies show that few or none have it.  That difference may be related to the ability of the lab to detect it. There needs to be a standardized way of detecting it so we can settle that once and for all. There has been a human study of an anti CMV  drug (Valcyte) that has shown very good results, but the study was questioned by others saying it wasn't designed properly.  My thoughts are we need more studies on anti-CMV therapies, but in the meantime it might be worth adding it to the planned treatment regimen.  It would be best to track patients who try this in our brain tumor virtual trial so we can quickly tell if there is any effect - good or bad.

  425. [01/05/2016] Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.  This article shows that intra-arterial administration - either with or without disruption of the blood brain barrier may be too toxic to use.

  426. [01/04/2016] SPAGNOLETTI & ASSOCIATES RAISING FUNDS FOR MUSELLA FOUNDATION  Thank you to the Spagnoletti family and friends who are helping us raise money for brain tumor research!  

  427. [01/03/2016] Florida Brain Tumor Associations ` 1st Annual Gala  From our good friends at the Florida Brain Tumor Association

  428. [12/24/2015] The Musella Foundation has awarded another pediatric brain tumor research grant  We funded yet another pediatric brain tumor research project. This time, we partnered with the Gray Matters Brain Cancer Foundation to pay for this grant!  

  429. [12/21/2015] Recurrent venous thromboembolism in glioblastoma.  As if we didn't have enough things to worry about: this report says about 1/3 of patients with a gbm developed blood clots.  This topic needs more research to weight the risks vs the benefits of putting all gbm patients on long term drugs to prevent blood clots.  The symptoms to watch out for are: acute (sudden) shortness of breath, chest pain,  coughing up blood, fainting, swelling of the legs, tenderness of the back of the legs, and warm legs.  These symptoms are an emergency and you have to see the doctor the same day. If your doctor isn't available, it is worth going to the emergency room.  

  430. [12/19/2015] Brain cancer patient beats odds with experimental treatment  Optune is approved in the USA but experimental in Canada.  The nice thing about this article and video  is how this man is able to continue working while using the Optune device. He doesn't try to hide it and he has the most public of jobs - being a teacher. He is able to travel and teach while using it.  The biggest reason I hear for people not wanting to use this treatment is they are afraid of how it would look to other people. Some people hide it with a wig, hat or do-rag.   Search youtube for "optune" to see many stories from patients and how they handle using the device - some hide it well but  others don't try to hide it. My response is to ask:  what is worse:  having to be seen walking around in public with something on your head or not being able to communicate and being pushed around in a wheelchair? .  This treatment allows gbm patients to function longer. On average, about 25% longer, which translates into an almost 50% increase in the chances of being alive in 2 years. Some people do much better and this may buy time for other treatments to work.  I routinely see people refuse to use it when they are doing well because they do not like the way it looks.  Then as the tumor progresses and they develop neurologic problems, then they realize how serious a gbm is and want to use it - but it is to late at that point. The best time to start it is right after radiation is over.  

  431. [12/15/2015] Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma  This may be the most important article of the year. It is the report on the phase 3 clinical trial for newly diagnosed GBM trial comparing Optune and the standard of care vs the standard of care alone.  Excellent results - best of any large phase 3 GBM trial. Better than the results that made Temodar the standard of care.  The trial was stopped early by the FDA when they saw the Optune group did so much better than the control group, and they allowed the control group to cross over into the treatment group. This is the first time (that I am aware of) this happened for brain tumors!  Hopefully this will remove all doubt that Optune works and should be included in the standard of care for newly diagnosed gbm.

  432. [12/15/2015] Experimental drugs that change energy supply in cells could slow brain tumor growth  Brilliant detective work. May offer hope to this specific subtype of tumor.

  433. [12/14/2015] New Data on Tumor Treating Fields’ Anti-Mitotic Mechanism of Action Published in Scientific Reports  Describes how tumor treating fields work and why it is important to use it as much time as possible.

  434. [12/13/2015] Patient with Brain Tumor Responds Dramatically to Targeted Therapy  This may open the door for a new treatment for papillary craniopharyngioma.

  435. [12/12/2015] A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.  Unfortunately another negative trial. Adding Enzastaurin to Avastin did not help.

  436. [12/12/2015] The Musella Foundation has awarded a pediatric brain tumor research grant  This project focuses on DIPG and has already found new biomarkers that might be able to be used as targets for new treatments.

  437. [11/27/2015] Experimental brain cancer treatment offers family hope  This is super selective intra arterial infusion.  There is an older video with more details at virtualtrials.com/video2012.cfm

  438. [11/27/2015] Existing Drug May Limit Recurrence and Metastasis of Glioblastoma Multiforme  As far as I know, this drug is not yet approved for humans. It is approved for dogs and is pretty inexpensive, so it is easily available.  I would love to see a human trial of it.

  439. [11/25/2015] The Musella Foundation announced that it has awarded a $50,000 brain tumor research grant to Ninh Doan, MD, PhD, of the Medical College of Wisconsin.  This is an exciting project, looking at a new target to treat Glioblastomas. This is the 81st brain tumor research grant awarded by the Musella Foundation! Thanks to the many donors who made it possible for us to fund these amazing projects!

  440. [11/23/2015] Tocagen Presents Interim Data from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology (SNO) Exciting reports from the SNO meeting!   Highlight is almost a  doubling of survival time for patients using Toca511 compared to historical controls. These were small uncontrolled trials but they show enough promise that they justify a large phase 2/3 trial which is starting right now!  (disclaimer: Tocagen is a sponsor of our organization)

  441. [11/23/2015] Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs PFS but not OS  We need to have a discussion about the value of increasing progression free survival (PFS) without increasing overall survival.  (The braintumor treatments group is the best place to discuss it). My thoughts are that  obviously, increasing PFS is good - you feel good for a longer period of time, but perhaps it may be better to try other things instead.  Shoot for increasing both PFS and overall survival.  There are a few interesting trials going on for recurrent GBM, and the Optune device has been shown to increase both PFS and OS.

  442. [11/22/2015] Groundbreaking Global Brain Cancer Trial Planned

           I tried to get something very similar off the ground years ago, but couldn't raise the money needed for it.  I had the major brain tumor centers and another brain tumor foundation willing but it was too expensive for us.  I hope this group does well. I think it is the fastest and cheapest way to find the best drugs and combinations.

  443. [11/20/2015] ImmunoCellular Therapeutics Ltd Presents Updated ICT-107 Phase 2 Survival and Immune Response Data at the Society for Neuro-Oncology Annual Meeting 2015  Good  news from the SNO meeting: Although they did not hit the original target of overall survival for all patients in the trial, they found a subgroup of patients where the vaccine worked very well. Newly diagnosed GBM patients with a blood type of HLA-A2+ did very well. If the MGMT methylation status was positive, there was a 58% increase in survival compared to the control group. If the MGMT status was negative, there was a 34% increase in survival.  This is for a treatment that is just a simple shot in the arm and once approved, could just be added to other treatments. They just started a new phase 3 trial that will require patients to be HLA-A2+.  This should show a big improval.

  444. [11/20/2015] New Phase 3 Data show Optune in Combination with Second Line Chemotherapy is Superior to Second Line Chemotherapy Alone in Glioblastoma Patients at First Recurrence  This is a new report on combining Optune with Avastin. Both are approved for recurrent GBM. The combination reduced the chance of dying by 39% compared to Avastin alone.  This should be the standard for recurrent gbm and investigated for newly diagnosed.

  445. [11/20/2015] Celldex vaccine improves long-term brain cancer survival in study  Amazing results.  25% of patients with recurrent gbm alive after 2 years compared with NONE in the control group!  The FDA should try to get this approved as soon as possible. We shouldn't have to wait years for another study.

  446. [11/18/2015] CURE Media Group’s Heroes of Glioblastoma Announced Today  Congratulations  to the four heroes!  

  447. [11/17/2015] Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data Amazing number of presentations for Optune. So glad to see the brain tumor community finally embracing this new treatment option!

  448. [11/17/2015] Drug That Could Limit Spread of Deadly Brain Tumours  This should be tested in combination with Avastin. Might make a big impact!

  449. [11/17/2015] Global brain cancer trial aims to rapidly respond to new treatments  Interesting new clinical trial design

  450. [11/07/2015] Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.  This is just theoretical, but it makes sense to me. Might be worth trying to add Dapsone if you are on Erlotinib.  At the least it will help the rash, and at best might kill the tumor better!

  451. [11/06/2015] Targeted treatment produces rapid shrinkage of recurrent, BRAF-mutant brain tumor  This is only in 1 patient so far but may lead to a major breakthrough in the treatment of this tumor type since they reported that nearly all patients with this tumor type have the mutation this drug targets.

  452. [10/30/2015] Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial.  This has an interesting result: Using Temozolomide right after surgery compared to waiting until radiation starts resulted in a big increase in median overall survival, but a decrease in progression free survival.  It makes a lot of sense to me to start the Temozolomide right away (although we have to study the effect on wound healing), but more research is needed to see why the progression free survival goes down while the overall survival goes up. 

  453. [10/30/2015] Swedish Medical Center in Seattle announces a clinical trial in humans for the treatment of glioblastoma  This is a very exciting trial.  It is now open and will show up on our website and clinicaltrials.gov in a few days but you can contact them directly if you are interested. It is for newly diagnosed gbm patients only.

  454. [10/14/2015] Santosh Kesari, M.D., Ph.D., F.A.N.A, F.A.A.N., has joined the Pacific Brain Tumor Center and the John Wayne Cancer Institute at Providence Saint John’s Health Center in Santa Monica,  Dr Kesari is a friend of mine, and a great brain tumor doctor and researcher!  Just wanted to let you know he moved.

  455. [10/14/2015] Cancer drug’s effectiveness overinflated in animal studies  This is a major problem. All research should be reported - even negative results. Negative results are just as important, as they can prevent people from using the drug and prevent other researchers from trying the same experiments over and over again wasting time and money

  456. [10/13/2015] Video Games Can Improve Cancer Survivors’ Cognitive Abilities Glad to hear this.  They researched a particular program which requires health coaches. I would like to see research on playing free or inexpensive games that kids love, such as candy crush and Mahjong to se if it can help.

  457. [10/11/2015] Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.  This is only in the test tube and in mice, so more research is needed. This is a perfect use of the brain tumor virtual trial... we have 7 patients who used Metformin in addition to Temodar, and they seem to be doing better than average. That is not enough patients to even consider using it but it is a good start. If everyone reading this joined the virtual trial project, we would have enough data to say it is worth using - or not.  Go to virtualtrials.com and click virtual trial to join and for details. It is free and easy - we do not tell you what to do - we just observe the outcome.

  458. [10/11/2015] New book about a husband and wife who both had brain tumors is raising money for brain tumor research!  Steve has very graciously donated the proceeds of the first 6 months' sale of his book to the Musella Foundation!

  459. [10/08/2015] A new way to donate without it costing you a penny!

    I need your help with this new fundraiser:  we are asking that you donate your refund from this class action settlement to the Musella Foundation.  We will use it to fund brain tumor research and to help patients get access to their treatments through our copayment assistance program.

    We did similar fundraisers in the past, and the donations add up quickly.  This is simple – takes less than 3 minutes to read and fill out a simple form. No receipts are necessary. You just enter your name, address and answer a few questions and submit the form online. No paperwork unless you like paper – in which case you can fill out the paper version and send it to us!

    Please pass this along to your friends and family and ask that they also donate their refund.  Share it on Facebook and Twitter! If you own a business, you can donate your company’s refund.  You can ask your employer if they would consider donating. 

    Your donation is tax deductible, and we will send a tax receipt for the amount you generate.

  460. [10/05/2015] FDA Expands Optune`s Glioblastoma Multiforme Indication  Fantastic news! The FDA acted quickly! They approved Optune for Newly Diagnosed Glioblastoma to be used in addition to the standard treatment!  It results in "the risk of progression or death was reduced by 37 percent "

  461. [10/04/2015] Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer  Very exciting trial. DNX-2401 is an oncolytic virus that had some success alone with GBMs - they reportedly even had 3 complete responses (out of 37 patients). At last report, these 3 patients are still alive and have no evidence of disease 3.2, 2, and 1.75 years after treatment - See details at: http://www.onclive.com/conference-coverage/sno-2014/Oncolytic-Virus-Shows-Early-Promise-in-Glioma#sthash.CQvVJ6Pr.dpuf  This used to be called Delta-24-RGD-4C. Keytruda is a checkpoint inhibitor which has the potential to reverse the immune inhibition that GBMs have.  Combining these 2 treatments might make a major breakthrough. When the oncolytic virus kills a tumor cell, the Keytruda might allow the body's immune system to recognize and learn from the dead gbm cells and to kill the living GBM cells.  

  462. [10/01/2015] Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients This is a relatively new, FDA approved robotic laser surgery. This article mentions the ability to target tumors in very hard to reach areas.

  463. [09/28/2015] 5th Annual Chili Cook Off October 3, 2015 Saturday 11 am – 5 pm NJ This is always a fun event and benefits one of my favorite brain tumor centers.

  464. [09/20/2015] Brain cancer drug approved for NZ  Unbelievable that New Zealanders could have access to this surgical aide and USA patients can't.

  465. [09/20/2015] EnGeneIC Ltd. to Initiate U.S. Phase 1 Clinical Study Using Targeted EDV™ Nanocells to Treat Advanced Glioma Patients  Sounds interesting

  466. [09/12/2015] Life After Brain Cancer Diagnosis: Max`s Story  This is a video about a patient that went through the Tocagen trial.

  467. [09/12/2015] Novocure to Present the Latest Data from the EF-14 Clinical Trial in Newly Diagnosed GBM at the 15th Interim Meeting of the World Federation of Neurosurgical Societies  This updated the results that were presented last year.  They still look great!

  468. [09/08/2015] Novocure Announces Optune® Now Available at more than 200 Leading Cancer Centers across the United States  This is a big milestone for the Optune system.  This treatment is now available in most areas of the USA. If it isn't available near you, you can ask your doctors to get certified.

  469. [09/04/2015] Voices Against Brain Cancer is now accepting Brain Tumor Research Grant Requests  Voices Against Brain Cancer is accepting letters of intent for brain tumor research grants. Deadline is 8/30/15.  Go to http://www.voicesagainstbraincancer.org/request-a-grant/ for details.  I am the chairman of VABC's grant committee!  

  470. [09/01/2015] Oncoceutics Awarded Grant for Phase II Brain Cancer Trial We helped fund the early work on this (They mention us in the press release!).  For details on how this drug works, go to: oncoceutics.com/therapeutic-approach/

  471. [09/01/2015] UCLA Researchers Develop a Likely New Combo Treatment for the Deadliest Form of Brain Cancer  This is an amazing concept. Hope it works out.

  472. [08/29/2015] Computed modeling of alternating electric fields therapy for recurrent glioblastoma.  It is always great to find out why a treatment fails, and how to make it work better. Novocure now has a system in place where the doctor can shape the field by determining placement of the electrodes to better hit the tumor compared to the first generation of the system

  473. [08/26/2015] Treating Brain Tumor with Microbeam Radiation Generated by a Compact Carbon-Nanotube-Based Irradiator: Initial Radiation Efficacy Study.  We funded some of the earlier studies mentioned. This is a big step toward human trials.

  474. [08/26/2015] Enrollment Begins In Expansion Phase of ONC201 Clinical Trial  This study will allow brain tumor patients to participate.  We funded some of the preclinical work on this. Great to see it move into human trials!

  475. [08/26/2015] WEBINAR ALERT: Consensus Recommendations for a Standardized Brain Tumor Imaging Protocol (BTIP) in Clinical Trials  This webinar is for the people who are involved in designing brain tumor clinical trials.   It is a project we are working on to speed up the search for the cure.  Standardizing the brain tumor scans across all MRI machines will allow for more accuracy when comparing scans, speeding up the process and reducing costs.

  476. [08/25/2015] FDA Grants Orphan Drug Designation for Tocagen`s Toca 511 & Toca FC, an Investigational Immuno-Oncology Treatment for Glioblastoma  Great news for brain tumor patients!

  477. [08/24/2015] NW Bio Confirms Phase III Trial of DCVax®-L for GBM Brain Cancer Is Ongoing Patients In Trial Continuing To Be Treated Per Protocol, Including In Germany  There have been a lot of rumors flying around. What we now know is that the DC-Vax trial has stopped screening new patients for inclusion in the trial but will continue treating and observing the patients already enrolled. The company that makes it says it is a temporary suspension while they have to file some regulatory paperwork.  Some of the financial websites have painted it as a much worse event - implying that it might be permanent.    I think that this is one of the most promising treatments in the pipeline - not only for brain cancer but possibly most types of cancer. I can not see it closing down at this point when they are so close to the finish line. Let's hope it is just a paperwork thing and will reopen soon.

  478. [08/14/2015] ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for ICT-107 Phase 3 Registrational Trial in Glioblastoma This vaccine therapy trial should open soon. Looking forward to it. 

  479. [08/14/2015] Cleveland Clinic researcher awarded National Cancer Institute`s Outstanding Investigator Award  Congratulations  to Dr Rich!  He is one of the bright stars in the brain tumor world and this grant should help speed up the search for the cure!

  480. [08/12/2015] Can a Lung Cancer Drug Fight Brain Tumors?  I love the concept of testing drugs approved for other types of cancer. 

  481. [08/09/2015] New Consensus Recommendations Announced for Standardized Imaging Protocol in Brain Tumor Clinical Trials        This new standard should be used for all new clinical trials, and if possible, even for brain tumor patients outside of clinical trials. It will allow for a better comparison from scan to scan by minimizing the differences between MRI scanners. Currently, you can do a scan in 1 MRI machine, and immediately do another scan in a different machine and the results could be off by as much as 20-25%. This makes it impossible to tell if you are doing better, worse or no change.   This standardization effort was the result of the Jumpstarting Brain Tumor Drug Development Coalition, which was started by the National Brain Tumor Society. The Musella Foundation, as well as ABC2 and the Society For Neuro-oncology are also participants in the coalition.        

  482. [08/05/2015] Colchicine derivative as a potential anti-glioma compound.  I thought about this a long time ago.. Colchicine is a drug that stops cells from dividing by stopping the cell cycle at a specific point. It would make sense that it would be useful for cancer but it is too toxic at high doses. I always thought it might be a good drug to try for brain tumors using it directly in the brain, not systemic so you don't get the systemic side effects.  Perhaps combining it with something like the Optune system would work much better as more tumor cells would be in the middle of the cell cycle where Optune works the best.  Creating derivatives of it that aren't as toxic is worth trying.

  483. [07/27/2015] Gadolinium-based Contrast Agents for Magnetic Resonance Imaging (MRI): Drug Safety Communication - FDA Evaluating the Risk of Brain Deposits With Repeated Use    This is a preliminary report on possible problems with getting too many MRIs with Gadolinium. Most (or all) brain tumor scans use Gadolinium.  I would think that the benefit of knowing how the tumor is doing far outweighs the risk when the patient is known to have a brain tumor or has symptoms of a brain tumor.  I know many people who have had over 20 scans with Gadolinium with no apparent problems related to it.  However, it may have an impact on MRIs that are used to screen for brain tumors.  They have to figure out what the actual risk of using the Gadolinium is compared to the risk of not finding a brain tumor before symptoms appear.  That is going to be close - might tilt toward NOT doing screenings.

  484. [07/18/2015] The Efficacy of Ketogenic Diet and Associated Hypoglycemia as an Adjuvant Therapy for High-Grade Gliomas: A Review of the Literature.  One of the common questions I hear about brain tumors is what diet should I be following.   I never really was convinced that diet made much difference but we are seeing more evidence that it may.  This article says that the Ketogenic diet in animal models increases survival. In humans there isn't enough information on survival yet but the diet was found to be well tolerated and let to a higher quality of life. It may be worth considering.

  485. [07/18/2015] ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma.  This is one of the most important articles of the year.  Rindopepimut is a simple off the shelf vaccine given as an injection under the skin (not into the brain).  Apparently it has minimal side effects. In this study, the early results for using it on recurrent glioblastoma shows an improvement of more than doubling the 6 month progression free survival rate and there are twice as many patients still progression free in the vaccine arm than the control arm. This is just one of a few clinical trials testing this vaccine. All have been showing good results. Let's hope this treatment gets FDA approval quickly so all eligible patients can benefit. (You need to be EGFRvIII positive to benefit from the vaccine).  

  486. [07/18/2015] Hyperbaric oxygen promotes malignant glioma cell growth and inhibits cell apoptosis.  This article says that hyperbaric oxygen may make the tumor grow faster.  There are some experiments which showed the opposite but this raises a red flag that we have to look into this treatment closer.

  487. [07/13/2015] FDA Grants Fast Track Designation to Tocagen’s Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma  Exciting news.  This will hopefully speed up the approval of this immunotherapy for brain tumors!  Notice that they mention the Musella Foundation!  

  488. [07/06/2015] An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas. This should be included in the standard of care for newly diagnosed glioblastomas. (Disclaimer: Novocure, the company that makes Optune, is a sponsor of our organization).    

  489. [07/06/2015] Epigenetic Driver of Glioblastoma Provides New Therapeutic Target  Brilliant research. This type of thinking may lead to a major advance quickly. There is research on using this approach for ovarian cancer (in the test tube) that showed good results.

  490. [07/05/2015] Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.  Although it is a small study, impressive results. Sounds similar  to a treatment that was done at Duke years ago which also showed good results but for unknown reasons development was stopped.

  491. [06/27/2015] IBTA Newsletter  From our good friends at the IBTA

  492. [06/23/2015] FEATURED ON THE CERN-FOUNDATION WEB SITE, A BOOK ABOUT BRAIN TUMORS RASIES FUNDS FOR RESEARCH. WRITTEN BY A BRAIN TUMOR SRVIVIOR, A POINGNANT STORY OF A FAMILY STRUGGLING WITH BRAIN CANCER.  The proceeds of the book are donated to us - the Musella Foundation!

  493. [06/20/2015] New City Of Hope Clinical Trial Harnesses The Power Of The Immune System To Fight Brain Cancers  This is a very exciting new trial. it has done very well with other types of cancers. We hope it will work the same for brain tumors.

  494. [06/18/2015] Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics  This is a hot topic in neuro-oncology now. The current issue of the Journal of Neurooncology has this article, as well as an editorial about it and a letter in response from Dr Cobbs - who first announced that CMV is present in most GBMs.  This article says there is no CMV in brain tumor samples.  The editorial says it is a controversy and they are leaning towards CMV not being associated with GBMs. The letter from Dr Cobbs explains how they found the CMV and showed that the methods used in this article did not have a chance of finding the CMV.  I tend to think Dr Cobbs is correct and he found a method that can find the CMV. Researchers at Duke were able to confirm the presence of CMV in most or all GBM samples. Other labs were also not able to detect it. What is needed is a standardized test where any lab can do it with the same results. Until that happens, the controversy remains. This is a very important topic because IF CMV is associated with most GBMs, it presents a target to be used to fight GBMs.

  495. [06/13/2015] Free summer camp in NJ - Camp Jinka  This free NJ  program is for kids and teens whose lives have been impacted by a brain tumor

  496. [06/05/2015] The Musella Foundation announced that it has awarded Tocagen Inc. a grant to support preclinical testing the compatibility of Tocagen’s therapy with 5-ALA or tumor treating fields.  This is one of the grants that I am most proud of. It is usually very hard to get different companies to work together on a project like this, but these 3 companies were eager and willing to work together to speed up the search for the cure!

  497. [06/04/2015] Blaze Bioscience Announces Open Enrollment for Phase 1 Clinical Trial of Tumor Paint BLZ-100 in Children with Brain Cancer  Exciting new technology for brain tumor surgery!

  498. [06/03/2015] Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Overall Survival and Emergence of Long-term Survival Benefit; Primary Endpoint of PFS6 Met  This is great news. Rintega has shown significant advantage in overall survival for recurrent GBMs. Let's hope the FDA approves this quickly.

  499. [06/03/2015] Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.  This type of research is brilliant. It is only in a mouse model, so we do not yet know if it applies to humans.  They looked at tumors that became resistant to BCNU and Temodar and found that the changes that allowed the resistance  to these drugs opened the door for different drugs to work.   Doxorubicin has been shown to be effective against brain tumor cells in the test tube but it is hard to get a high level of it in the brain so it is not used much today. 10 years ago there was a paper (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1635000/) reporting on using Doxorubicin wafers implanted into rat brain tumor and they did pretty well.  It may be time to look at this again especially for recurrent GBMs that became resistant to temodar.

  500. [05/31/2015] MUSELLA FOUNDATION AWARDS 6 BRAIN TUMOR RESEARCH GRANTS

    The National Walk To End Brain Tumors raised over $230,000 this month for the Musella Foundation to use for research. We awarded $210,000 this round and will save the remaining $20,000 to use with the next round of grants.  These events were run by individuals who are committed to helping speed up the search for the cure. None of them had prior experience! They all did a fantastic job.  If you would like to host a fundraiser for us, just contact me at musella@aol.com

  501. [05/31/2015] Novocure Announces First Analysis of Full 700 Patient Dataset from Successful Newly Diagnosed GBM Phase III Trial  This confirms the good results they reported in the interim analysis a few months ago. 2 year survival for newly diagnosed GBM patients went up from 29%  in the standard therapy group to 43% in the standard + Novocure group.  More of the details will come out on June 2, 2015.  When I discussed the interim results with neuro-oncs , many took the cautious viewpoint of "wait for the full results - it can't be that good".  Well - these are the full results and almost as good as the interim results.  They also had concern that perhaps a major difference in prognostic factors between the control group and treatment group might account for the difference. Hopefully we will find out in a few days when more details are released. 

  502. [05/28/2015] Novocure Hosts First Glioblastoma-focused Hackathon to Develop New Support Tools for the GBM Brain Cancer Community  This sounds like a lot of fun and a great idea! It is a contest with nice prizes to create tools to help GBM patients. [Disclaimer: Novocure is a sponsor of our organization]

  503. [05/28/2015] Adding Bevacizumab (Avastin) Has No Impact on Quality of Life in Glioblastoma  This article is confusing. They first say adding Bevacizumab  (Avastin) to the standard of care has no impact on quality of life, then they say "Adding bevacizumab to radiotherapy with temozolomide (RT/TMZ) resulted in statistically longer deterioration-free survival across all health-related quality of life items."  In my view, they are intentionally being misleading with the headline. In the fine print at the end they say "there is no impact on quality of life DURING the progression free period." I take that to mean the until there is progression, quality of life in both groups was relatively good. Once quality of life deteriorates, there is progression. So of course there won't be much difference in the period before progression - how can you get better than good?  They downplay the part about statistically significant longer deterioration free survival.  To me that is very important and a good reason for using Avastin for newly diagnosed.  By having the same quality of life with and without Avastin, that means adding Avastin does not have a negative impact on quality of life - no more serious side effects than the placebo. And you have a longer period of feeling good.  [Disclosure - the company that makes Avastin is a sponsor of our organization)  

  504. [05/28/2015] MN Brain Tumor 5K Breaks Previous Record for Attendance, Fundraising  This event is part of our National Walk To End Brain Tumors.  Volunteers from around the country host 5k events for us to raise money for brain tumor research. See WalkToEndBrainTumors.org for details and for the remaining events for this year.  Other brain tumor foundations are also invited to participate.  All of our volunteers do a great job and are appreciated. All of these events start our small and grow each year.  The volunteers at our MN event have outdone themselves. They had the largest year to year increase we ever had - almost triple the previous year! 100% of the money raised at these events (except the Long Branch, NJ event which also goes to educational activities)  goes to brain tumor research. The expenses were paid by the sponsors, so ALL of the money raised goes to research quickly. Our medical advisory board is considering many grant applications and we will announce the winners in about a week. Thanks to all of the volunteers and we would welcome people to volunteer to host an event in your city next year!  

  505. [05/28/2015] Novocure Announces Commercial Launch of Optune (the NovoTTF-100A System) in Japan  Optune is now available in Japan!

  506. [05/24/2015] Family Brings Awareness to Brain Tumors  There are 3 more events this month in our National Walk To End Brain Tumors.  Tomorrow in Utah, and 2 events in NJ next week! See walktoendbraintumors.org for details!  

  507. [05/21/2015] Brain Tumor Biotech Summit 2015 Friday, May 29, 2015 at at 7:00 AM – 5:00 PM  One more week before the conference. There are only a few seats left. Patients are welcome. (Sign up as a student - it is OK).  

  508. [05/19/2015] Oncolytics Biotech® Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors  This trial may be a good option for kids with high grade brain tumors. 

  509. [05/19/2015] 2015 CNS Anticancer Drug Development and Delivery Conference This is the announcement for an exciting conference the 2 days before the society of neurooncology conference.  It is for medical people only.

  510. [05/15/2015] Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies  Excellent news. This treatment is very elegant. They inject a virus into the tumor - in 1 of 3 different ways - this virus can only infect cancer cells (see tocagen.com for how that works). When it infects them, it inserts a gene that encodes for an enzyme which converts a nontoxic oral fungus medication into a powerful chemotherapy - only in the cancer cells theoretically leaving normal cells alone. They let the virus spread for a month or so, then give the oral medication.  This kills the cancer cells that have enough copies of the gene.  The cells that were infected but did not get enough copies of the gene acts as a reservoir to start the cycle again.  They wait another month and repeat the oral medications.   If that sounds scary, they did build in a safeguard. They designed the virus to be very sensitive to oral anti-viral drugs so that if something bad did happen (and it hasn't yet), they can give a drug and clear the virus from your system in about a day. Also the virus can't live in normal healthy cells.   The Musella Foundation has funded a small part of these studies.

  511. [05/15/2015] Agenus (AGEN) Provides Update on its Brain Cancer Vaccine By itself the increase in survival doesn't sound like a lot but this adds a new possible tool to the toolkit that can be used to put together a cocktail that might have a long lasting effect.   Best part is it is well tolerated with no serious side effects.  

  512. [05/13/2015] Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data.  This is only in the test tube, so it is too early to get excited about it, but I love the methodology of this research and it can be used to identify other approved drugs which can be repurposed to fight brain tumors!  Thioridazine used to be used in the USA mental disorders but was stopped because it had a bad side effect of causing heart problems.

  513. [05/13/2015] NCCN Guidelines Recommend Tumor Treating Fields as a Standard Treatment Option for Recurrent Glioblastoma Novocure  This is a good first step but way too little. The NCCN guidelines should have made it a standard treatment for both newly diagnosed as well as recurrent glioblastoma. The upgrade from Category 3 to Category 2B will help with insurance coverage issues, but again, they are too conservative and should have upgraded it to a Category 1, which should eliminate all insurance issues and allow access to everyone who needs Optune..  Hopefully when the results of the recent phase 3 trial for newly diagnosed GBM patients is published, they will revise the guidelines again and give it a Category 1 for both newly diagnosed as well as recurrent GBM.

  514. [05/13/2015] Adam Kutner & Associates Help Fight Brain Tumors by Donating to the Desert Gray Matters 5K  Proceeds from this event go to the Musella Foundation, to support brain tumor research!

  515. [05/13/2015] GenSpera Expands Phase II Glioblastoma Trial of Mipsagargin  It's a great sign that they expanded the trial!

  516. [05/12/2015] Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial  Donepezil (Aricept) is a drug approved for Alzheimer's disease. This study shows that it might be beneficial for brain tumor patients who have had brain radiation. It may even help people who already have deficits.  

  517. [05/12/2015] Neurocognitive Challenges in Brain Tumor Survivors: Is There Anything We Can Do?  This is an editorial about the preceeding article

  518. [05/11/2015] ZIOPHARM Announces Initiation of Phase 1 Study of Ad-RTS-IL-12 Gene Therapy in Patients With Brain Cancer  Another gene therapy trial is starting up for recurrent GBM and Anaplastic Astrocytoma.  I love the concept and will be watching this one.

  519. [05/11/2015] Novogen up 13% premarket on positive brain cancer study results Sounds promising. It hasn't been tried in humans yet but the key here is that it preferentially kills tumor cells over normal brain cells, at least in the test tube.

  520. [05/11/2015] FDA Grants Priority Review Status for Novocure’s PMA Supplement Application of Optune in Newly Diagnosed Glioblastoma  This is great news.  Hopefully the FDA will quickly approve the Optune system for newly diagnosed GBM patients. Right now it is only approved for recurrent GBM patients but with results like this ( a 48% increase in 2 year survival rate), of course newly diagnosed patients should be using it. Newly diagnosed patients can use it now off label.  I just had a patient request my help in fighting his insurance company - they rejected the claim for Optune for his newly diagnosed GBM saying it is experimental for newly diagnosed.  I sent a nice letter along with the research and they reversed the decision, saying they will now pay for it.  Getting the FDA - then the NCCN - to support it's use for newly diagnosed will speed things up and avoid that problem.

  521. [05/06/2015] Study points to possible treatment for lethal pediatric brain cancer Although it is only in the test tube, this may be a big breakthrough in the treatment of DIPG.  Lets hope the clinical trial gets started quickly and shows great results.

  522. [05/06/2015] The Musella Foundation for Brain Tumor Research & Information Inc, announces the awarding of a $5,000 grant to Dr. Resnick of the Children`s Hospital of Philadelphia for the project: Genomic Analysis of DIPG.

    DIPG is a type of pediatric brain tumor that is among the most devastating pediatric diseases.   There hasn't been enough research on this type because they are so rare. A genetic analysis may open the door for finding existing treatments that might work against this tumor type.  This particular project is just a small part of a huge effort to create a new informatics platform for the sharing, analysis and storage of raw and analyzed data on pediatric brain tumors  in an open access environment. The results of this project will be shared with researchers worldwide with the goal of accelerating pediatric brain tumor research.

  523. [05/05/2015] Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Address Challenges in the Glioblastoma Community  We will be participating in most of these events!  

  524. [05/01/2015] Correction: The Brain Tumor Biotech Summit does welcome patients to attend!  Right after I sent the news blast this morning, I was told that patients are welcome to attend the Brain Tumor Biotech Summit!  Sorry for the mistake. As I said, I will be attending and it is one of my favorite conferences of the year.  

  525. [05/01/2015] Removing the Insurance Roadblock: I Propose the Cancer Patient Treatment Coverage Act  I agree 100% with this.  This is a major problem and only going to get worse as new treatments are approved.  The FDA is no longer the problem.  They have been excellent at quickly approving new treatments. The insurance companies now block access to these treatments.

  526. [05/01/2015] Brain Tumor Biotech Summit 2015 This is one of my favorite conferences of the year.  The target audience is researchers, oncologists, surgeons, CEOs, hedge fund managers, venture capitalists, and leaders in the biotech and pharmaceutical industries.  The idea is to get the researchers with new ideas a way to present them to the right people in order to speed up the process of getting treatment sto patients. I will report back on what I learn there.

  527. [04/29/2015] The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. There has been predjuduce against marijuana as a treatment for cancer simply because in most states it is illegal.  Removing the psychoactive components should immediately remove that barrier.

  528. [04/25/2015] Investigational Brain Cancer Vaccine Produces Strong Immunological Response  Pretty good results!

  529. [04/25/2015] New Optune You-Tube Video Channel  There is a new video on that page which shows the effect Optune has on dividing cancer cells. They show cancer cells in culture dividing, the ones on the left are treated with Optune, the ones on the left are not treated.  Aside from the amazing video of showing cells blow up when they try to divide, the end result is a huge reduction in the number of tumor cells at the end.

  530. [04/20/2015] Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer  (Disclaimer: I am on the  advisory board of the Brain Tumor Biotech Center at the Feinstein Institute).  The new brain tumor biotech center at the Feinstein Institute on Long Island, NY is designed to speed up the process of pre-clinical and clinical studies of new treatments for brain tumors, and to do it at a lower cost than traditional methods!  I would love to see more of these partnerships!

  531. [04/14/2015] TROUGH THE EYES OF A SURVIVOR, A BRAIN TUMOR PATIENT CHRONICALS HIS UNUSUAL STORY IN A NEW BOOK.  Proceeds from this book benefit the Musella Foundation!

  532. [04/14/2015] Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response.  Metformin is a cheap, easily available drug used to treat type 2 diabetes.  Sounds interesting.

  533. [04/14/2015] Brain surgeon Dr. Andrew Parsa dies at 48  I am shocked by the news. Dr Parsa was one of the brightest stars in the brain tumor world. I was just talking to him at a conference recently about his vaccine work - he was so excited that his vaccine was going to have a big impact on the fight against brain cancer.  He came so far and unfortunately won't be able to see the impact he made on the field.  My condolences to the family.

  534. [04/14/2015] May 30 walk in New Egypt will boost brain tumor research  I will (hopefully) be participating in this event!  My good friend Bruce Blount organized it!  Always a fun event.  If it is too far from you - you can still donate to it - or find other events in your area at walktoendbraintumors.org

  535. [04/10/2015] Symposium on Genetic Predisposition to Brain Cancer t  From our friends at Nationwide Childrens Hospital. Sounds like a great conference for families interested in pediatric brain tumors

  536. [04/10/2015] Go Gray in May with A Kids’ Brain Tumor Cure Foundation for Brain Tumor Awareness Month  This is from our good friends at the  A Kids’ Brain Tumor Cure Foundation. Don't forget that we (the Musella Foundation) also has Go Grey in May events - such as the National Walk To End Brain Tumors at Walktoendbraintumors.org , and that we need volunteers to help do fundraisers for us!

  537. [04/10/2015] Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study).  5-aminolevulinic acid (also known as Gliolan) is a simple dye that is given before surgery that makes the tumor visible during surgery. It has been approved for years in Europe but not in the USA yet. This study shows that there is a better chance of removing the entire tumor and patients live longer when using it.  Doesn't make sense that it is not available in the USA.

  538. [04/09/2015] PharmaCyte Biotech`s Novel Approach to Brain Cancer  Sounds interesting.

  539. [04/09/2015] Doctors Test Tumor Paint In People Very cool technology!

  540. [04/03/2015] Musella Foundation issues request for proposals for brain tumor research grants  Our big fundraiser for the year is the National Walk To End Brain Tumors.  See WalkToEndBrainTumors.org for details.  We time this round of granting so that when the money from the walks comes in, we already have approved the best grant requests and can quickly give out the money we raise!  The National Walk is actually a collaboration of many brain tumor charities. The walk website shows which events benefit the Musella Foundation. Of our events, 100% of the money raised goes to research - very quickly, with the exception of our Long Branch, NJ event which also benefits educational activities.

  541. [03/31/2015] Childhood Cancer Survivorship Conference: Focus on Brain Tumors  Sounds like a great conference.

  542. [03/30/2015] More events added to National Walk To End Brain Tumors  We just added an event in Las Vegas!  Follow the link to find an event near you. 

  543. [03/18/2015] Help beat brain cancer by filling out your NCAA Tournament bracket  Nice fundraiser you can do from home!

  544. [03/15/2015] 2nd Hoops For Hannah Bracket Contest  Fun  fundraiser for brain tumor research.

  545. [03/15/2015] New clinical trials at JFK Brain Tumor Center in Edison, NJ  I usually do not list trials at an individual brain tumor center, but this one is special. These are 4 of my favorite  trials, all done at one medical center, and they are also certified to use the Optune treatment as well.  For more information, look at virtualtrials.com  click on LEARN ABOUT then Tocagen, then Learn About and Vaccines.

  546. [03/15/2015] Y Combinator backs cancer drug combo testing service Notable labs was created by a friend of mine. They have a great concept: they grow a patient's tumor in the lab and try thousands of combinations of existing drugs on it to pinpoint the best combination to try.  They will be starting a clinical trial of it soon to prove the concept works.  Good luck to them!

  547. [03/15/2015] Long Island, NY SUPPORT GROUP MEETING FOR BRAIN TUMOR PATIENTS, FAMILY MEMBERS, AND CAREGIVERS  There is a new support group on Long Island.

  548. [03/11/2015] Study: Tetanus Shot May Aid Treatment of Deadly Brain Cancer  Great results.  Of course it is too small to prove it works but it looks like it has no side effects and may have a huge benefit.   Hope the larger trial opens soon.  Perhaps the tetanus vaccine could help boost the other vaccines in trial now also. There will be a segment on cbs evening news tonight about it

  549. [03/07/2015] IBTA e-News From our friends at the IBTA 

  550. [03/06/2015] How A Group Of Lung Cancer Survivors Got Doctors To Listen

    The NCCN guidelines define the standard of care in the USA. Insurance companies- including Medicare - use the guidelines to deny claims for treatments that are not given a good rating by the guidelines. We have that problem with Optune (which used to be called the Novocure Novo-TTF100a system and the NCCN refers to as 'alternating electric field therapy').  The NCCN guidelines for GBM originally gave this treatment a fairly good rating - at least as good as many other treatments in use. This was reasonable, as the large trial for recurrent GBM  directly compared tumor treating fields to all of these other treatments and did at least as well or better. Then at the last update, the NCCN unexpectedly  lowered the rating to the worst category - even though all of the research articles th